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ABSTRACT 
 
a) The nitrite anion has traditionally been considered an inert by-product of nitric oxide 
(NO) metabolism, but is now thought to be an important source of bioactive NO. Work 
from our department and others have implicated intrinsic vascular wall heme-proteins 
in nitrite-induced vasodilatation. These experiments were designed to test the hypothesis 
that vascular wall myoglobin is the protein responsible. Aortic rings from wild-type and 
myoglobin knockout mice were challenged with nitrite, before and after exposure to the 
heme-protein inhibitor carbon monoxide (CO). CO inhibited vasodilatation in wild-type 
rings but not in myoglobin-deleted rings. Restitution of myoglobin using a genetically 
modified adenovirus both increased vasodilatation to nitrite and reinstated the wild-type 
pattern of response to CO. cGMP accumulated in tissue exposed to nitrite. This was 
lower in myoglobin-deficient aorta and was abolished by an NO-scavenger. These results 
imply that myoglobin contributes significantly to nitrite-induced vasodilatation in the in 
vitro model, and acts through release of free NO. The prolonged vasorelaxation 
previously seen in the human forearm model was confirmed in vitro, and found to be 
partially myoglobin-dependent. 
b) Reduction by heme proteins such as myoglobin contributes to a potentially clinically 
useful feature of nitrite – hypoxia-targeted release of NO. We hypothesised that sodium 
nitrite, which preferentially dilates veins rather than arteries, may have advantages over 
organic nitrates in the treatment of acute decompensated heart failure. The use of 
nitrates is often limited by development of hypotension and tolerance; limitations that 
the specific attributes of nitrite may overcome. We investigated the haemodynamic 
effects of short systemic sodium nitrite infusions in patients with advanced but stable 
heart failure. 18 consecutive patients undergoing right heart catheterisation as part of a 
clinical heart transplant assessment protocol were recruited to the study. Sodium nitrite 
was infused into the right internal jugular vein at three escalating doses (1, 10 and 50 
μg/kg/min), and pressure and cardiac output measurements were taken using a Swan-
Ganz catheter. Patients were divided by baseline pulmonary capillary wedge pressure 
(PCWP) into predefined groups (≥ or < 15mmHg, n = 13 and 5 respectively). Nitrite 
reduced pulmonary vascular resistance (by 30%, n = 13, p = 0.03), and increased stroke 
volume (by 7.1ml, p = 0.008) in the high PCWP group, with a minimal effect on systemic 
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vascular resistance or blood pressure (p = NS for both). Change in estimated trans-
septal gradient (PCWP - right atrial pressure), a measure of effective left ventricular 
filling pressure) positively correlated with change in cardiac output (R = 0.79, p < 0.001) 
and stroke volume (R = 0.67, p = 0.004). This is consistent with relief of diastolic 
ventricular interaction through systemic venodilatation and reduced pulmonary artery 
pressure. Over this short time period, the increase in methaemoglobinaemia was small 
(maximum of 2.4%), but we went on to test this potential problem in longer infusions. 
c) Longer infusions of nitrite were tested in both health and heart failure. Patients with 
decompensated heart failure often need treatment for hours or days, so we sought to 
establish the safety and haemodynamic profile of sodium nitrite over a more clinically 
relevant time frame. Initially, long infusions were given to healthy volunteers, 
principally to assess the development of methaemoglobinaemia. A safe dose for longer-
term infusion was established at 10 µg/kg/min. The maximum metHb measured in this 
group was 2.2%, which appeared to reach a plateau at approximately three hours. This 
dose was then tested in participants with advanced heart failure, as before, to assess the 
haemodynamic effects of this dose over a period of three hours. Early results were 
favourable, though recruitment was extremely challenging. The haemodynamic effects 
of longer nitrite infusions in advanced heart failure (n = 3) appeared to increase 
throughout the three-hour infusion. This regime also appeared to be safe. Further work 
will establish the full clinical effect of this protocol. 
d) Nitric oxide plays a central role in preconditioning – the protection of tissues from 
ischaemic injury by a preceding “warning shot”, consisting of short periods of 
ischaemia. This effect can be mimicked pharmacologically and is an exciting avenue of 
current research in cardiovascular disease. Nitrite has been shown to protect against 
ischaemic injury in a variety of animal models. Human studies are underway but are yet 
to report. Mitochondrial aldehyde dehydrogenase (ALDH2) has been implicated as a 
central player in preconditioning with a variety of stimuli. We investigated the effects of 
systemic nitrite in the ischaemic human forearm model, with genetic and 
pharmacological inhibition of ALDH2, in order to establish the efficacy of nitrite and 
the role this enzyme may play in conferring protection. 35 volunteers underwent 51 
studies divided in three protocols. Venous occlusion plethysmography was used to 
measure changes in forearm blood flow in response to intra-arterial ACh (25, 50, 100 
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nmoles/min), before and after 20 minutes of forearm ischaemia. This established model 
of transient forearm endothelial dysfunction was used to assess the protective effects of 
intravenous nitrite (1 µg/kg/min for 10 minutes) in three different protocols. In protocol 
1, 1 µg/kg/min sodium nitrite for 10 minutes, given 24 hours preceding ischaemia 
prevented ischaemic endothelial dysfunction. Participants of East Asian origin were 
recruited to protocol 2, utilising a common genetic polymorphism in order to assess the 
role of ALDH2 in protection. 1 µg/kg/min sodium nitrite for the latter 10 minutes of 
ischaemia protected those with the variant ALDH2*1/*2 enzyme. Participants with the 
wild-type enzyme (ALDH2*1/*1) were not protected by peri-ischaemia nitrite. In 
protocol 3, pharmacological inhibition of the wild-type enzyme with disulfiram did not 
recapitulate the variant phenotype. In vitro studies revealed differences between the two 
enzymes in nitrite reduction and superoxide formation. This study provides evidence 
that systemic nitrite may be clinically useful, either in the pre-operative setting or 
during ischaemic events, in certain individuals. The role of ALDH2 in protection by 
systemic nitrite is complex and invites further study. 
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1. INTRODUCTION 
 
1.1. Biology of Nitric Oxide 
The discovery of nitric oxide (NO) as the endothelium-derived relaxation factor was one of 
the most important scientific advances of the 20th century. NO is generated by a group of 
nitric oxide synthases (NOSs) via the oxidation of the amino acid L-arginine to citrulline. 
Oxygen and a variety of co-factors also participate in this reaction. NO gas crosses the cell 
membrane to bind and activate the heme group of soluble guanylate cyclase (sGC). This leads 
to increased conversion of GTP to cGMP, which exerts multiple effects to produce smooth 
muscle relaxation. NO is inactivated by superoxide or scavenged by heme-containing 
proteins, with a half-life of only a few seconds. 
 
While the earliest work concentrated on the vasodilating effects of NO, over the last 15 years 
myriad other effects have been elucidated. Experiments investigating the effects of NO in 
human biology are complicated by the precise temporal-spatial production of NO. NO-donors 
are a crude tool to investigate such subtle effects (Seddon et al., 2007). Expression of the 
various NOSs is not limited to their classical cell-types, for example “neuronal” NOS (nNOS) 
will have an effect in whole organ preparations which may previously have been assumed to 
contain only “endothelial” NOS (eNOS), and high-output “inducible” NOS (iNOS) can be 
expressed in many different tissues in various pathological states. 
 
Nitrite has in the past been considered a relatively inert end-product of NO metabolism. 
However, it can be reduced (back) to NO by several mechanisms and in recent years 
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excitement has grown that it may in fact be a circulating store of physiologically active NO. 
This is discussed in detail in section 1.3. below. 
 
1.2. Control of Vasodilatation 
1.2.1. Hypoxic vasodilatation  
Hypoxic vasodilatation is a fundamental physiological process: decreased vascular resistance 
in response to local reduction in oxygen saturation of Hb. It refers to local means of regulation 
of blood flow to specific groups of cells, as opposed to centrally mediated effects through 
circulating hormones or the autonomic nervous system, which subserve globally increased 
flow. Guyton and colleagues first established hypoxic vasodilatation in a series of studies in 
the late 1950s and early 1960s (Ross et al., 1962). 
 
Hypoxic vasodilatation matches oxygen delivery to metabolic demand, possibly through 
signalling to pre-capillary resistance vessels (Segal and Duling, 1986). Nitric oxide is a 
critical determinant of vasodilatation and there is broad support for the involvement of NO or 
related species (S-nitrosothiols, N-nitrosamines, iron nitrosyls, nitrated lipid (Freeman et al., 
2008), and nitrite (Gladwin et al., 2006)) in this process. Other work has implicated adenosine 
(Edmunds et al., 2003), ATP, vasoactive peptides, K+ and H+. The relative contribution of the 
thus far established pathways remains open to debate, and in some cases controversial. The 
current consensus position is that there are multiple overlapping pathways, of which some 
may remain undiscovered at present (Segal, 2005). 
 
1.2.2. Functional and exercise hyperaemia 
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Exercise hyperaemia is the much-studied physiological phenomenon of increased blood flow 
to working muscles. Functional hyperaemia is a term for demand-induced increase in blood 
flow to any organ, including non-muscular tissues such as brain, liver and kidneys. Exercising 
muscles promote increased blood flow through a variety of mechanisms: especially 
adenosine, potassium, and acidosis. These mechanisms are shown in figure 1.1. 
 
The high-energy phosphate bond of ATP is hydrolysed to generate contractile force in 
muscle, leaving ADP and AMP. AMP is metabolised to adenosine by 5'-nucleotidase. 
Adenosine is particularly important in the regulation of coronary blood flow. K+ leaves the 
cell with every action potential in contracting cardiac and skeletal muscle, and with sustained 
exercise begins to accumulate in the extracellular space. Extracellular K+ produces 
hyperpolarization of the membrane potential of vascular smooth muscle, stimulates the 
Na+/K+-ATPase pump and increases membrane conductance to K+ through K+ activated K+ 
channels. Hyperpolarisation of the membrane closes voltage-dependent calcium channels, 
leading to smooth muscle relaxation and vasodilatation. Carbon dioxide is a by-product of 
oxidative metabolism. CO2 diffuses from muscle cells to vascular smooth muscle, causing 
vasodilatation directly or through decreased pH. CO2 is also particularly important in 
regulation of cerebral blood flow. Lactic acid is produced during anaerobic metabolism, and 
also vasodilates through decreased pH. Inorganic phosphate, released by the hydrolysis of 
adenine nucleotides may also have a role in exercise hyperaemia. 
 
Around 50% of the total resistance to blood flow across muscles resides in small muscular 
arteries outside the muscle itself. These arteries are not directly exposed to vasodilating 
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signals from exercising muscle units, but vasodilatation spreads proximally through cell-to-
cell signalling with increasing recruitment of motor units (Segal and Jacobs, 2001). 
 
1.3. The nitrite anion 
Nitrite (NO2-) is present in human plasma at a concentration of approximately 150 – 500 nM 
(Dejam et al., 2005; van Faassen et al., 2009). The exact concentration varies from day-to-
day, depending on endogenous production and diet, and is higher in the plasma of arterial 
blood than venous blood (Table 1.1.). Circulating nitrite is lower in pregnancy (Hata et al., 
1999), and higher with adaptation to altitude (Erzurum et al., 2007). Nitrite is concentrated in 
red blood cells compared to plasma. Erythrocytes represent about half of total blood volume, 
making them the largest nitrite pool in whole blood (Dejam et al., 2005). Tissue 
concentrations of nitrite vary widely: brain and aortic tissue contain significantly higher 
concentrations than heart, liver, kidney or lung (Table 1.2.). 
 
Physiological nitrite has three sources: ingestion of nitrite in the diet, reduction of dietary 
nitrate (NO3-) following absorption into the boodstream and concentration in the salivary 
glands, and metabolism of NO released by the endothelium. Nitrite-rich foods include cereals, 
corn, and green leafy vegetables such as pak choi or spinach, which contain 2.0 - 4.0 mg of 
nitrite per kilogram of food. Cured meats have artificially increased levels of nitrite, which is 
used in the curing process. Nitrate is ingested in a wide variety of foods, especially vegetables 
such as spinach, lettuce or beetroots. Plasma nitrate is secreted and concentrated by the 
salivary glands (Spiegelhalder et al., 1976). Bacteria in the oral cavity efficiently reduce 
salivary nitrate to nitrite, producing a 1,000-fold increased concentration of nitrite in saliva 
compared to plasma (Lundberg et al., 2004). Humans produce around 1.5 litres of saliva per 
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day, which is generally swallowed. Nitrite is absorbed across the gastric mucosa, though some 
is reduced directly to NO in the strongly acidic milieu of the stomach lumen. Production is 
maximal at the gastro-oesophageal junction where salivary nitrite first meets gastric acid. The 
junction is also the most common site for the development of squamous metaplasia and 
gastric carcinoma. Restriction of nitrite- and nitrate-rich foods can reduce plasma levels of 
these species by about 50% (Gladwin et al., 2000b). 
 
The remainder of plasma nitrite is derived from endothelially-released NO. Mice with 
disrupted function of eNOS show lower levels of both plasma and cardiac nitrite (Bryan et al., 
2008). Conversely, mice with enhanced eNOS function (over-expressing human eNOS), 
exhibit higher levels (Elrod et al., 2008). Oxidation of NO radicals is slow in vitro, but is 
significantly faster in blood (Rassaf et al., 2002). Firstly, NO is apolar, and naturally 
partitions into low polarity lipid or protein fractions, thereby increasing its relative 
concentration by a factor of 10. This is particularly important, as the oxidation reaction is 
second order in NO concentration (Liu et al., 1998). Secondly, the copper-storage plasma 
enzyme ceruloplasmin catalyses the first step of nitrite synthesis, oxidation of NO to NO+. 
NO+ is then rapidly hydrolysed to NO2- (Shiva et al., 2006). 
 
Infused sodium nitrite diminishes with a half-life of several minutes (Lundberg and 
Weitzberg, 2005). Nitrite reacts with haemoglobin to form metHb and nitrate, which is then 
excreted in the urine and, to a lesser extent, the faeces as an inert salt. A small amount of 
nitrite is excreted in the urine. The lethal dose of nitrite is considered by the US Food and 
Drug Administration to be 22 mg sodium nitrite per kilogram, in the adult human 
(corresponding to an average concentration of 320 μM). Death results from 
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methaemoglobinaemia, which is discussed in section 1.3.4. (van Faassen et al., 2009). Nitrite 
in food has previously been restricted due to concerns over carcinogenicity, though such 
concerns have now been largely refuted (van Faassen et al., 2009). 
 
1.3.1. NO release 
NO can be generated from nitrite directly: by acid disproportionation, or reduction by 
oxidoreductase enzymes (e.g. xanthine oxidase (Baker et al., 2007; Godber et al., 2000; Li et 
al., 2001), aldehyde dehydrogenase (Li et al., 2008) or by deoxy- forms of heme globins (Li 
et al., 2008), and recently proposed was carbonic anhydrase (Aamand et al., 2009). The 
relative contribution of each of these methods in physiology is controversial. 
 
1.3.1.1. Acid disproportionation 
Benjamin and Lundberg independently demonstrated that nitrite derived from dietary nitrate 
was a substrate for NOS-independent production of NO in the acidic conditions of the human 
stomach (Benjamin et al., 1994; Lundberg and Govoni, 2004). In normoxic conditions 
elsewhere in the body, this mechanism of NO production probably does not occur. However, 
pH in the ischaemic myocardium may fall as low as 5.5 (Zweier et al., 1995), making NO 
release from nitrite possible in these conditions. 
 
1.3.1.2. Nitrite reductase: haemoglobin 
The most-studied (and most controversial) proposed nitrite reductase is haemoglobin. In 
2003, Gladwin and colleagues sought to definitively prove that nitrite was a vasodilator in 
vivo (Cosby et al., 2003). This study is discussed in more detail later, but briefly they showed 
that nitrite could vasodilate the forearm of healthy volunteers at pharmacological and near-
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physiological doses, with a greater increase on exercise. The observation that vasodilatation 
was associated with the formation of iron-nitrosyl-haemoglobin and SNO-Hb, led the authors 
to investigate the in vitro nitrite reductase activity of haemoglobin. They found that both 100 
and 200 μM nitrite plus deoxygenated erythrocytes (5 ml RBCs at 1000 μM of heme), 
released NO into the gas phase. The level of oxygen is not given, but can be assumed to be at 
or about anoxia as the whole volume was purged with helium. The level of nitrite is also 
much higher than physiology (Table 1.1.) so this experiment pertains more to 
pharmacological nitrite. Further studies in aortic rings suggested that added red blood cells 
potentiate the vasodilating effect of nitrite. Remarkably, 2 μM nitrite had no vasodilating 
effect, even in hypoxia. 
 
Nagababu and colleagues also used chemiluminescence to follow the production of NO from 
nitrite directly (Nagababu et al., 2003). They extended the observations above by showing 
that the majority of iron-nitrosyl-Hb was in the ferric (3+) state. The authors claim that 
manipulation of samples led to experimental error when using previous photolysis-
chemiliuminescence techniques. 
 
Huang and colleagues showed that the greatest rate of NO generation occurs at the R-to-T 
transition point of Hb oxygen saturation (Huang et al., 2005b). This was shown to be due to 
the concerted action of two opposing forces. First, reduction of nitrite to NO proceeds at a 
faster rate at a more negative heme reduction potential. This is highest at 100% oxygen 
saturation. On the other hand, nitrite is reduced primarily by deoxyHb, with oxyHb acting 
solely as a potent scavenger of NO, and therefore NO production is also favoured by 0% 
oxygen saturation. The balance of the two forces at the R-to-T transition point explains the 
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maximal generation of NO at this point. Isbell and colleagues, in further studies using aortic 
rings, contend further that deoxyhaemoglobin has a unique dual-function, with both NO-
production and scavenging abilities (Isbell et al., 2007). This, they say, allows deoxyHb to 
play a central role in intravascular NO homeostasis, though they also admit a role for vessel 
wall enzymes. 
 
The major problem with theories of NO release from nitrite by Hb or red cell enzymes is that 
Hb is a very efficient scavenger of free NO. Proposed explanations include the formation of 
S-nitrosothiols (SNOs) or N2O3 or as intermediates, both of which possibilities are discussed 
below. A minority of mathematical models also purport to explain how this could occur 
(Tsoukias, 2008). 
 
1.3.1.3. Nitrite reductase: myoglobin 
 
Myoglobin is a 16,700 KDa heme-containing protein, consisting of a densely packed 153 
amino acid polypeptide chain. It is a molecular relative of haemoglobin and is abundantly 
expressed in skeletal and cardiac muscle. In vitro, Mb can act either as an NO scavenger (in 
normoxia) or as a nitrite reductase (in hypoxia) (Shiva et al., 2007a; Rassaf et al., 2007). The 
redox potential of Mb is lower than that of R-state Hb, meaning a greater ability of the heme 
to donate an electron to nitrite, and deoxyMb may in fact reduce nitrite and generate NO at a 
faster rate than deoxyHb (Huang et al., 2005a). The bimolecular rate constant for the reaction 
of deoxyMb in isolated cardiomyocytes was measured at 12.4 mol/L/s, compared to 0.35 
mol/L/s for deoxyHb (Shiva et al., 2007a). In this preparation, deoxyMb released NO in 
proximity to the mitochondria, and inhibited respiration through cytochrome C oxidase (Shiva 
et al., 2007a), confirmed in Hendgen-Cotta et al. (Hendgen-Cotta et al., 2008). Myoglobin 
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has other important effects in the cell, which may be particularly relevant to ischaemia-
reperfusion injury. For example, the dioxygenase function of oxygenated Mb (NO + O2 + 
NAD(P)H ↔ NO3- + NAD(P)+ + H+) can prevent damage from the overproduction of NO 
radicals in the heart (Ishibashi et al., 1993; Flogel et al., 2001) by protecting the respiratory 
chain against nitrosative stress (Brown, 2000).  
 
In studies in our department we observed a prolonged vasodilating response to nitrite in the 
forearms of healthy volunteers, which persisted for around 45 minutes after the nitrite 
infusion was stopped (unpublished data, Maher et al., 2007). Intriguingly, this prolonged 
vasodilatation was only observed in the infused arm, even though levels of nitrite were raised 
in both arms during the infusion. Vasodilatation persisting after 30 minutes cessation of nitrite 
infusion was also reported in Cosby et al. (Cosby et al., 2003), but is not discussed further. 
This led us to hypothesise that an intrinsic vascular wall protein was involved. We had found 
only minor effects of xanthine oxidase inhibition with allopurinol in this model (unpublished 
data, Maher et al., 2007) and so we resolved to test the role of myoglobin in nitrite-induced 
vasodilatation. This forms the rational for the work presented in Chapter 3. 
 
1.3.1.4. Nitrite reductase: eNOS, XO and ALDH2 
Endothelial NOS (eNOS) has been proposed as a nitrite reductase in ischaemia or hypoxia, 
when its NO synthase activity is inhibited (Webb et al., 2008a; Gautier et al., 2006; Vanin et 
al., 2007; Mikula et al., 2009). Milsom and colleagues used renal-targeted knockout of eNOS 
to investigate this role in their model of bilateral kidney IR (Milsom et al., 2010). Topical 
nitrite prior to reperfusion was protective in the wild-type animal (n = 8 vs. 4, p < 0.001). 
Interestingly, in this study nitrite appeared to worsen renal dysfunction post-IR in the eNOS 
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knockout (n = 7 vs. 4, p < 0.001). Also, eNOS knockout in itself appeared to be protective (n 
= 8 vs. 7, p < 0.001). This may reflect the dual nature – protective or harmful - of NO release 
in ischaemia-reperfusion, discussed in greater detail in section 1.8.3. 
 
Xanthine oxidase (XO) catalyses the oxidation of hypoxanthine to xanthine and xanthine to 
uric acid. It is also capable of reducing nitrite to NO in vitro (Li et al., 2001). Erythrocyte XO 
has been proposed as an important intravascular nitrite reductase (Webb et al., 2008a), though 
this assertion suffers from the same drawbacks as that proposing haemoglobin – namely, how 
can the NO generated escape from the cell? Inhibition of xanthine oxidase prevented 
cytoprotection by nitrite in a number of studies (Webb et al., 2004; Baker et al., 2007) but this 
result was not universally seen (Shiva et al., 2007a; Rassaf et al., 2007).  
 
Work from the Zweier group implicated xanthine oxidase and aldehyde dehydrogenase as the 
critical vascular wall nitrite reductases and discounted the role of red blood cells (Li et al., 
2008). Overall, NO production from red blood cells was very limited, except when nitrite was 
in large excess (500 μM). Inhibition of haemoglobin with carbon monoxide (CO) increased 
NO production from red blood cells, implying that scavenging activity of Hb was dominant. 
Importantly, this study relates to production of free NO, and therefore does not rule out the 
possibility that Hb, through intermediates, might have a role in nitrite-derived NO-like effects 
(this is discussed in more detail below). They went on to investigate liver and heart samples 
with rotenone, oxypurinol and raloxifene to inhibit mitochondrial complex I, XO and ALDH2 
respectively. They do not report results of inhibition of tissue nitrite reductase activity with 
CO, and in any case the effects of this non-specific heme-inhibitor would be difficult to 
interpret in this model. We adapted this method, but (critically) combined with genetic 
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knockout to investigate the role of myoglobin in vasodilatation in the work reported in 
Chapter 3. 
 
1.3.2. Protein S-nitros(yl)ation 
NO has important cGMP-independent cellular effects, most of which involving post-
translational protein modification. S-nitros(yl)ation of protein cysteine residues by NO 
generates S-nitrosothiols (SNOs), which may also regulate cell function. (Foster et al., 2003; 
Hess et al., 2005). Other SNOs, for example those of albumin (Stamler et al., 1992) or 
haemoglobin (Singel and Stamler, 2005; Allen et al., 2009) are believed to act as a reservoir 
of NO bioactivity, ready to be released in areas of hypoxia or low pH. Terminology in this 
area is variable: both S-nitrosation and S-nitrosylation refer to the covalent binding of a 
nitroso group (NO) to a thiol. However, S-nitrosylation is frequently used specifically to 
mean post-translational modification of proteins, as found in both cell-to-cell and intracellular 
signalling (Allen et al., 2009). The composite term, S-nitros(yl)ation is often used to signify 
the broad effects of nitroso group binding. 
 
Consistent with an important role in cellular signalling, S-nitros(yl)ation is not merely an 
indicator of NO production. Individual components of the signalling network are in a constant 
balance between nitros(yl)ation and de-nitros(yl)ation (Lima et al., 2010). High molecular 
weight SNOs are present in the plasma at a concentration of approximately 50 nM (van 
Faassen et al., 2009) and in vivo levels of SNOs depend linearly on nitrite concentration 
(Bryan et al., 2005). 
 
Stamler and colleagues initially proposed a theory of hypoxic vasodilatation in which SNO-
Hb releases NO by R-to-T transition of Hb to produce vasodilatation. Free NO is bound by 
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heme to produce iron(II)-nitrosyl-Hb, and then finally re-nitrosylates the β-93 cysteine of Hb 
when the heme-bound NO is replaced by O2 in the pulmonary circulation (Gow et al., 1999). 
Nitrite was not included in the early formulations of this theory. The theory was challenged 
on several levels. Firstly, measured arterial-venous gradients of iron-nitrosyl-haemoglobin 
(Stamler et al., 1997; McMahon et al., 2002) could be confirmed in rodents but not in humans 
(Rassaf et al., 2003). There was no detectable iron-nitrosyl-Hb found in humans in the latter 
study. Gladwin and colleagues reported much lower levels of both iron-nitrosyl-Hb, and of 
SNO-Hb (Gladwin et al., 2000a). There were also no AV gradients of either product. 
Secondly, there were several problems with the proposed chemical processes: the majority of 
endothelium-derived NO is produced in the arterial circulation, where deoxyHb is low (Huang 
et al., 2001; Joshi et al., 2002); NO bound by ferrous (Fe2+) may be too tightly bound to 
transfer to the β-93 cysteine to replenish SNO-Hb; and finally the R-to-T transition of Hb was 
not shown to facilitate release of NO from SNO-Hb in subsequent studies (Patel et al., 1999; 
Wolzt et al., 1999) 
 
The theory was modified to include a direct SNO synthase activity of haemoglobin itself, 
using nitrite as substrate, to overcome the objections raised above (Angelo et al., 2006). The 
observation that scavenging by haemoglobin should prevent haemoglobin release from red 
blood cells, despite the undoubted ability of deoxyhaemoglobin (and erythrocytic xanthine 
oxidase) to act as a nitrite reductase under certain conditions, has led to the hypothesis that 
SNOs, rather than free NO, produce NO-like bioactivity from nitrite. In this model, nitrite 
nitrosylates Hb, which shifts NO to protein intermediates by S-transnitrosation, with sGC (or 
Ca2+-dependent K+ channels (Bolotina et al., 1994) and vasodilatation as a final target (Jia et 
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al., 1996).  It has been shown SNOs can have NO-like effects which do not require the release 
of free NO (McMahon et al., 2000) 
 
Against this paradigm, the effects of nitrite-derived NO – particularly vasodilatation 
(Crawford et al., 2006; Dalsgaard et al., 2007) and cardioprotection (Duranski et al., 2005; 
Webb et al., 2004) - have been consistently shown to be inhibitable by NO scavengers, often 
using the cell-impermeable scavenger carboxy-PTIO. Substitution of the β-93 cysteine on 
haemoglobin, the critical cysteine for S-nitrosylation, actually increase the rate of nitrite 
reduction, by decreasing the heme redox potential (Crawford et al., 2006). The authors in the 
latter study argue that the short burst of vasodilatation seen when red cells are added to a 
hypoxic preparation is in fact due to ATP release, rather than SNOs. 
 
1.3.3. N2O3 as an intermediate 
Dinitrogen trioxide (N2O3) is the anhydrous form of nitrous acid (HNO2). N2O3 has been 
suggested to be both an NO donor and an effective nitrosylating agent. It can be generated by 
the reaction of nitrite with ferric heme-proteins, such as metHb. The metHb binds nitrite to 
form a nitrite radical, which generates N2O3 through a radical-radical reaction with NO 
(Gladwin and Kim-Shapiro, 2008; Perissinotti et al., 2008):  
 
metMyoFe3+-NO2- + NO → MyoFe2+ + N2O3 
 
N2O3 is relatively more stable than NO, and is lipophilic and diffusible (Gladwin and Kim-
Shapiro, 2008). While the involvement of such or similar intermediates is theoretically 
possible, practical demonstration is challenging and has not been achieved as yet. 
- 13 - 
 1.3.4 Generation of methaemoglobin 
Methaemoglobin (metHb) is an oxidised form of the heme-protein haemoglobin, where the 
iron of the heme group is in the ferric (Fe3+) rather than ferrous (Fe2+) state. It is chocolate 
brown in colour. This change removes the capacity of haemoglobin to carry oxygen and, 
consequently, high levels of methaemoglobinaemia cause morbidity and death (Atkinson, 
1888; Oppe, 1951). The normal level of metHb is below 1%. Higher levels can be caused by 
genetic disorders or environmental factors such as drugs (anti-malarials, some older 
analgesics, and sulphonamide antibacterials) or industrial chemicals (chromates, 
chlorobenzene, arsine and aromatic amines). Importantly, nitrite can oxidise Hb to form 
metHb: 
 
NO2- + HbFe2+ + H+ → NO + HbFe3++ OH- 
 
The reaction is complex and depends upon the oxygenation level of Hb (Kim-Shapiro et al., 
2005). In vivo, metHb is reduced back to Hb by methaemoglobin reductases, also known as 
cytochrome b5 reductases, a widely expressed group of NADH-dependent enzymes. 
 
The induction of metHb by nitrite has proved useful in the treatment of cyanide poisoning 
(Vale, 2001). Untreated, cyanide binds and inhibits cytochrome c oxidase, a crucial 
component in cellular respiration. In this multi-step process, cyanide preferentially binds 
sacrificial metHb, produced by nitrite, giving cyanmethaemoglobin. Thiosulfate, given 
intravenously as the sodium salt, reacts with cyan-metHb to form thiocyanate, and sulfite. 
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Thiocyanate can be excreted in the urine and remaining methaemoglobinaemia treated with 
methylene blue.  
 
The reaction of metHb with very high levels of nitrite in conditions of low pH gives a green 
product known as nitri-Hb. A similar product, nitri-myoglobin, is responsible for the 
“greening” seen in cured meats (Kim-Shapiro et al., 2005).  
 
1.4. A short history of research into nitrite 
Sodium nitrite was observed to be a dilator of smooth (then known as “non-striped”) muscle 
as early as 1888 (Atkinson, 1888). The reaction of nitrite with haemoglobin, to form 
methaemoglobin, was also noted. When studied in aortic ring preparations, this vasodilating 
effect was weak (Furchgott and Bhadrakom, 1953) with supra-physiological amounts of 
nitrite required. This supposition limited the interpretation of experiments that later showed 
that nitrite can activate soluble guanylate cyclase (sGC) (Mittal et al., 1978; Ignarro and 
Gruetter, 1980). 
 
The limiting factor in these early experiments appears to be the high level of oxygenation. 
Nitrite reduction to NO is strongly favoured by hypoxia, such that physiological levels may 
produce significant vasodilatation in vivo when tissue oxygenation is low (Dezfulian et al., 
2007; Lundberg and Weitzberg, 2005). Additionally, the discovery that nitrite is consumed 
across the vascular bed, with significant arterial-to-venous differences, implied that nitrite 
might have a signalling role in physiology (Gladwin et al., 2000b; Gladwin et al., 2005). This 
realization kick-started a rapidly growing field of research into several areas of potential 
therapeutic interest:  
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 1. Therapeutic vasodilatation, including in pulmonary and systemic hypertension 
2. Therapy in diseases of haemolysis and NO-scavenging such as sickle cell anaemia 
3. Cytoprotection from ischaemia-reperfusion (IR) injury  
 
1.5. Nitrite in physiological and therapeutic vasodilatation 
As mentioned above, the consumption of nitrite across the vascular bed suggests that nitrite 
has a physiological role in the circulation (Gladwin et al., 2000b). It was long thought, largely 
on the basis of ex vivo studies, that nitrite could not vasodilate in micromolar concentrations 
(at the upper end of the physiological range) (Lauer et al., 2001). However, recent evidence 
from both in vitro and in vivo studies has called this assumption into question. 
 
1.5.1. In vitro studies 
Early in vitro studies established that nitrite could activate sGC and relax arterial and venous 
tissue at supra-physiological levels (0.1 - 10 mM) (Moulds et al., 1981), and focused on the 
role of S-nitrosothiols as intermediates in this reaction (Ignarro and Gruetter, 1980; Ignarro et 
al., 1981). Nitrite was not considered a physiological vasodilator due to the large amounts 
required in these studies. 
 
The study of vasodilatation by nitrite intensified with the nitrite revival at the turn of this 
century. In acidic conditions, physiological concentrations of nitrite were found to relax 
isolated aortic rings (Modin et al., 2001), and the importance of oxygen tension in these 
studies was definitively shown by Dalsgaard and colleagues using the wire myograph 
(Dalsgaard et al., 2007). This latter work used two concentrations of O2 in the perfusing gas 
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(1% and 95%), and also high (1 μM) and low (0.02 μM) concentrations of norepinephrine 
(NE) for preconstriction. Hypoxia potentiated vasorelaxation to nitrite by two log orders. 
Removing endothelium, adding allopurinol (to inhibit xanthine oxidase), or adding 
myxothiazol (to inhibit mitochondrial bc1 – complex III or cytochrome c oxidase) did not 
appear to affect the response to nitrite, though ODQ (a G-protein inhibitor) abolished 
response. Together, they interpreted these results to mean that nitrite vasodilates by 
conversion to NO, and that the bioconvertor is not xanthine oxidase, nor cytochrome c 
oxidase, nor is resident in the endothelium. They postulated that the bioconvertor is instead 
resident in the vessel wall, and that the reaction is first order with respect to concentration of 
nitrite, and is enhanced by hypoxia. They discuss nitrite reductase activity and possible 
candidates, focusing on haemoglobin (though they accept that their data do not support such a 
conclusion), and do not discuss myoglobin despite it being inherently oxygen-sensitive thanks 
to its heme group. 
 
ODQ prevented nitrite-induced vasodilatation, which was interpreted as proving the 
requirement for free NO in this process. In fact, ODQ is not as specific an inhibitor of sGC as 
claimed, and may block nitrite reductase activity by other heme-proteins as well as sGC 
activation (Alzawahra et al., 2008). The other inhibitors had no effect on nitrite-induced 
vasodilatation, suggesting that neither XO nor cytochrome c oxidase are important players in 
this process. Finally, haemoglobin was a net scavenger in all conditions studied. 
 
1.5.2. In vivo studies 
In an important study, Cosby and colleagues definitively showed that sodium nitrite 
vasodilates the forearm when infused into the brachial artery (Cosby et al., 2003). Initially, a 
- 17 - 
high dose of 36 μmol/min (2.4 mg/min) was tested and found to significantly increase forearm 
blood flow (FBF) both with and without NOS inhibition by L-NMMA (n = 10, p <0.01). FBF 
increased further on forearm exercise, despite relative reduction in nitrite concentration due to 
increased blood flow. They went on to test a near physiological dose of 400 nmoles/min (27.6 
μg/min), which significantly increased FBF from 3.5 ± 0.2 to 4.5 ± 0.3 ml/min/100ml tissue 
(n = 10, p < 0.006) at rest and to a greater extent on exercise. The authors concluded that 
basal levels of nitrite are capable of influencing resting vascular tone and subserving hypoxic 
vasodilatation. 
 
In 2007, the same group extended their previous observations using systemic doses of sodium 
nitrite. A low dose of just 350 nM was found to cause a significant drop in blood pressure in 
healthy volunteers (Dejam et al., 2007). In a clinically relevant aside, experiments in monkeys 
reported in the same paper suggest that nitrite might not induce tolerance in the same way as 
inorganic nitrates. Studies in our department revealed that sodium nitrite, when infused into 
the brachial artery of healthy volunteers, modestly dilates arterioles in normoxia, but 
profoundly vasodilates in conditions of hypoxia (Maher et al., 2008). 
 
Hypoxic vasodilatation requires a sensor, a signal and an effector. Many proposed nitrite 
reductases (discussed in detail in section 1.3.1.) contain heme and therefore have oxygen-
sensing capacity.  The reaction of haemoglobin with nitrite, in particular, requires both a 
proton and oxygen, making it a hypoxia or acidosis sensor (Huang et al., 2005b), with direct 
release of NO or NO-like bioactivity and vasodilatation the consequence of activation. This 
theory is self-contained, which may explain part of its popularity, but it suffers from the 
drawbacks discussed above. The role of nitrite in physiological hypoxic vasodilatation is 
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therefore unresolved, but the ability of exogenous nitrite to act as a vasodilator – potently in 
certain conditions - is established beyond doubt. 
 
A consistent feature of nitrite-induced vasodilatation is its targeting of hypoxia. Vasodilators 
are used in acute decompensated heart failure (ADHF), more for their effects on preload than 
afterload. There are no specific venodilators in clinical use, and so arterial hypotension is 
often the limiting factor in treatment of ADHF, requiring admission to intensive care and 
inotropic therapy. We hypothesized that nitrite, as a hypoxia-targeted vasodilator, would 
principally cause venodilation and preload reduction in normoxic patients with heart failure, 
without the drop in arterial blood pressure that comes with nitrate-therapy. This hypothesis 
was investigated in the experiments presented in Chapters 4 and 5. 
 
1.5.3. Pulmonary hypertension 
Pulmonary hypertension (PH) is defined as a mean pulmonary artery pressure of >25 mmHg 
at rest, or >30mmHg on exercise. It is conventionally divided into primary pulmonary 
hypertension, a disorder of unknown aetiology, and pulmonary hypertension from secondary 
causes. These secondary causes include cardiac causes (heart failure or primary valve 
disease), pulmonary disorders such as chronic obstructive pulmonary disease and chronic 
pulmonary embolic disease, and connective tissue disease (most commonly scleroderma). 
 
Utilising the established hypoxia-potentiated vasodilatory properties of nitrite, several studies 
have investigated the possibility of treating pulmonary hypertension with nebulised or 
intravenous nitrite. Mark Gladwin and his associates did the majority of this work (references 
below). 
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 Inhaled sodium nitrite decreased pulmonary hypertension to a similar degree as 20 ppm NO 
gas, in hypoxic and normoxic lamb models of PH (Hunter et al., 2004). The pulmonary 
vasodilatation depended upon deoxyHb and was potentiated by low pH. The effect of nitrite 
was confirmed in a later study using both hypoxic and inflammatory (monocrotaline-induced) 
models in mice and rats (Zuckerbraun et al., 2010). 3 – 300 mg sodium nitrite was nebulised 
in 5 ml of PBS, and given intermittently in an exposure chamber. Development of hypoxic 
PH was prevented by low-dose nebulised nitrite (3 times per week for 20 minutes per 
exposure) throughout the 28 days of hypoxia (n = 9, p < 0.001). It also reversed changes 
already seen when started two weeks into the hypoxic period (n = 14, p < 0.001). The effect 
of nitrite was not increased at the higher dose. Inflammatory PH was reversed by low-dose 
nebulised nitrite given 3 times per week during weeks 4 - 6 following monocrotaline exposure 
(n = 8, p < 0.001). Nebulised nitrite, 3 times per week, would be a cheap and safe 
intervention, especially when compared to inhaled NO gas. This study did show marked 
increase in superoxide generation in the lung, as part of experiments intended to show the 
necessity of XO in nitrite-dependent generation of NO, and long-term effects were not 
investigated. Research in Cardiff University has begun to extend these observations to human 
subjects. 18 healthy volunteers underwent nitrite infusions and showed a decrease in 
pulmonary arterial pressure, as estimated by echocardiography, in normoxia, as well as 
prevention of hypoxic vasoconstriction (Ingram et al., 2010).  
 
Pulmonary hypertension can occur acutely (as well as chronically) as a result of pulmonary 
embolism. Dias-Junior et al. induced PH by infusing clots of venous blood into the right 
atrium of mongrel dogs (Dias-Junior et al., 2006), which produced the expected rise in 
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pulmonary vascular resistance (PVR) and pulmonary arterial (PA) pressure. One group of 
embolised animals received intravenous sodium nitrite at a dose of 6.75 μmol/kg nitrite over 
15 minutes, followed by a maintenance infusion of 0.28 μmol/kg/min for the remainder (31.1 
μg/kg/min followed by 19.3μg/kg/min), which increased the mean plasma concentration of 
nitrite by approximately 2 μM (from ~1 μM to ~3 μM). Cardiac index in embolised animals 
was significantly increased by nitrite (+28%, n = 10, p < 0.05 compared to placebo). 
Interestingly, this moderate dose of nitrite produced significant vasodilatation in control 
animals, which contrasted with the effect in embolised dogs and was associated with a drop in 
cardiac index. The authors suggest that this may be due to consumption of nitrite in the 
pulmonary vasculature. In a later small study, sildenafil was found to potentiate the effect of 
nitrite (Dias-Junior et al., 2008). There was a transient but significant drop in mean arterial 
pressure (24 mmHg), which suggests that extreme caution is warranted in the co-
administration of nitrite and sildenafil, as with organic nitrates. 
 
1.5.4. Cerebral vasospasm 
Stroke is the clinical syndrome of sudden loss of brain function due to cessation of blood 
supply. It is a common cause of death and disability in people of all ages. Strokes are 
pathophysiologically divided into ischaemic (caused by embolisation of material, commonly 
blood clot, into the cerebral circulation) and haemorrhagic (bleeding into the brain 
parenchyma). Ischaemic stroke causes damage through necrosis of brain tissue and ischaemia-
reperfusion (IR) injury. The role of nitrite in prevention of IR injury is discussed in section 
1.8.4.  
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Sub-arachnoid haemorrhage (SAH) caused by a burst aneurysm may also result in stroke. 
Damage is frequently exacerbated by cerebral vasospasm, caused by the irritating effect of 
blood surrounding small arteries. Nitrite prevented cerebral vasospasm after subarachnoid 
haemorrhage in a primate model (Pluta et al., 2005). One group (n = 3) received 90 mg 
sodium nitrite intravenously over 24 hours plus a 45 mg bolus daily for 14 days. A second 
group (n = 3) received a 180 mg infusion of sodium nitrite every 24 hours continuously for 14 
days. 90 mg over 24 hours equates to approximately 70 - 200 μg/kg/min assuming an average 
weight of 3 - 9 kg; weights and sexes are not given and the cynomolgus monkey is variable 
between subspecies as well as sexually dimorphic in this regard. There was a control group 
that received no nitrite (n = 8). This model uses a band of autologous clot around the middle 
cerebral artery. Interestingly, this intervention produced vasospasm in all control animals, 
peaking at 7 days. This contrasts with the clinical syndrome of human SAH, in whom 
vasospasm only develops in 50%. No animal in either nitrite group developed significant 
vasospasm, and the degree of clinically insignificant vasospasm correlated inversely with the 
level of nitrite measured in the cerebrospinal fluid. 
 
Asymmetric dimethyl-L-arginine (ADMA), a naturally-occurring NOS inhibitor was 
increased in patients with SAH and cerebral vasospasm (n = 12), compared to a control group 
without vasospasm (n = 5), which underscores the potentially important role of NO in this 
pathology. With these results in mind, a human trial of nitrite in sub-arachnoid haemorrhage 
began recruiting in 2009 (reported by Calvert and Lefer (Calvert and Lefer, 2010)). Systemic 
infusions of nitrite will be given for 14 days following confirmation of a ruptured cerebral 
aneurysm with the intention of providing both safety and efficacy data for a future therapeutic 
role. 
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 1.6. Nitrite in the treatment of systemic hypertension 
It is estimated that 11% of global disease is directly related to chronic hypertension (WHO 
2002). As discussed in the preceding section, nitrite causes vasodilatation in animal models 
(Kozlov et al., 2005; Modin et al., 2001) and human volunteers (Dejam et al., 2007; Maher et 
al., 2008). It is also cheap and orally bioavailable, both important attributes in a potential 
therapy. 
 
Prehypertension is defined as elevation of blood pressure above “normal” levels but below 
those that trigger treatment. As such, this condition is a product of national and international 
treatment guidelines, and the recognition that blood pressure is normally distributed across a 
population. Currently, prehypertension is diagnosed with a systolic blood pressure of 120-139 
mmHg or a diastolic pressure of 80-89 mmHg (Chobanian et al., 2003). It is felt that people at 
increased risk of developing hypertension may benefit from therapy, albeit in a less 
aggressive manner (Julius et al., 2006). Thus the risk-benefit balance is different; therapies 
must be safe and cheap. Dietary supplementation with nitrite has been suggested as a 
candidate that would meet these goals (Webb et al., 2008b). 
 
Supplementation of dietary nitrate by administration of sodium nitrate (0.1 mmol/kg/d) to 
healthy volunteers over 3 days reduced diastolic (but not systolic) BP by 3.7 mm Hg 
compared to sodium chloride (Larsen et al., 2006). In a later randomised open-label study of 
500ml beetroot juice or water, nitrate-rich (34.0 ± 0.1 mmol/L) beetroot juice caused a fall in 
systolic blood pressure of 10.4 ± 3.0 mm Hg at 2.5 hours (Webb et al., 2008b). The test 
substance contained undetectable amounts of nitrite, but spitting saliva, rather than 
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swallowing, during the period after ingestion abolished the effects. This intervention 
interrupts the enterosalivary circulation and prevented the rise in plasma nitrite seen in the 
swallowing group. Thus, the effects of an oral nitrate load were attributed to bacterial 
reduction of nitrate to nitrite in the mouth. 
 
Chronic kidney disease caused by long-standing hypertension is a major public health 
problem worldwide. Dietary nitrite at a very low dose prevents chronic renal injury caused by 
NOS inhibitor (Kanematsu et al., 2008) 
 
1.7. Nitrite in sickle cell disease 
Sickle cell disease (SCD) is a single gene recessive disorder with high prevalence in the black 
African population. It is caused by a single nucleotide substitution in the short arm of 
chromosome 11 (A to T), which leads to the replacement of glutamate with hydrophobic 
valine at position 6 of the β-subunit of haemoglobin. Haemoglobin S (HbS) thus formed is 
relatively normal at high oxygen concentrations but conformational change in low oxygen 
concentration exposes a novel hydrophobic patch. HbS then aggregates to form long chains, 
which distort red cells into the characteristic sickle shape. Heterozygotes show mild sickling 
of red cells and possess relative protection against malaria (known as heterozygote 
advantage), while homozygotes experience the full clinical spectrum of SCD. 
  
Polymerisation of HbS causes red blood cell rigidity, microvascular obstruction, inflammation 
and infarction. Red cell membrane damage leads to severe intravascular haemolysis and 
anaemia. The consequence of intravascular free haemoglobin is NO-scavenging, which causes 
a global deficiency of NO, leading to chronic vasoconstriction and activation of cell adhesion 
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molecules in both endothelium and platelets (Reiter et al., 2002). Deficiency of NO is 
exacerbated by the release of red cell arginase, which converts arginine to ornithine, thereby 
reducing the availability of substrate for NO synthase (Schnog et al., 2004; Morris et al., 
2005), and (as in subarachnoid haemorrhage) increased levels of the naturally occurring 
eNOS inhibitor, ADMA (Schnog et al., 2005). As a whole, this process causes a diffuse 
vasculopathy in sickle cell patients, with complications including: pulmonary hypertension, 
acute chest syndrome, marrow and fat infarction, multiple stroke, priapism, dactylitis, and 
cutaneous ulceration (Gladwin et al., 2004; Stuart and Nagel, 2004). Even with the best 
available therapy, life expectancy in SCD is severely reduced (Platt et al., 1994). 
 
1.7.1 Vaso-occlusive crisis in SCD 
Most patients with SCD experience intermittent painful episodes known as vaso-occlusive 
crises. Damage can occur in any organ but pain commonly results from bone or fat infarction. 
Abdominal organs may be affected, leading to generalised pain and jaundice, and irreversible 
organ damage may result. Acute chest crisis is a form of vaso-occlusive crisis, which can be 
fatal. 
 
The pathology of vaso-occlusive crisis is multi-factorial. Increased platelet activation in 
steady state SCD was noted over 25 years ago (Westwick et al., 1983), and it has since been 
discovered that activation increases during vaso-occlusive crisis (Wun et al., 1998). Again, 
the proportion of circulating platelets that are activated correlates well with intravascular 
haemolysis, and indeed pulmonary hypertension (Villagra et al., 2007). Increased sickling 
leads to mechanical blockage of flow, worsened by NO-scavenging and inflammation. 
Intravenous nitrite targets NO-release to areas of hypoxia and acidity, in ischaemia and 
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infarction. It can be theorised that NO-dependent vasodilatation would increase blood flow in 
vaso-occlusive crisis, but modulation of inflammation and cell adhesion may be equally 
important in this pathology. This two-pronged action makes nitrite particularly worthy of 
investigation in SCD. 
 
1.7.2 Nitrite as a therapy in sickle cell disease 
The best-characterised consequence of NO-scavenging in SCD is pulmonary hypertension. 
Pulmonary hypertension is an independent risk factor for death in SCD and is found in around 
30% of SCD patients. Even relatively mild elevations of pulmonary arterial pressure are 
associated with a 10-fold rise in early mortality (Gladwin et al., 2004). This risk is further 
increased when combined with left ventricular diastolic dysfunction (Sachdev et al., 2007). 
Rates of pulmonary hypertension are strongly correlated with lactate dehydrogenase levels (a 
red cell enzyme released in haemolysis), which supports a causative role of intravascular 
haemolysis in the development of this complication (Kato et al., 2006; Hsu et al., 2007). 
 
Inhaled NO reduced pulmonary and systemic vasoconstriction in a canine model of 
intravascular haemolysis (Minneci et al., 2005). Inhalation of the gas restored vascular 
reactivity to sodium nitroprusside (SNP) in this study, though it should be cautioned that SNP 
is not a pure NO-donor as claimed. A randomised double-blind placebo-controlled trial in 20 
children with SCD and veno-occlusive pain crisis showed significantly lower pain scores and 
patient-controlled morphine use in those given NO compared to placebo gas (Weiner et al., 
2003). However, inhaled NO is expensive and inconvenient to administer, and is therefore not 
an option outside acute hospital care. The effects of inhaled NO, which occur beyond the 
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physiological diffusion distance of this ephemeral gas, imply that the therapeutic benefit may 
rely upon nitrite as an intravascular intermediate (Cannon, III et al., 2001). 
 
The relative resistance to nitrite seen in these studies is consistent with the diminished 
response to other NO donors seen in mouse models and in humans with SCD (Reiter et al., 
2002; Eberhardt et al., 2003; Gladwin et al., 2003; Kaul et al., 2004). The mechanism of 
resistance is closely related to NO consumption by plasma cell-free haemoglobin (Hsu et al., 
2007) 
 
The ability to release NO in a hypoxia-targeted manner, coupled with the central role of NO-
deficiency in SCD, makes intravenous sodium nitrite an attractive candidate therapy in SCD. 
Preliminary data from the canine model of intravascular haemolysis provide reason for 
optimism with regard to potential benefits of nitrite therapy in PH and vaso-occlusive crisis. 
Nitrite appeared superior to SNP in both pulmonary and systemic vasodilatation in this model 
(Minneci et al., 2008). However, in one study of 14 SCD patients, brachial artery nitrite 
infusion produced a substantially smaller increase in forearm blood flow when compared to 
that in healthy volunteers (Mack et al., 2008). This blunting of vascular responsiveness was 
acknowledged to be typical of the response to NO-dependent therapies in SCD and should 
temper enthusiasm until trial evidence is available. 
 
Beyond SCD, haemolysis and NO-scavenging may underlie some of the adverse outcomes 
associated with transfusion of stored blood (Gladwin and Kim-Shapiro, 2009). It may be 
hypothesized that addition of nitrite to banked blood might be beneficial in this regard. 
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1.8. Nitrite in protection from ischaemia-reperfusion (IR) injury 
The phenomenon of reperfusion injury (i.e. injury distinct from that caused directly by 
ischaemia) was first described fifty years ago (Jennings et al., 1960). The hypothesis that such 
injury may be preventable led directly to the discovery of ischaemic preconditioning by 
Murry and colleagues (Murry et al., 1986), an experiment wherein four five-minute canine 
coronary artery occlusions, before a final ligation, reduced absolute infarct size by 23%. 
Ischaemic preconditioning proved to be the archetype for a host of protective stimuli, initially 
given before ischaemia, and subsequently after the onset of reperfusion. This latter is now 
known as postconditioning, and again an ischaemic stimulus is the gold standard (Zhao et al., 
2003). Ischaemic postconditioning has definitively entered the clinical arena, with a real-life 
reduction in peak creatine kinase (a marker of infarction), and improved ejection fraction 
(Hansen et al., 2010). Myocardium is the best-studied tissue, especially in terms of 
elucidation of the signalling pathways, but endothelial, renal, hepatic and brain tissues have 
all been shown to respond to similar stimuli and also represent legitimate therapeutic targets. 
 
1.8.1. Ischaemia-reperfusion injury 
Several factors contribute to ischaemia-reperfusion injury; including neutrophils cell 
adhesion, ATP depletion, generation of reactive oxygen species (ROS), and mitochondrial 
calcium overload (Buja, 2005). Seminal work by Crompton and colleagues proposed opening 
of the mitochondrial permeability transition pore (mPTP), a non-selective pore located on the 
inner mitochondrial membrane, as the critical determinant of cell death (Crompton et al., 
1987). Opening of this massive multi-potent channel results in loss of membrane selectivity; 
oxidative phosphorylation is uncoupled leading to ROS generation and energy loss; and 
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finally the mitochondrion swells and releases pro-apoptotic factors as the membrane breaks 
down, resulting in apoptosis or necrosis of the cell. 
 
Prevention of mPTP opening appears to be the final common pathway of ischaemic 
preconditioning and postconditioning. The pore is “primed” by pro-cell death factors, but 
remains closed in the acidic conditions of ischaemia (Griffiths and Halestrap, 1995). Opening 
of the mPTP therefore occurs in the first few minutes of reperfusion, affording a window of 
opportunity for therapeutic intervention that extends into the post-ischaemic period 
(Halestrap, 2009). Illustrating this phenomenon, a direct inhibitor of mPTP opening, 
sanglifehrin-A, reduces infarct size by 50% when given during the first 15 minutes of 
reperfusion, but fails to do so when administered later in this period (Hausenloy et al., 2003). 
 
1.8.2. Mechanisms of cytoprotection 
The evident risks of exposing tissue to repeated periods of ischaemia makes the identification 
of signalling pathways in cytoprotection, and therefore identification of downstream 
pharmacological stimuli, a priority. The pathways are detailed below and summarized in 
figure 1.2. 
 
1.8.2.1. RISK pathway 
The Reperfusion Injury Salvage Kinase (RISK) pathway, thus termed by Hausenloy and 
Yellon, was the first such signalling pathway described and remains the best studied 
(Hausenloy and Yellon, 2004). This pathway is activated in both ischaemic preconditioning 
and postconditioning, and involves binding of G-protein coupled receptors by their ligands, 
and downstream activation of PI3K and Akt, or activation of MEK then ERK (extracellular 
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regulated kinase). These kinases, perhaps combined in a “signalosome” (Garlid et al., 2009), 
travel to mitochondria and activate final common pathway targets, leading ultimately to 
prevention of opening of the mPTP. This is shown in more detail in figure 2. 
 
Cardio-protective signalling pathways within the mitochondrion have recently begun to be 
elucidated. Mitochondrial Protein Kinase Cε1 and 2 (PKCε1 and 2) have been identified as 
part of the final common pathway of cardio-protective signalling (Budas and Mochly-Rosen, 
2007). Activation of PKCε1 results in opening of mitochondrial ATP gated potassium 
channels (KATP), causing a small burst of reactive oxygen species (ROS) production by 
complex 1 of the respiratory chain. This small increase in ROS activates PKCε2, which 
inhibits mPTP opening and prevents cell death (Garlid et al., 2009).  
 
The difference between a small burst of ROS being essential and a large one being 
detrimental - the same being true of NO and also TNFα - mirrors the fundamental paradox of 
cardio-protection: short bursts of ischaemia are beneficial, while ischaemic damage results 
from longer exposure. 
 
1.8.2.2. SAFE pathway 
TNFα plays a well-defined role in inflammation and cell death, and has been hypothesised to 
exacerbate IR injury (Mann, 2003). Recent evidence suggests it is essential in both pre- and 
post-conditioning (Deuchar et al., 2007; Lacerda et al., 2009; Smith et al., 2002a) and 
activates a separate adaptive pathway in myocardial injury, termed the Survivor Activating 
Factor Enhancement (SAFE) pathway (Lecour et al., 2005). This pathway is shown in more 
detail in figure 1.2. 
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 1.8.2.3. Non-RISK non-SAFE signalling 
Adenosine protects independently of activation of Akt/Erk, and (at least the early part of) the 
RISK pathway (Schulz et al., 2001). However, TNFα knockout mice can still be 
preconditioned with adenosine, suggesting that neither is activation of the SAFE pathway 
required (Smith et al., 2002b). The presence of multiple pathways is suspected (Heusch et al., 
2008) but there may also be significant cross-talk between the classical RISK and SAFE 
pathways (e.g. Erk phosphorylates STAT-3 (Nakagami et al., 2001), at least in endothelium, 
and a SAFE pathway inhibitor also prevents MEK phosphorylation (Matsumiya et al., 2002). 
Definitive proof of separate non-RISK non-SAFE pathways would require studies in multiple 
knockout animals, with knockout, silencing or specific inhibition of critical steps in both 
pathways (Lecour, 2009). 
 
1.8.3. NO in cytoprotection 
Endogenous NO from eNOS is essential for ischaemic postconditioning (Penna et al., 2006) 
but not preconditioning (Schulz et al., 2004). However, exogenous NO does trigger 
preconditioning (Hataishi et al., 2006; Schulz et al., 2004). Even though ischaemic 
preconditioning appears not to require endogenous NO production, this result should be 
interpreted with caution as NO may be released by acid disproportionation or reduction of 
endogenous nitrite, independent of eNOS. Endogenous NO also has an important role in 
delayed preconditioning, through expression of iNOS (Bolli et al., 2007). The multiple levels 
of interaction of NO in cytoprotection are shown in figure 1.3. 
 
1.8.4 Nitrite in cytoprotection 
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As discussed in the previous section, nitric oxide plays a variety of roles in cytoprotection. 
Any of these entry points may potentially be accessed by nitrite, as a hypoxia-targeted store of 
NO. Mitochondrial exposure to nitrite causes nitrosylation of critical thiols on mitochondrial 
complex I, inhibiting it (Raat et al., 2009). Flux through the electron chain is reduced, which 
protects downstream complexes II-V from the increase in ROS associated with reperfusion. A 
wide variety of other mitochondrial proteins are also vulnerable to oxidative damage. 
Protection from damage prevents release of cytochrome c and induction of apoptosis (Shiva et 
al., 2007b).  
 
Nitrite-mediated protection is a recognized phenomenon in many different animal models, 
oral nitrate has been tested in humans, and several human studies of nitrite in IR injury are 
planned or underway but are some way from reporting (clinicaltrials.org). This rapidly 
growing field is summarized in the following sections. Where possible, doses are additionally 
given in the form µg/kg/min, for easier comparison. Even so, multiple routes of 
administration, among a variety of tissue models, make direct comparison challenging. 
 
1.8.4.1. Nitrite in the protection of myocardium 
NOS-independent generation of NO occurs in the ischaemic myocardium; this is attributed to 
reduction of the nitrite store (Zweier et al., 1995). Low pH, hypoxia and reduced substrate 
availability results in uncoupling of eNOS and markedly reduced production of NO, while 
also strongly favouring nitrite reduction.  
 
The first demonstration of preconditioning by nitrite was in the Langendorff isolated rat heart 
model in 2004 (Webb et al., 2004). Nitrite administered immediately before reperfusion (48 
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nmol, ~110 µg/kg, intraperitoneally) produced a 67% reduction in infarct size in the whole 
mouse (Duranski et al., 2005). Preconditioning with nitrite depends upon on the opening of 
KATP channels (Baker et al., 2007) and was abolished in both animal models by addition of an 
NO scavenger (carboxy-PTIO), implying a free NO intermediate. Interestingly, in the second 
study (Duranski et al., 2005) there was a biphasic dose-response, with the top dose of 1920 
nmol (~ 4 mg/kg) providing no protection. 
 
Nitrite confers delayed preconditioning (i.e. when the preconditioning stimulus is delivered 
24-72 hours before ischaemia, sometimes known as “second-window”) (Shiva et al., 2007b), 
which may underlie the protective effects of high-NOx diets, such as the “Mediterranean Diet” 
(Raat et al., 2009). The short half-life of nitrite in vivo suggests a mechanism involving post-
translational modification (Shiva and Gladwin, 2009). Nitrite also protects myocardium when 
administered after the onset of ischaemia. This is termed peri- or per-conditioning, and is 
generally thought to be more similar to postconditioning than preconditioning, given that 
signalling molecules are unlikely to reach the ischaemic tissue in any quantity until 
reperfusion. Recently, Gonzalez and colleagues demonstrated a 34% absolute reduction in 
infarct size (from 70 ± 10% to 36 ± 8%) in a canine model, where nitrite was given during the 
last five minutes of a two hour ischaemic period (Gonzalez et al., 2008). A significant 
increase in the levels of S-nitrosylated proteins was detected following the 60-minute 
infusion. However, after the 5-minute infusion, protection occurred in the absence of any 
significant increase in nitrosylated species. This suggests that nitrite itself is the primary 
mediator of protection (Gonzalez et al., 2008). 
 
1.8.4.2. Nitrite in the protection of endothelium 
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Endothelium is uniquely sensitive to ischaemic injury (Mankad et al., 1997), and endothelial 
dysfunction is a ubiquitous finding in cardiovascular disease in general. In contrast to other 
tissue models, endothelial IR injury is more difficult to study in animals than in humans, 
which may explain the lack of data on endothelial protection by nitrite. 
 
Webb and colleagues, in the second part of the study on blood pressure reduction discussed in 
section 1.6., found that ingestion of beetroot juice (500 ml, 2 hours before ischaemia, 
containing 45.0 ± 2.6 mmol/L nitrate and undetectable nitrite) prevented ischaemia-induced 
endothelial dysfunction as measured by flow-mediated dilatation (FMD) (n = 10, p < 0.05) 
(Webb et al., 2008b). FMD is more convenient than venous-occlusion plethysmography 
(VOP), as it is quicker to perform and does not require arterial cannulation. However, it has 
the disadvantage that only one level of flow stimulus can be assessed before and after 
ischaemia, and the error associated with measuring arterial diameter by ultrasound is high. In 
this context, the group numbers are quite low. Unfortunately, the elegant spit-swallow 
differentiation of nitrite vs. nitrate effects was not performed in this part of the study. Even so, 
these data provide indirect evidence that nitrite might have an effect in first window 
preconditioning (stimulus given in the 1-2 hours before ischaemia). We decided to investigate 
the more clinically relevant windows – delayed (or second-window) preconditioning 
(stimulus given 24-72 hours before ischaemia), and periconditioning (stimulus given during 
ischaemia and before reperfusion). These experiments are reported in Chapter 6. 
 
1.8.4.3. Nitrite in the protection of kidney, liver and brain 
Nitrite has been investigated in the prevention of renal IR injury (Tripatara et al., 2007). 103 
male Wistar rats were subjected to 60 minutes of bilateral renal ischaemia and 6 hours of 
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reperfusion. Rats were randomly allocated to 3 groups: saline placebo, 30 nmol sodium nitrite 
administered topically 1 minute before reperfusion, and 30 nmol (~0.4 µg/kg/min) nitrite 
intravenously 1 minute before reperfusion. Renal injury was estimated by measurement of 
serum AST, and dysfunction by serum creatinine. The authors showed a significant 
attenuation in both renal injury and glomerular dysfunction in the topical nitrite group (n = 12 
vs. 6 for each, p < 0.05 compared to IR alone) but the effect sizes were modest (~20% 
absolute reduction of creatinine rise, ~30% absolute reduction in AST rise). Surprisingly, 
systemic administration of nitrite had no effect on any parameter. These two results challenge 
interpretation of the finding that allopurinol abolished protection by nitrite, and the authors 
claim of a central role for xanthine oxidase (Tripatara et al., 2007). It should be noted that 
larger reductions in renal dysfunction were shown in a later study in mice from the same 
group, previously discussed in section 1.3.1. (Milsom et al., 2010). 
 
Duranski and colleagues, in the study discussed above, additionally showed that 
intraperitoneal injection of 48 nmol (~110 µg/kg) sodium nitrite entirely prevented the rise in 
AST after hepatic IR (Duranski et al., 2005). The NO-scavenger carboxy-PTIO prevented this 
protective effect, and only the most effective dose of nitrite was assessed in the liver. A study 
by Lu and colleagues of a similar vintage reported protection of the liver from IR injury in 
rats (Lu et al., 2005) with a central role proposed for xanthine oxidase. Unusually, all animals 
were given sodium nitrite (2 mg/kg intraperitoneally, 45 minutes before ischaemia). This is a 
large dose, especially since IP nitrite is well absorbed and quickly distributed (Bryan et al., 
2005), and since there was no group without nitrite, it is difficult to evaluate the extent of the 
proposed inhibitory effect of allopurinol. In the previous study, 4 mg/kg was found to provide 
no protection to the myocardium, as it was at the top of the biphasic dose-response. It is 
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certainly possible that the dose chosen in the latter study is too high to provide meaningful 
support for the role of xanthine oxidase in this model.  
 
In a more recent study of hepatic IR injury, dietary supplementation of nitrate or nitrite was 
given to mice in order to replicate the cardioprotective “Mediterranean Diet”. Mice given 
either natural nitrate or a low NOx diet supplemented with nitrite were protected from hepatic 
IR injury, as measured by release of ALT and AST, compared to those on the low NOx diet 
alone (Raat et al., 2009). Low NOx mice were given de-ionised water to remove that source of 
dietary NOx. As expected, plasma nitrite was much lower in the low NOx group (29 ± 2 μM, 
n = 12) compared to the group given 300 mg/L sodium nitrite in the drinking water (47 ± 5 
μM, n = 12), which were similar to those in mice on a normal chow/normal water diet (54 ± 7 
μM, n = 12). An immediate concern is that all these levels are rather high compared with 
other published literature (van Faassen et al., 2008) – in fact the low NOx mice had plasma 
nitrite levels well above what is considered normal elsewhere. It is unlikely that this simply 
relates to the mouse strain, C57bl6 mice were used, and perhaps merely underscores the 
variability of NOx levels seen across the literature. 
 
Jung and colleagues investigated the protective effects of sodium nitrite and nitrate in a rat 
model of brain IR injury (Jung et al., 2006). 48, 480 or 4800 nmoles sodium nitrite (in a 
volume of 500mcL PBS) was infused into the tail vein during the first minute of reperfusion. 
This is equivalent to 16.5 - 1656 µg/kg/min for 1 minute. 48 nmoles and 480 nmoles nitrite 
protected (with a 33% and 77% reduction in infarct size respectively, n = 12, p < 0.05 for 
both). The top dose of nitrite (4800 nmoles) showed no reduction in infarct size, and nor did 
480 nmoles of sodium nitrate. Carboxy-PTIO given 30 minutes before ischaemia prevented 
- 36 - 
the protective effect of nitrite. Functional recovery was better in the nitrite-treated groups 
after 1 day (p < 0.05), but the clinical significance of functional tests using groups of only 3 
animals is questionable. Later, the same group demonstrated that the protective effect of 
nitrite was still present when given at the same dose up to 3 hours into reperfusion (Jung et 
al., 2009). Biochemical study of neuroglobin using absorption spectroscopy suggests that this 
newly characterised heme-globin should be at least as capable as myoglobin of acting as a 
nitrite reductase in hypoxic conditions, and may in fact be a less avid scavenger (Petersen et 
al., 2008). Interestingly, in this study cytoglobin was unreactive with nitrite. The presence of 
neuroglobin may make brain tissue particularly susceptible to NO-overload when treated with 
nitrite, potentially shedding some light on the result above. 
 
In contrast to the results above, Schatlo and colleagues found that nitrite in combination with 
thrombolysis (with rtPA) did not provide any additional protection over thrombolysis alone, 
in a model of middle cerebral artery stroke (Schatlo et al., 2008). The investigators in this 
study administered a bolus then 7.5 or 0.5 µmol/L sodium nitrite for 50 minutes, which even 
at the low dose amounted to ~9mg/kg in total. This total dose is very high, even though the 
authors claim that the infusion rate is comparable to previous work, and this may account for 
the lack of effect. 
 
1.8.4.4. Nitrite in organ transplantation 
A major cause of graft failure in liver and lung transplantation is IR injury (Calvert and Lefer, 
2010), making studies of nitrite in this area a priority. So far there are no published studies of 
nitrite in human transplantation, but inhaled NO has had success in both transplantation of the 
lung (Yerebakan et al., 2009) and of the liver (Lang, Jr. et al., 2007). However, the objections 
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to inhaled NO on the grounds of cost and invasiveness still apply. Dietary nitrite prevented 
rejection of cardiac allografts in one study in the rat (Zhan et al., 2009). Unfortunately, the 
authors give only (undistinguished) plasma NOx levels making interpretation of the dose the 
rats actually received even more challenging than usual. On the basis of an approximate 
doubling of plasma NOx, it would seem that the dose is at least similar to previous dietary 
supplementation studies (Raat et al., 2009; Shiva et al., 2007b). All rats received 
immunosuppression with tacrolimus, a calcineurin-inhibitor, at a dose of 0.5 mg/kg/day for 7 
days to prevent acute rejection. Clearly, the subsequent high rate of graft failure is due to the 
lack of immunosuppression, and so direct comparison to the human (who continues 
immunosuppressive therapy beyond the acute rejection stage) is not possible. Still, this study 
provides proof-of-concept for future investigation. Overall, a range of windows and doses 
have been tested in vitro and in animal models, but there has so far been very little clinical 
translation of the protective effects of NO and nitrite. 
 
1.9. Concluding remarks and hypothesis 
The study of the physiology and clinical potential of the nitrite anion is a rapidly advancing, 
and occasionally controversial, field. Much has been discovered in the last 10 years, but many 
important questions remain; these include:  
 
1. What is the predominant nitrite reductase in vivo in physiological conditions?  
2. Does hypoxia-dependent vasodilatation give nitrite an advantage over current 
vasodilators?  
3. Does nitrite protect against ischaemia-reperfusion injury in humans?  
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In this thesis I will present several groups of experiments, each intended to provide answers to 
these important questions and, ultimately, to assess the future of the nitrite anion as a 
therapeutic agent in cardiovascular disease. First, I present experiments comparing 
vasorelaxation in mouse aortas, using transgenic mice and virus vectors, in order to 
investigate the role of this vascular wall heme-protein in nitrite metabolism. I will show that 
myoglobin is an important bioconverter of nitrite, at least in hypoxia, and may play an 
important role in vasorelaxation by nitrite in vivo. Myoglobin contributes to a prolonged 
vasorelaxation by nitrite, as well as the phenomenon of hypoxia-potentiated vasorelaxation, 
both of which were initially observed in human forearm studies, and may be useful in the 
treatment of heart failure. 
 
The second group of experiments investigates the safety and feasibility of nitrite infusions in 
severe heart failure, making use of the phenomenon of hypoxia-augmented vasorelaxation 
investigated in the preceding chapter. Five-minute infusions of nitrite produced varied and 
generally beneficial haemodynamic effects in severe heart failure, though this was at the 
expense of the development of methaemoglobinaemia. I went on to investigate the 
development of methaemoglobinaemia during longer infusions in healthy volunteers, in order 
to establish a safe dose of nitrite. Having established a safe dose, I investigated whether the 
beneficial haemodynamic effects would persist over the course of longer infusions in patients 
with heart failure.  
 
The third group of studies assesses the ability of nitrite-infusion to act as a cytoprotective 
agent, using the human forearm model in healthy volunteers, with Mendelian randomisation 
to elucidate the role of ALDH2 in this phenomenon. Previous work has suggested that 
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cytoprotection by a variety of stimuli proceeds through activation of ALDH2. I will show that 
a ten-minute systemic infusion of nitrite, given 24 hours before the onset of an ischaemic 
insult, prevents endothelial ischaemia-reperfusion injury. The same infusion, given during the 
last ten minutes of ischaemia, protected those with the variant ALDH2*2 enzyme, but not 
those with the wild-type *1 enzyme. This result was contrary to our initial hypothesis, and I 
present preliminary data to begin to explain this unexpected result. 
 
Hypothesis: 
We aimed to test the hypothesis that the nitrite anion, at least in part through reduction to 
nitric oxide by heme proteins (including myoglobin), causes beneficial vasodilatation in heart 
failure and protects against ischaemic injury. 
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1.10. Tables 
 
Table 1.1. 
 
 
 
 
 Arterial Venous 
Nitrite (NO2-) 540 ± 74 nM 466 ± 79 nM 
Nitrate (NO3-) 40.7 ± 4.5 μM 41.3 ± 4.5 μM 
SNO-Hb 161 ± 42 nM 142 ± 29 nM 
 
Table 1.1: Plasma levels of NOx and nitrosylated Hb in humans on a normal diet  
Data from van Faassen et al., 2009; Dejam et al., 2005. Note the arterial to venous plasma 
nitrite gradient. 
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Table 1.2. 
 
 
 
 
 [Nitrite] 
(μM) 
Mouse   
Plasma 1.6 - 20 
eNOS-/- Plasma 0.7 ± 0.1 
Rat   
Plasma 0.3 - 10 
Heart 0.8 ± 0.1 
Liver 0.5 ± 0.1 
Kidney 0.6 ± 0.1 
Lung 0.5 ± 0.1 
Brain 1.7 ± 0.3 
Aorta 22.5 ± 9.2 
 
Table 1.2: Plasma and tissue nitrite levels in mice and rats 
Note the wide range of values reported for plasma nitrite. Data from Bryan et al., 2004; 
Tracey et al., 1995; Godecke et al., 1998. 
- 42 - 
1.11. Figures 
 
Figure 1.1. 
 
 
 
 
 
Figure 1.1: Exercise hyperaemia proceeds through several distinct and overlapping 
pathways 
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Figure 1.2. 
 
 
 
 
 
 
Figure 1.2: The RISK and SAFE pathways in cytoprotection 
These pathways are stimulated by ischaemic preconditioning and postconditioning, and exert 
downstream mitochondrial effects leading to protection from IR injury. 
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Figure 1.3. 
 
 
 
Figure 1.3: Nitric oxide interacts with established pathways of protection at multiple 
levels 
NO can activate the SAFE pathway. NO is released by Akt (RISK pathway) and STAT3 
(SAFE pathway) through activation of eNOS and induction of iNOS respectively. Activated 
PKCε1 phosphorylates and opens KATP channels, causing increased K+ uptake, increased 
pH and increased ROS. ROS stimulate both PKCε1 and PKCε2, the latter inhibiting the 
mPTP, leading to protection. NO can also directly stimulate PKCε2 and can inhibit complex I 
in a protective manner. 
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2. METHODS 
 
This chapter contains generic methods for techniques used in chapters 3 - 6. 
 
2.1. Mouse aortic myography 
 
2.1.1 Generation of myoglobin-deleted mice 
The myoglobin-deleted mice used in the experiments presented in chapter 3 were developed 
and kindly provided by Professor J. Schrader of Heinrich-Heine-Universität, Düsseldorf 
(Godecke et al., 1999). In brief, the vital heme-binding site encoded in myoglobin exon 2 was 
replaced by the neomycin-resistance gene in embryonic stem cells. Correctly targeted clones 
(3 of 98 screened) were identified using PCR (Primers:  Myo, 59-
GAGGGAGCTGGTGTCAACAG-39; neo, 59- TTGCAAAACCACACTGCTC-39) and were 
subsequently aggregated with 2.5-day old mouse embryos to generate chimeric mice (NMRI 
background). Heterozygous mice were rederived by the Biomedical Services Unit in 
Birmingham University and genotyped to identify homozygous animals. Where possible, 
littermate wild-type mice were used as controls in these experiments, but unrelated NMRI 
mice were also used. 
 
2.1.2. Preparation of tissue 
Mice were housed in an environment that conforms to the requirements set down in the 
Scientific Procedures (Animals) Act 1986. They were kept three to a cage, with bedding and 
environmental enrichment. Photoperiod was maintained in a 12:12 reversed light: dark cycle. 
Experiments were performed on male C57/BL6 mice (in-house), myo (colony), or NMRI 
mice (from colony or Charles Rivers) as indicated. All animals were provided with food 
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pellets (SDS RM3 diet, Lillico) and water ad libitum. Cage temperature was maintained at 21 
± 2ºC. Animal weights were recorded twice weekly during which cage cleaning took place. 
The colony was held under the authority of the Candidate’s personal licence (#23502). All 
experiments were done on tissue harvested after schedule 1 killing, and so were exempt from 
the requirement for a project license. 6-7 week old male mice were killed humanely by 
cervical dislocation. Female mice were not used so as to avoid any effects of the oestrus cycle 
on vascular function.  
 
The thoracic aorta from the arch to the diaphragm was removed en bloc and immediately 
immersed in ice-cold oxygenated buffer. Krebs-Hensleit buffer was used throughout, with the 
following composition: NaCl 120.0 mM, KCl 4.7 mM, MgSO4 1.2 mM, K2PO4 1.2 mM, 
Glucose 11.0 mM, CaCl2 2.5 mM, NaHCO3 25 mM. All chemicals were obtained from 
Sigma-Aldrich Co (St Louis, Missouri, USA), apart from sodium nitrite (Martindale 
Pharmaceuticals, Romford, UK). All adherent fat and adventitia was stripped under direct 
vision using a variable-magnification binocular microscope (Carl Zeiss AG, Jena, Germany), 
taking care not to over-stretch the aortic tissue. The tissue was held by pieces of adherent fat 
using two microsurgery forceps, which were then distracted. The effect is to remove fat from 
the aorta with as little stress on the muscular wall as possible. The endothelium was removed 
by bubbling vigorously with air; a 1ml syringe and 23G needle were used for this purpose.  
 
2.1.3. Myography 
The aorta was cut into four 2mm rings and hung in a four-well wire myograph (Danish Myo 
Technology model 610M, A/S, Denmark) in Krebs-Hensleit buffer. The experimental setup is 
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shown in figure 2.1. The strain gauge was calibrated using the moment force of a known 
weight (1g = 9.81 mN), as below: 
 
For each experiment, the rings were attached to an isometric tension transducer and resting 
tension was increased stepwise (5 mN increase every 15 minutes) to a maximum of 20 mN. 
This resting tension is estimated to exert 90% of the wall tension, T, that would be 
experienced by the artery at a blood pressure of 100 mmHg, where T = 100(internal 
circumference/2π). This optimal resting tension was determined in a preliminary experiment: 
rings were mounted and the internal circumference was increased stepwise, using the built-in 
micrometer. The developed increase in force was measured by the force transducer and 
recorded as below:  
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 When plotted, this produces an exponential curve, which intersects the straight line T = 
100(internal circumference/2π), as below, giving the wall tension value for 100 mmHg: 
 
The myograph wells were cleaned after each experiment by rinsing several times with double 
distilled water, incubating each chamber with 1 M HCl for 15 minutes, and again rinsing 
several times with water.  
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In each run, the segments were preconstricted with 50 mM KCl or 1 μM phenylephrine. This 
response was allowed to plateau at a higher tension force. Rings that failed to develop an 
additional 5% of the resting tension on preconstriction, were discarded as the response to 
vasodilators would be too small to measure accurately. The response to vasodilators was 
measured as the percentage reversal of this preconstriction, averaged over at least two 
segments. An example trace is shown in figure 2.2. 
 
2.2. Polymerase chain reaction and immunoblotting 
These experiments were performed by the candidate under supervision in Prof Watkins’ 
group in Oxford University. 
 
2.2.1 RNA extraction and PCR from aortic rings 
Fresh tissue was harvested from myo-/- and NMRI mice to perform analysis of RNA and 
protein content. Several aortas were pooled in each group on order to gain sufficient quantities 
of RNA and protein. Tissue RNA was extracted from aorta and heart (as a positive control) 
using the Tri-reagent system (Applied Biosystems, Foster City, California, USA). The reagent 
contains a high-salt solution of guanidine thiocyanate and phenol. Homogenised tissue is then 
separated into an aqueous and organic phase by adding bromochloropropane (BCP). RNA 
partitions to the aqueous phase (ready to be precipitated, washed, quantified and used), DNA 
to the interphase (which was discarded in this experiment) and protein to the organic phase. 
Tri-reagent has the advantage over spin-column based methods of RNA extraction as the yield 
is often higher, with less contamination. Each aorta weighs approximately 2 mg, and 
myoglobin is a relatively rare transcript, so maximum yield was considered essential. With 
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this system, yield is approximately 1-1.5 µg RNA per milligram of tissue. The protocol was as 
follows: 
 
− Tissue was homogenized with a blade homogeniser, in 10-20 volumes of Tri-reagent 
and incubated for five minutes at room temperature 
− 100 µl BCP was added, incubate at room temperature for 15 minutes and centrifuge 
(12,000g for 15 minutes) to separate into aqueous and organic phases 
− The aqueous phase (RNA) was separated to a new tube, the interphase (DNA) was 
discarded and the organic phase (Protein) was frozen for later use 
− RNA was precipitated using isopropanol (500 µl per ml of initial Tri-reagent) 
− Centrifuge at 4°C (12,000g for 8 minutes) and discard supernatant 
− The pellet was washed with 75% ethanol (excess removed) and briefly air dried 
− The pellet was then suspended in ultrapure water 
 
RNA was quantified using a commercial analyser (Nanodrop spectrophotometer, Thermo 
Scientific, Waltham, Massachusetts, USA). The Nanodrop system requires only a very small 
volume (0.5 µl) to measure RNA content very accurately, and can also quantify 
contamination with DNA or RNA. It removes the need for a glass or plastic cuvette by 
creating a tube of solution between light source and detector. Effectively, the air-solution 
interface created by the surface tension of the drop of solution acts as the walls of the cuvette. 
cDNA was prepared using a reverse transcriptase kit (Promega, Fitchburg, Wisconsin, USA). 
20 μl reaction volumes contained the following: 25 mM MgCl2, 10X Buffer, 10 mM dNTP 
mixture, 25 u ribonuclease inhibitor, 15 u reverse transcriptase, 0.5 μg random primers, 1 μg 
total RNA, and nuclease-free water to make up volume. The mixture was incubated at room 
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temperature for 10 minutes, then at 42°C for 60 minutes, then at 95°C for 5 minutes and at 
5°C for 5 minutes. These last two steps inactivate the reverse transcriptase enzyme and 
prevent it binding the cDNA product. 
 
40 cycles of PCR were performed using cDNA to the following protocol: Melt at 95°C for 1 
minute, anneal at 55°C for 1 minute, elongate at 72°C for 1 minute, repeat x 39. Each reaction 
mixture contained 500 ng template DNA, 200 nM forward and reverse primers, 10X reaction 
buffer with 15 mM MgCl2, 200 μM dNTPs, Taq polymerase (all Promega, as before), and 
sterile water to make up reaction volume of 20 μL. Primer sequences and protocol are given 
below. 
 
Murine primer sequences:  
Myoglobin f: ATGGGGCTCAGTGATGGG  r: TCAGCCCTGGAAGCCTAGCT 
sGC f: CCCCTGGTCAGGTTCCTAAG  r: GGAGACTCCCTTCTGCATTCT ;  
GAPDH f: TCCCACTCTTCCACCTTC r: CTGTAGCCGTATTCATTGTC 
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2.2.2. Protein extraction and western blotting of aortic rings 
The Tri-reagent system was less successful for protein extraction in our hands. We therefore 
used fresh tissue samples, which were snap frozen for storage and subsequently blade-
homogenized in lysis buffer (25 mM Tris/HCl, pH 7.4, 1 mM EDTA, 1% SDS, 1 mM 
dithiothreitol and complete-mini protease inhibitor cocktail tablet (Roche Applied Science, 
Basel, Switzerland) and then boiled with Lamelli buffer. The general principle of western 
blotting is as follows: proteins are separated by mass, each sample using a separate vertical 
lane, and then transferred to a porous membrane. The membrane is incubated with antibodies 
specific to the target proteins, along with random protein (milk powder) to block non-specific 
interaction. The membrane with bound antibody is then incubated a second time with 
antibody specific to the Fc (constant) domain of the species of antibody used (in this case goat 
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IgG specific to rabbit Fc). This antibody construction is fluorescent and can be quantified 
using a digital CCD in darkness. 
 
SDS-polyacrylamide gels are used to separate proteins of different sizes. The pore size, and 
hence speed at which protein moves through the gel, depends upon the acrylamide 
concentration chosen (and so the number of cross-links formed). The size of the pore 
decreases as the polyacrylamide: bis ratio increases, making correct gel choice for a given 
polypeptide length absolutely critical. The gel consists of stacking and resolving components. 
Gels were mixed and poured into 1 mm plastic cassettes (NC2010, Invitrogen, Carlsbad, 
California, USA) with the following composition (15% gel; Tris HCL 375 μM (Stock 1 M, 
pH 8.8), Tetramethylethylenediamine (TEMED) 5.6 μM, Acrylamide/Bis-Acrylamide 
(ACR/BIS) 15 % (w/v), Ammonium persulfate (APS) 0.1 % (w/v), Sodium dodecyl sulfate 
0.1 % (w/v)).  Gels were topped with isopropanol and left to polymerise for 45 minutes. The 
addition of isopropanol produces a smooth surface at the interface between the stacking and 
resolving gels. Once the resolving gel was fully polymerised the isopropanol was poured off 
and replaced with a 5% stacking gel (Tris HCL 130 μM, TEMED 8.6 μM, ACR/BIS 5%, APS 
0.1% (w/v), SDS 0.1% (w/v)), and combs for the loading lanes were inserted before the 
acrylamide had polymerised.  
The combs were carefully removed, leaving loading lanes for protein samples. The tank is 
filled with electropheresis running buffer and loaded with two cassettes. 10 μL of sample was 
added to 5 μL of loading buffer (TRIS 60mM, Glycerol 25% (v/v), SDS 2% (v/v), β1-
mercaptoethanol 14.4mM, bromophenol blue) samples were heated to 95ºC for 3 minutes to 
denature secondary structure and each sample was then loaded into a lane. SDS is an anionic 
detergent that denatures the secondary and non–disulfide–linked tertiary protein structures, 
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and applies a negative charge to each protein in proportion to its mass (allowing for a linear 
relationship between migration and mass during electrophoresis). β-mercaptoethanol is 
included to disrupt disulphide bonds within the sample. Glycerol increases the density of the 
sample, to ensure it sinks to the bottom of the well. One well in each gel was loaded with 10 
μL of a pre-prepared standard that contains proteins of a known molecular weight. 100V is 
applied across the stacking gel, this is increased to 150V in the resolving gel, and continues 
until the bromophenol dye reaches the bottom of the gel.  
Gel-separated proteins were transferred to a polyvinylidene difluoride (PVDF) membrane 
(pore size 0.4 μm, Millipore, Fisher), pre-soaked in 100% methanol for 15 seconds. PVDF 
membrane, scotch brite pads and filter paper were soaked in transfer buffer (TRIS 25 mM, 
Glycine 192 mM, methanol 20% (v/v)). The stacking gel was removed from the resolving gel 
and discarded. The gel was then added to a sandwich constructed as below. From the bottom 
up this consisted of: negative cathode, fibre pad, filter paper, resolving gel, and PVDF 
membrane. The sandwich is completed with a second layer of filter paper, another fibre pad 
(or more if required) and the positive anode. Each layer was rolled to remove air bubbles, 
which would otherwise prevent efficient protein transfer. The tank was placed in a 
refrigerated room and run at a voltage of 25V for 12 hours.  
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The PVDF membrane saturated with 5% fat-free milk in 0.1% Tween-20 (Sigma-Aldrich, St 
Louis, Missouri, USA) in phosphate buffered saline (PBS) (blocking solution) and hybridised 
with α-myoglobin rabbit polyclonal antibody (Santa Cruz, (FL-154) sc-25607) at 1:1000 
dilution overnight at 4°C. The membranes were washed four times (10 minutes each at RT) 
with 0.1% Tween-20 in PBS and then incubated with goat anti-rabbit IgG (HRP) (Abcam 
ab2721-1) at 1:4000 dilution for 1 hour at room temperature, washed four times and finally 
visualized with the ECL advance immunoblotting detection system (GE Healthcare, Little 
Chalfont, Bucks, UK). 
 
2.3. Measurement of intra-cardiac pressures 
The pulmonary artery catheter (PAC) has been in clinical practice since its invention in 1970 
by Swan and Ganz of the Cedars-Sinai Medical Centre (Swan et al., 1970). It can be used to 
measure the pulmonary capillary wedge pressure (a surrogate of left ventricular end diastolic 
pressure or left atrial “filling pressure”), pressures in the right ventricle and atrium, and 
cardiac output by the thermodilution method. The same basic design has been widely used for 
over thirty years. Its popularity has waned somewhat in recent times due to large-scale studies 
failing to show an improvement in mortality or length of ITU stay (Sandham et al., 2003); 
importantly, in these studies there was no increase in mortality associated with the use of a 
PAC (Harvey et al., 2005). They are still commonly used in investigation, intensive care and 
high dependency contexts: over 1 million PACs per year are inserted in clinical practice in the 
USA alone. The risks of pulmonary artery catheterisation are markedly reduced by operator 
experience and good patient selection. The most severe complication is pulmonary artery 
rupture, which is uncommon (<1%) but more likely in high-risk patients (those with severe 
pulmonary hypertension or receiving anticoagulants). 
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The distal lumen is at the tip of the PA catheter, with a 1.5 cubic cm balloon positioned just 
proximal to this. Proximal to the balloon is a thermistor, which may be used to measure 
temperature changes over time for the thermodilution method of calculation of cardiac output. 
The catheter has two additional lumens at 19 cm and 30 cm proximal to the tip, residing 
approximately within the right ventricle and right atrium (or superior vena cava). The basic 
design is shown below: 
 
A sheath is inserted into the right internal jugular vein under sterile conditions with lignocaine 
local anaesthetic (1%, 10mg/ml, maximum 3mg/kg), using the Seldinger technique. The 
Seldinger technique describes the use of a guide-wire, which is initially inserted into the 
jugular vein down the lumen of a wide-bore seeker needle. “Flashback” of venous blood 
confirms correct positioning of the seeker needle though care must be taken to ensure the 
carotid artery is not cannulated. The sheath is then threaded over the guide-wire, which is then 
withdrawn, and position is confirmed with fluoroscopy. The PA catheter is inserted into the 
sheath, with the natural curve pointing to the patient’s left shoulder, after being attached to 
monitoring equipment to measure pressure waveforms. A non-compressible tube with a 
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column of heparinised saline leads from the PA catheter tip to a fluid-filled pressure 
transducer. This transmits pressure measured at the tip and must be calibrated to ambient air 
pressure by opening the distal end to the air and zeroing the measuring equipment. The 
catheter is advanced to the right atrium using the pressure trace as a guide, or fluoroscopy 
depending upon operator preference. Pressure waveform is recorded in the right atrium 
(figure 2.3a), and the catheter is advanced through the tricuspid valve. The pressure 
waveform changes to reflect the new position.  
The catheter is turned one-quarter clockwise to aim cranio-postero-medially, and the balloon 
is inflated to “float” the catheter tip into the right ventricular outflow tract, where it is 
followed with fluoroscopy into the pulmonary artery at about 40 cm of insertion. The pressure 
waveform can be measured in the PA (figure 2.3b) and, by inflating the balloon, the 
pulmonary capillary wedge pressure (PCWP) is achieved (figure 2.3c). The balloon prevents 
anterograde flow from proximal to the tip. The pressure at the tip therefore equalises across a 
continuous column of blood to the left atrium, thereby approximating to left atrial pressure. 
Example pressure waveform traces are given in figure 2.3. Each value used was an average of 
at least three cardiac cycles and was measured by an expert technician. 
Resistance to flow is given by the change in pressure across a vascular bed, divided by the 
rate of flow. The rate of flow through both the pulmonary and systemic circulations must be 
equal and equivalent to the cardiac output. Pulmonary vascular resistance is given by the 
calculation: 
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The normal range is 1.25 – 2.5 wood units (mmHgminL-1). Systemic vascular resistance is 
given by the calculation: 
 
The normal range is 11 - 15 wood units. The trans-pulmonary gradient (PA - PCWP) is an 
important prognostic factor in transplantation. If this value is > 12 mmHg, and not reversed 
by vasodilators, the patient is generally considered ineligible for transplantation. This is 
because the recipient’s right heart will be accustomed and have adapted to high pressures, for 
example with a degree of muscular hypertrophy, but the donor heart will not. Exposing a 
naïve heart to such pulmonary pressures is likely to result in catastrophic failure of the right 
ventricle and death of the patient. 
 
2.4. Measurement of forearm blood flow 
Venous occlusion plethysmography (VOP) is a long-established technique and is considered 
the gold-standard against which other techniques are assessed (Roddie and Wallace, 1979). 
VOP has been used to study forearm blood flow responses for more than 90 years, though the 
method has been much simplified with the advent of mecury-in-silastic strain gauges, which 
are used in place of the original, unwieldy water jackets (Benjamin et al., 1995)). The same 
technique can be used to measure baseline endothelial function between different groups of 
patients, or, as in the present work, the endothelial response to ischaemia-reperfusion injury. It 
has become a commonly used technique to assess preconditioning agents in man. 
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The alternative is flow-mediated dilatation (FMD). The technique relies on the physiological 
phenomenon whereby shear stress in the brachial artery (induced by a sudden increase in 
flow) leads to dilatation of the vessel. The dilatation relies on intact endothelium. Briefly, a 
cuff is inflated on the forearm (or upper arm in an alternative technique) and released while 
the brachial artery is visualised with ultrasound. The diameter before and after the flow 
stimulus can be measured later and a ratio determined. This ratio is proportional to endothelial 
function and so can be used to measure the effect of forearm ischaemia. FMD provides a 
single ratio whereas VOP measures endothelial function at three levels of ACh infusion. The 
spatial resolution of ultrasound also reduces the sensitivity of the technique. Due to these 
limitations, despite the clear advantage of not requiring cannulation of the brachial artery, we 
chose to use VOP in these experiments. 
The patient sits upright in bed, with both arms outstretched at the level of the heart (figure 
2.4). The hands are excluded from the circulation during measurement periods by inflation of 
a wrist cuff to 200 mmHg or 20 mmHg above systolic blood pressure (whichever is the 
greater). Blood flow in the hands is predominantly to the skin, with a great number of arterio-
venous shunts as part of temperature regulation. These features contribute to a different 
pharmacology overall in the hands compared to the forearm (Robinson, 1984; Collier and 
Robinson, 1974). Forearm blood flow (FBF) is measured by occluding venous outflow (with 
a rapid-inflation cuff at 40 mmHg), and recording the rate of increase of forearm 
circumference. Mercury-in-silastic strain gauges measure forearm circumference dynamically 
and are attached to a recording computer (figure 2.5). This rate is constant initially, and is 
proportional to FBF, but will change as the forearm deep veins fill. Consequently, only the 
linear initial slope is used (figure 2.6). Rate of change of circumference is measured in both 
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arms, and recorded as a ratio of infused to control arm (FBF ratio). The values used in each 
experiment were an average of 3-5 cuff inflations. 
Absolute forearm blood flow can be estimated using the forearm volume, but, as this is in 
itself an estimated value, FBF ratio may be considered more reliable. Some groups express 
measures as a calculated forearm resistance, though as the mathematics of flow assume a 
uniform (“Newtonian”) fluid flowing at a constant rate through a non-distensible conduit, this 
is, again, an approximation when applied to pulsatile blood in arteries (Benjamin et al., 1995). 
Vascular resistance is estimated using the formula: 
 
Hence, it can be seen that, while vasodilating drugs will affect the tone of resistance vessels, 
flow may also be affected by arterial blood pressure. Every effort is made to keep blood 
pressure and sympathetic arousal constant during each study. The participant is made 
comfortable at the beginning of every study, and the experiment proceeds in a quiet, dedicated 
vascular laboratory at a constant temperature of 21-24ºC. A large change in perfusion 
pressure would affect the measurement of FBF ratio in an unpredictable way, but the effect of 
the inevitable small changes are compensated for by normalising measurements in the infused 
arm to those in the control arm (Greenfield and Patterson, 1954). Absolute responses to 
vasodilating drugs vary through the day, with a circadian rhythm (Panza et al., 1991), but the 
ratio between arms should be unaffected. 
- 61 - 
2.5. Figures 
Figure 2.1. 
 
 
 
 
 
Figure 2.1: Photograph of the experimental setup used in Chapter 3  
Two myographs are connected to a computer, which records real-time tension traces from 
each aortic ring. 
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Figure 2.2. 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Example aortic myography trace  
Recorded using aortic myography, as utilized in the work in Chapter 3. Shown above is the 
effect of preconstriction, then that of progressively increasing levels of nitrite.  
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Figure 2.3. a) 
 
b)  
 
c) 
 
 
Figure 2.3: Example waveform recordings from the pressure probe of a Swann-Ganz 
catheter 
a) Mean right atrial pressure of 10 mmHg b) mean pulmonary arterial pressure of 31 mmHg 
c) mean pulmonary capillary wedge pressure of 23 mmHg; from a high PCWP patient in the 
study of intravenous nitrite in advanced heart failure (Chapter 4). Three leads of 
electrocardiogram are shown above. 
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Figure 2.4. 
 
 
 
 
Figure 2.4: Photograph of the experimental setup used in chapter 6 
The participant sits upright in bed with the arms outstretched at the level of the heart. Rapid-
inflation blood pressure cuffs are around both wrists and both upper arms, with mercury-in-
silastic strain gauges around both forearms.  
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Figure 2.5. 
 
 
a) b) 
c) d) 
  
 
Figure 2.5: Further items of equipment from chapter 6 
a) Vasodilating drugs were infused intra-arterially b) a rapid-inflation pump was used to 
occlude venous blood flow for each measurement of FBF c) strain gauges were attached to 
plethysmographs with computer recording (d). 
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Figure 2.6. 
a) 
 
b) 
 
Figure 2.6: Example forearm plethysmography traces  
Taken from control and infused arms during measurement of forearm blood flow (FBF); from 
a participant in the cytoprotection study (Chapter 6). The y-axis represents time, with voltage 
in mV up the x-axis a) FBF-ratio is measured at baseline and b) after infusion of vasodilators 
(acetylcholine or GTN). The initial slope in each arm was measured using the highlighted 
gradient tool (black box in 2.6b). Each pair of slopes represents one measurement of FBF-
ratio, which is given by the automatic measurement software; an average of at least 3 
measurements was used for each data point. 
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3. MYOGLOBIN IS INVOLVED IN 
VASODILATATION BY NITRITE 
 
3.1. Introduction 
Myoglobin (Mb) is widely expressed in the cytoplasm of vertebrate muscle cells, both skeletal 
and cardiac, with a much lower or absent expression in smooth muscle (Wittenberg and 
Wittenberg, 1989). The tertiary structure of the globular protein was derived using x-ray 
crystallography in the 1950s (Kendrew, 1961). Myoglobin consists of a densely packed, 153 
amino acid polypeptide chain, with an iron-porphyrin heme group that is identical to that of 
Hb. This feature allows Mb to reversibly bind and release O2, though the saturation kinetics 
are different (due to differences in the globular protein as well as the lack of quaternary 
structure) and act as a short-term store of oxygen in exercising muscle. The heme of 
myoglobin achieves 50% saturation at intracellular levels of O2 as low as 2.4 mmHg 
(Schenkman et al., 1997) and so is fully saturated under normal conditions. Exercising muscle 
can, however, reach near anoxia at very high workloads. Intriguingly, despite this important 
physiological role, the myoglobin knockout mouse is remarkably healthy, with tissue 
oxygenation maintained primarily by an increased capillary density (Garry et al., 1998; 
Godecke et al., 1999). 
 
It is believed that myoglobin subserves an intracellular process known as “facilitated 
diffusion” of oxygen. Deoxygenated Mb binds O2 at the cell membrane and diffuses through 
the cytoplasm to the mitochondria, where it releases O2 to the respiratory chain. The 
deoxygenated Mb then diffuses back down its concentration gradient to the membrane to 
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repeat the cycle (Wittenberg, 1970). Experimental evidence for this phenomenon is far from 
unambiguous, with model calculations both supporting and refuting myoglobin’s contribution 
to cellular O2 flux (Gardner and Schubert, 1997).  
 
The chemistry of nitrite activation in vivo remains uncertain (Li et al. 2008). Several (non-
exclusive) bioconvertors have been identified including: pH-dependent enzyme-independent 
nitrite reduction (Benjamin et al. 1994); microsomal cytochrome P-450 (Kozlov, Staniek, & 
Nohl 1999; Li et al. 2006); xanthine oxidase (Li et al., 2008); aldehyde oxidase (ALDH2) (Li 
et al., 2008); neuroglobin (Petersen et al., 2008); hemoglobin (Basu et al., 2007; Crawford et 
al., 2006; Grubina et al., 2007; Huang et al., 2005a; Isbell et al., 2007); and myoglobin (Shiva 
et al., 2007a). It is uncertain which of these, alone or in combination, contributes to the in vivo 
conversion of endogenous and exogenous nitrite. In particular, the role of heme moieties, e.g. 
hemoglobin, in nitrite metabolism, is still uncertain (Alzawahra et al., 2008). We devised 
experiments to test the hypothesis that vascular myoglobin, like cardiac myoglobin (Rassaf et 
al., 2007), can act as a bioconvertor for exogenous nitrite. 
 
In our department we have observed a prolonged vasodilating action of nitrite, which 
persisted for 45 minutes after the infusion of nitrite was stopped (unpublished data, Maher et 
al., 2007). Intriguingly, this vasodilatation was only observed in the infused arm, even though 
plasma nitrite levels rapidly equilibrated between the two arms. We hypothesized that an 
intrinsic vascular wall protein was therefore responsible. This hypothesis was supported by 
work from the Zweier lab indicating the same (Alzawahra et al., 2008; Li et al., 2008). Their 
experiments also implicated an intrinsic vascular wall protein, and narrowed the search to 
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heme-proteins by inhibition of such using carbon monoxide gas. Accordingly, we undertook 
experiments to investigate directly the role of myoglobin in nitrite-induced vasorelaxation. 
 
3.1.1 Hypothesis 
Ablation or inhibition of myoglobin, genetically or with carbon monoxide gas, will reduce the 
vasodilating response of aortic tissue to sodium nitrite 
 
3.2. Methods 
 
3.2.1 Animals  
Male C57bl6, NMRI and myo-/- mice were used at 6-7 weeks of age (26-32g in weight). We 
housed all animals under standard lighting parameters and provided food and water ad 
libitum. Animals were killed by cervical dislocation as approved under Schedule 1 of the 
Animals (Scientific Procedures) Act 1986. The aorta from arch to diaphragm was quickly 
removed en bloc, and immediately plunged into ice-cold oxygenated Krebs solution. Aorta 
was cleaned of all adherent fat and adventitia, and cut into four 2 mm rings. These were 
mounted in organ baths on a wire myograph (Danish Myo Technology). 
 
3.2.2. Mouse aortic ring myography  
Aortic myography was done according to standard procedures (detailed description in 
Methods 2.1.) Pretension force was 20 mN. Preconstriction was produced using 50 mM KCl 
except where stated. Myography wells were open to the air and bubbled with 95% N2 - 5% 
CO2, 95% O2 - 5% CO2, or 20% CO - 75% N2 - 5% CO2. Buffer was allowed to reach steady 
state, which using this equipment produced an oxygen tension of 82 ± 2 and 83 ± 2 mmHg 
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(~11 kPa) for the low oxygen gases (with and without CO respectively), and 158 ± 2 mmHg 
(~22 kPa) for the high oxygen mix as measured by blood gas analyser (Instrumentation 
Laboratory, Bedford, MA). The lower level, which was used for the majority of experiments, 
was chosen in order to approximate to in vivo intravascular conditions, as it is between the 
average oxygen tension of arteries (90 mmHg) and veins (40 mmHg) (van Faassen et al., 
2009). This level was stable over time. The same equipment was used to monitor pH, which 
was stable at 7.4 with both gas mixtures. 
 
3.2.3. Generation of replication-defective adenoviruses  
This virus was made on behalf of the candidate by Prof Watkins’ group in the University of 
Oxford. Both Ad5-Myo-GFP and Ad5-GFP (control virus) were generated using the AdEasy 
XL Adenoviral vector system (Stratagene). Human wild-type myoglobin cDNA was cloned 
into the pShuttle-IRES-hrGFP-1 vector (Stratagene), allowing co-expression of GFP with 
myoglobin (a stop codon was introduced to prevent fusion of the FLAG tag). The vector was 
linearised by PmeI digestion and recombined with the pAdEasy-1 (viral backbone vector) in 
BJ5183 Escherichia coli. The recombined adenoviral constructs were transfected into DH10β 
E. coli to allow higher plasmid yields. After confirmation of recombination by BstXI and Pac-
1 restriction digestion and sequencing, Pac1 linearised recombinant Ad plasmids were then 
transfected into AD293 cells (Stratagene) using oligofectamine (Invitrogen). AD293 cells 
were scraped from cell culture vessels and lysed by 4 freeze-thaw vortex cycles. Lysates 
containing recombinant adenoviruses used to infect further AD293 cells for amplification. 
The viruses were purified by caesium chloride gradient ultracentrifugation. The viral titre was 
estimated by infecting HEK293 cells (not expressing capsid proteins) and counting GFP 
expressing cells. 
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3.2.4. Transfection and incubation of myo-/- aortic tissue 
Thoracic aortas from myo2/2 mice were obtained as before. These rings were then exposed to 
either adenovirus expressing myoglobin (AdMYO) or control virus (AdCtl) (at a 
concentration of 1028 PFU/mL) diluted in Opti-MEM (Sigma), supplemented with 11 mM 
glucose, for 120 min under continuous bubbling with carbogen gas. Rings were washed with 
Opti-MEM to remove adherent virus particles, and then incubated at 37°C in Krebs-Henseleit 
buffer for 270 min. This incubation time was determined in preliminary experiments to be 
sufficient for recapitulation of the low levels of myoglobin seen in wild-type aorta. Response 
to nitrite both in the presence and absence of CO was assessed as before. Nitrite was used at a 
final concentration of 9 mM (~EC90) in order to focus solely on the effect of myoglobin (i.e. 
after saturating other pathways). 
 
3.2.5. End-point PCR and western blotting  
Aortas from myo-/- and wild-type control mice were harvested as before and flash frozen in 
liquid nitrogen. RNA and protein were extracted using TriReagent (Sigma). cDNA was 
transcribed from purified RNA using a standard kit (Applied Biosystems) and 40 cycles of 
PCR were performed. The protein fraction was purified and used for western blotting 
(described in detail in Methods 2.2.). The RNA analysis and western blotting were done by 
the candidate in Prof Watkins’s laboratory in the University of Oxford. Presented are the best 
examples of four blots and two gels. 
 
3.2.6. Measurement of cGMP accumulation 
Fresh aortas were harvested as before. Tissue was exposed to 10 mM nitrite in Krebs-Hensleit 
buffer at 37 ºC for 15 minutes, with and without the NO scavenger carboxy-PTIO. A 
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phosphodiesterase inhibitor cocktail was used in the buffer, as in previous work in the 
Feelisch group (Bryan et al., 2005). Samples were flash frozen in liquid nitrogen and 
homogenised by crushing in a frozen mortar and pestle, as the blade homogeniser was 
ineffective for aortic tissue. cGMP was measured using a commercial ELISA kit (Amersham 
Biotech, UK). 
 
3.3. Results 
 
3.3.1. Protein and RNA analysis in the wild-type mouse aorta  
Myoglobin is present at the mRNA (figure 3.1a) and protein (figure 3.1b) level. 
 
3.3.2. The response of C57bl6 aortic rings to 9mM nitrite at high and low oxygen levels 
In preliminary experiments in C57bl6 mice (a commonly-used laboratory mouse), reducing 
the buffer oxygen tension increased vasorelaxation to 9 mM sodium nitrite (n = 6, p < 0.05 by 
two-tailed t-test) (figure 3.2).  
 
3.3.3. The response of wild-type and knockout aortic rings to nitrite, in the presence and 
absence of carbon monoxide 
Acute vasorelaxation induced by sodium nitrite was assessed during exposure to 95% N2/5% 
CO2 and then to 20% CO/ 75% N2/ 5% CO2. The level of CO was chosen to inhibit only 
heme-proteins, as previously described23, and did not in itself cause vasorelaxation. 
Preliminary experiments with a fixed dose of sodium nitrite (9 mM) showed a differential 
response to carbon monoxide. Bubbling with the 20% CO mix inhibited relaxation in the 
wild-type (NMRI) group (n = 5, p < 0.05 by ANOVA), but potentiated relaxation in the myo-/- 
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mouse vessels (n = 4, p < 0.01 by ANOVA). Further experiments assessed the contribution of 
myoglobin at several increasing doses of sodium nitrite. CO inhibited nitrite-induced 
vasorelaxation in the murine wild-type aortae (n = 5, p < 0.001 by two-way ANOVA) (figure 
3.4a). The effect of 50 μM oxypurinol (an inhibitor of xanthine oxidase) and 50 nM 
raloxifene (an inhibitor of aldehyde dehydrogenase) is shown for comparison. To assess 
whether myoglobin was this heme moiety, myo-/- mice were compared to wild-type controls. 
Overall response to nitrite was markedly reduced in myo-/- rings (figure 3.4b) (n = 5, p < 
0.001 by two-way ANOVA). In contrast to wild-type aortae, CO did not inhibit 
vasorelaxation in myo-/- rings (figure 3.4b). 
 
3.3.4. The response of transfected knockout rings to nitrite, in the presence and absence 
of carbon monoxide 
To confirm the role of myoglobin as a nitrite bioconvertor and to exclude the possibility that 
the changes noted in the myo-/- mice were artefactual adaptations to gene manipulation, we 
investigated the effect of restoring myoglobin in myo-/- mouse vessels. Transduction of 
myoglobin augmented the baseline response to nitrite from 28.6 ± 6.5% to 60.7 ± 7.6% (p = 
0.024 by ANOVA), compared to control virus-treated rings (figure 3.5). The pattern of 
response to CO was similar. Thus, treatment with control virus did not change the effect of 
CO (from 28.6 ± 6.5% to 31.6 ± 7.0%). Viral transduction of myoglobin reinstated the 
inhibition of nitrite relaxation by CO seen in wild-type mice (from 60.7 ± 7.6% to 25.8 ± 
3.7%, p = 0.014 by ANOVA). The concentration of nitrite (~EC90 at 9 mM) used in this study 
was chosen to facilitate accurate determination of the vasorelaxing effect of nitrite with other 
pathways saturated. Western blotting confirmed the presence of myoglobin in aortic tissue 
treated with adMYO (figure 3.1b). 
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 3.3.5. The response of wild-type and knockout aortic rings to sodium nitroprusside, in 
the presence and absence of carbon monoxide 
Sodium nitroprusside (SNP) was used to assess the effect of CO on vasorelaxation by a 
nitrite-independent NO donor. Importantly, myo-/- aortic rings retained their response to NO 
(i.e., the extent of vasorelaxation to a fixed concentration of SNP (0.1 µM) was comparable in 
tissues from wt and myo-/- mice) and relaxation was not significantly changed by the addition 
of CO (37.7 ± 3.5% to 43.7 ± 4.2%, p = NS by ANOVA). In wild-type mice, relaxation was 
increased from 42.3 ± 4.7% to 58.7 ± 6.0% (p = 0.029 by ANOVA) (figure 3.6).  
 
3.3.6. The effect of xanthine oxidase and aldehyde dehydrogenase inhibition in knockout 
aortic rings 
50 μM oxypurinol caused a 32% inhibition of vasorelaxation (from 21.3 ± 0.4% to 14.4 ± 
1.4%, p < 0.05 by ANOVA) whereas 50 nM raloxifene produced a 32% inhibition (from 21.3 
± 0.4% to 14.3 ± 0.5%, p < 0.05 by repeated measures ANOVA). The two agents in 
combination inhibited nitrite-induced vasodilation by 60% (from 21.3 ± 0.4% to 8.5 ± 1.1%, p 
< 0.001 by repeated measures ANOVA, n = 4 for each group) (figure 3.7). Preincubation 
time of vascular rings with inhibitors was five minutes with each agent separately or together; 
optimal concentrations of inhibitors used were determined in preliminary experiments. 
 
3.3.7. The effect of the NO-scavenger carboxy-PTIO and the sGC inhibitor ODQ on 
cGMP accumulation and vasorelaxation 
In the presence of a phosphodiesterase inhibitor cocktail, exposure of vascular tissue to 9mM 
nitrite for 15 minutes caused accumulation of cGMP, which was lower in myo-/- tissue than in 
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wild-type and abolished by preincubation with the NO-scavenger, carboxy-PTIO (figure 
3.8a). Moreover, relaxation of aortic rings by nitrite was completely abolished by 
preincubation with 20 µM oxygenated haemoglobin (oxyHb) or by the addition of 10 µM 
ODQ to the organ bath (figure 3.8b). 
 
3.3.8. The effect of prolonged exposure to higher levels of nitrite in wild-type and 
knockout aortic rings 
Aortic ring studies were also performed to investigate the initially recorded phenomenon of 
prolonged vasodilatation, first seen in human studies (Maher et al, unpublished data, as 
above). Ten-minute exposure to 18 mM nitrite induced a characteristic persistent 
vasorelaxation in aortic rings a) Typical traces for nitrite-induced relaxation in NMRI (broken 
lines) and myo-/- (solid lines) aortic rings b) Latency time, T(0), is shorter in myo-/- compared 
to wild-type controls, (n = 4 for each, p < 0.05 by two-tailed t-test) (figure 3.9).  
 
3.4. Discussion 
 
Myoglobin was present in the normal mouse aorta at the RNA and protein level, a result that 
has been previously disputed. This was therefore essential to confirm before embarking on an 
investigation of myoglobin’s possible effects in the vasculature. Expression of myoglobin is 
however extremely low. The semi-quantitative tests performed cannot estimate the level of 
expression with any greater accuracy, but this may explain why the protein has been reported 
to be absent in the past. Experiments in low and high oxygen conditions show that nitrite-
induced vascular relaxation is potentiated by hypoxia. This confirms previous observations 
(Dalsgaard et al., 2007), and again was important to confirm in these particular experimental 
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conditions. This result was fundamental in driving our hypothesis that myoglobin is an 
important biocionvertor as, containing a heme-group, it is exquisitely placed to sense oxygen-
levels in the cell. 
 
Deficiency (by knockout) or inhibition of myoglobin (by CO) in mouse aorta appeared to 
diminish vasorelaxation to nitrite. Confirming this observation with both chronic and acute 
inhibiton of myoglobin is important. In the first instance, it would appear likely that the 
absence of myoglobin from conception would induce compensatory changes elsewhere. In the 
second instance, CO will additionally inhibit any molecule containing a heme-group, and so it 
is only by comparing the response to CO in the presence and absence of myoglobin that the 
true role of myoglobin can be isolated. Finally, restitution of myoglobin to knockout aorta 
recapitulates the wild-type response to carbon monoxide. This supports the supposition that it 
truly is myoglobin, rather than a compensatory change in knockout animals, that underlies the 
difference between them and the wild-type mouse. Expression of virally-inserted myoglobin 
in the smooth muscle was very low, though it was similar to that seen in wild-type aorta, and 
functionally the tissue reacted in a similar manner.  
 
Relaxation to sodium nitroprusside was increased by carbon monoxide in both wild-type and 
myo-/- rings, implying that the net effect of heme-molecules as a group is scavenging of NO. 
The difference in magnitude of the effect of CO is consistent with greater scavenging of NO 
by myoglobin in the wild-type mouse. This is an interesting result, and implies that 
myoglobin may be acting as both reductase and scavenger at all times, with the relative 
contribution of each activity determined by the level of oxygen. 
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Xanthine oxidase and aldehyde dehydrogenase also exhibit nitrite reductase activity, as shown 
in the myoglobin-knockout mouse, as inhibitors of these enzymes reduced residual nitrite 
effects. As with ODQ, compounds believed to be specific inhibitors may later be found to be 
relatively prolific in their effects, and further testing (perhaps demonstrating correlation with 
directly measured enzyme activity) would be needed to determine this result with certainty. 
Additionally, the knockout mouse may have undergone changes in other nitrite reductase 
pathways that are as yet unknown, so this result should be applied to the wild-type animal 
with caution. 
 
The effects of nitrite were abolished by a G-protein inhibitor (with the caveats described 
above) and by NO-scavengers. This implies that the effects of nitrite are mediated by the 
stimulation of soluble guanylyl cyclase by free NO. This was not confirmed with direct 
measurement of NO 
 
High levels of nitrite induced prolonged relaxation of mouse aorta, which was also seen in 
human studies form our department (Maher et al., unpublished data, as before). Prolonged 
vasodilatation to nitrite appears to be partially myoglobin-dependent, in that the time required 
to revert to resting tension was significantly longer in wild-type aortas. This may be due to 
increased nitrite reductase activity in the initial nitrite exposure, but myoglobin could also act 
as a store of NO-activity in the form of a nitrosothiol, releasing small amounts of NO 
throughout this period. Other molecules can also become nitrosylated, which would explain 
the (shorter) latent period in myo-/- aortae. 
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In summary therefore, the main findings of the in vitro study are that: a) vascular 
bioconversion of exogenous nitrite is sensitive to CO, and therefore is likely to depend upon a 
heme-protein; b) in contrast, when CO is used in rings from myoglobin-deleted mice 
vasorelaxation is unchanged or increased; this implies that the contribution of remaining 
heme-proteins (other than myoglobin) is net NO scavenging; c) deletion of myoglobin 
substantially diminishes exogenous nitrite-mediated vasorelaxation; indicating that myoglobin 
is a major bioconvertor of exogenous nitrite in aortic rings; d) restitution of myoglobin to 
myo-/- mouse aortas results in increased vasodilation; and the wild-type pattern of response to 
CO (i.e. inhibition of vasodilation) is restored; e) further studies using inhibitors imply that 
the other major bioconvertors in this model are non-heme enzymes, including xanthine 
oxidase and aldehyde dehydrogenase. 
 
Carbon monoxide, an inhibitor of heme-proteins, had differing effects on wild-type and 
myoglobin-deleted aortic rings; this is only explicable by the presence of myoglobin in 
murine vasculature. This is confirmed by the demonstration of myoglobin at the transcript and 
protein level. The results summarised in a) to d) above support the hypothesis that myoglobin 
is a significant bioconvertor of exogenous nitrite. 
The experiments were designed to focus on smooth muscle myoglobin, and so the majority of 
aortic rings had the endothelium removed. Also, in this model the relative contribution of 
myoglobin is only clear at higher levels of nitrite than are found in normal human physiology. 
However, nitrite levels recorded in humans vary over more than an order of magnitude; for 
example, micromolar levels a have been measured in altitude-adapted individuals (Erzurum et 
al., 2007). Levels of nitrite recorded in aortic tissue are strikingly higher than in plasma (>20 
μM) (Table 1.1). Oxygen tension in resting muscle is approximately 24 mmHg, and working 
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muscle exhibits even greater hypoxia (8 mmHg) (Bylund-Fellenius et al., 1981), which 
together mean that myoglobin is likely to participate in vasodilatation during physiological 
circumstances, and not just in pathology (anoxia, extreme acidosis) as previously 
hypothesised (section 1.5). 
 
3.4.1. Limitations 
A major controversy that cannot be resolved by this system is the relative contribution of 
haemoglobin to nitrite-induced vasodilatation, either in physiology or therapeutics. Stamler 
and others have proposed that SNO-Hb, created by nitrite, can provide a source of NO-like 
bioactivity, without need for free NO. Certainly, these results (particularly those using the 
scavenger carboxy-PTIO) imply that free NO is important, but the lack of either haemoglobin 
or intact erythrocytes in the experimental setup means that this work can shed no light on the 
controversy. The oxygen tension in these studies was chosen to represent low arterial levels, 
and it was assumed that tissue levels would quickly equilibrate with the surrounding buffer. It 
cannot be excluded that certain areas of aortic tissue, or sub cellular compartments, 
experience much lower oxygen levels. This would explain the apparent discrepancy between 
biochemical studies of myoglobin’s nitrite reductase activity and the present organ bath study. 
It is of course similarly possible that such effects would be present in vivo. 
 
3.5. Conclusions 
Low pharmacological concentrations of nitrite relax aortic rings at near physiological levels 
of oxygen. Nitrite may be present in much higher quantities in certain tissues. Vasorelaxation 
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proceeds through the liberation of NO, as it may be blocked by G-protein inhibitors or NO-
scavengers, and myoglobin is important in this process. Xanthine oxidase and ALDH2 
contribute to the remainder of the vasorelaxing effect. A summary of this model is given in 
figure 3.10. Prolonged latency is a hallmark of nitrite-induced vascular relaxation; it is also 
partially myoglobin-dependent. Overall, these properties of nitrite make it an attractive 
pharmacological candidate, as investigated in later chapters. Nitrite can have acute and 
chronic effects on blood flow, responsive to oxygen levels and pH (though this was not 
investigated in the present study). It is tempting to speculate that the nitrite store, reduced by 
myoglobin in the vessel wall, would be sufficient to underlie a primitive system of hypoxic or 
exercise-induced vasodilatation. 
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3.6. Figures 
 
Figure 3.1. 
 
 
 
a)  
 
b) 
 
 
Figure 3.1: RNA and protein analysis in mouse aorta and heart 
a) End-point PCR showing presence of myoglobin mRNA in aortic and cardiac tissue from a 
wild-type (NMRI) mouse, and absence in myo-/- tissue b) Western blot showing presence of 
myoglobin in aortic and cardiac tissue from a wild-type (NMRI) mouse, and absence in myo-/- 
tissue. Myoglobin is restored in myo-/- tissue using a recombinant adenovirus (AdMYO) 
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Figure 3.2. 
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Figure 3.2: The effect of oxygen level in wild-type (C57bl6) mouse aorta 
Confirming previous work, lowering the buffer oxygen tension from 158 mmHg to 84mmHg 
increased relaxation to 9 mM sodium nitrite from 26.0 ± 4.5 to 33.1 ± 5.1 in C57bl6 mouse 
aortas, *p < 0.05 
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Figure 3.3. 
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Figure 3.3: The effect of oxygen and carbon monoxide in wild-type (NMRI) and 
myoglobin knockout aortas 
a) Relaxation to 9 mM sodium nitrite is inhibited by exposure to 20% CO gas in NMRI 
mouse aorta, whereas b) relaxation to 9mM sodium nitrite is lower overall in myo-/- aorta 
compared to NMRI and is potentiated by CO gas; the effect of reducing oxygen tension is 
similar to that in C57bl6 aortas (figure 3.2) for both; *p < 0.01. 
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Figure 3.4. 
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Figure 3.4: The effect of carbon monoxide on the concentration response curve in wild-
type (NMRI) and myoglobin knockout aortas 
a) Concentration response curve showing the response of wild-type (NMRI) aorta to bubbling 
with CO gas. Wild-type aorta shows an inhibition of nitrite–dependent vasorelaxation in 
response to CO (n = 5, p < 0.001 by two-way ANOVA). The combined effect of oxypurinol 
and raloxifene is shown for comparison b) Inhibition with CO is not seen in myo-/- aortas, (n = 
5, p = 0.44 by two-way ANOVA). *p < 0.01 compared to wild-type, **p < 0.001 compared to 
baseline 
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Figure 3.5. 
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Figure 3.5: The effect of myoglobin-containing and blank virus exposure on myoglobin-
knockout aortas 
Restitution of myoglobin to myo-/- aorta using a recombinant adenovirus (AdMYO) increases 
vasodilatation to 9 mM sodium nitrite compared to myo-/- aorta treated with control virus 
(AdCtl) (n = 4 for each, p < 0.01). The inhibitory effect of carbon monoxide is restored, *p < 
0.05 by ANOVA 
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Figure 3.6. 
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Figure 3.6: The effect of the NO-donor SNP on wild-type and myoglobin knockout 
aortas 
Response to the NO-donor SNP (0.1 µM) is not diminished in myo-/- rings. CO has no effect 
in knockout aortas but increases response to nitrite in wild-type rings, consistent with 
increased scavenging of NO in the presence of myoglobin, *p < 0.05 by ANOVA compared 
to baseline 
- 87 - 
Figure 3.7. 
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Figure 3.7: The effect of other candidate nitrite reductase inhibitors on myoglobin-
knockout aortas 
The majority of the remainder of (9 mM) nitrite-dependent vasodilatation in myo-/- aorta is due 
to xanthine oxidase and aldehyde dehydrogenase as shown by the addition of specific 
inhibitors (oxypurinol and raloxifene) (n = 4 for each), *p < 0.05 compared to nitrite only, 
**p < 0.05 compared to oxypurinol or raloxifene only, and p < 0.001 compared to nitrite only 
(repeated measures ANOVA with post-hoc tests) 
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Figure 3.8. 
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Figure 3.8: The effect of ODQ and NO-scavengers on wild-type and myoglobin-
knockout aortas 
a) 15 minute exposure to 9 mM sodium nitrite causes accumulation of cGMP which was 
lower in myo-/- tissue than wild-type (n = 6 for each), and was prevented by co-administration 
of the NO-scavenger carboxy-PTIO (n = 5); b) Vasorelaxation to 9 mM sodium nitrite is 
prevented by the presence of the NO-scavenger oxyHb and the G-protein inhibitor ODQ (n = 
4 for each). *p < 0.05 compared to control, **p < 0.001 compared to control and myo-/- by 
ANOVA. 
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Figure 3.9. 
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Figure 3.9: The effect of 10 minute exposure to 20 mM nitrite on wild-type and 
myoglobin-knockout aortas 
a) Incubation of aortic tissue with 20 mM sodium nitrite for 10 minutes produces a prolonged 
vasorelaxation, which persists after removal of sodium nitrite (broken lines: WT, solid lines: 
myo-/-, %change from baseline measured every 15 minutes, smoothed curve of intermittent 
data points (Excel)) b) The duration of prolonged vasorelaxation is markedly reduced in myo-
/- aortas, T(0) taken as first time-point where tension reaches baseline (n = 4 for each), *p < 
0.05 by two-tailed t-test 
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Figure 3.10. 
 
 
 
 
Figure 3.10: A model of myoglobin’s role in vasorelaxation induced by nitrite 
NO is liberated by various species, including myoglobin, xanthine oxidase and ALDH 
(above). Other heme-containing proteins have a net scavenger role (below). A typical 
myography response to nitrite is shown (bottom). Exposure to CO inhibits myoglobin (second 
left), reducing magnitude of vasorelaxation in wild-type aortas. Myoglobin-deficient aortas 
(second right) may have partially compensatory upregulated nitrite reductases. When exposed 
to CO gas (far right), relief of scavenging (and hence increased magnitude of vasorelaxation) 
is the only effect. 
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4. INVASIVE MEASUREMENTS OF THE ACUTE 
HAEMODYNAMIC EFFECTS OF 
INTRAVENOUS NITRITE IN HEART FAILURE 
 
4.1. Introduction 
Heart failure is a syndrome in which there is insufficient cardiac output to meet the metabolic 
needs of the body, initially on exercise but in severe cases at rest. It is a common cause of 
admission to hospital, intensive care, and a common cause of death. Intensive therapy often 
includes inotropic agents which improve cardiac function at the expense of increased 
myocardial lactic acidosis, and which do not improve mortality. The only established options 
available to patients with end-stage heart failure are ventricular assist devices and 
transplantation, both of which are resource intensive and have limited availability in the NHS. 
This is due to expense but also to scarce organ supply for transplantation. Both interventions 
are far from universally available worldwide and new therapies are desperately needed. 
Overall, around 1.8% of Europeans and 2% of Americans meet a diagnosis of chronic heart 
failure (Davies et al., 2001; Lloyd-Jones, 2001). Heart failure is a dynamic disease, with most 
patients suffering episodes of acute decompensation, interspersed with periods of a variable 
duration where their symptoms are stable. 
 
Therapy for acute decompensated heart failure (ADHF), which often manifests as pulmonary 
oedema, includes morphine for anxiolytic and pulmonary vasodilating effects, and 
intravenous diuretics and organic nitrates which both act as vasodilators (Davies et al., 2001; 
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Lloyd-Jones, 2001; Cohn, 1985; Cohn et al., 1986). Organic nitrates, such as glyceryl 
trinitrate (GTN), dilate both veins and arteries, and therefore relieve both preload (i.e. 
ventricular filling) and afterload (i.e. resistance to flow). Though a small reduction in 
afterload is often beneficial in ADHF, too great a drop in arterial blood pressure will reduce 
perfusion of vital organs, especially the kidneys and the brain. Thus, development of severe 
hypotension is often a reason to reduce or discontinue nitrate therapy.  
 
Venodilation decreases right atrial pressure, and hence right ventricular filling. Patients with 
dilated heart failure often exhibit a phenomenon known as diastolic ventricular interaction 
(DVI), wherein increased right ventricular diastolic volume and pressure, contained within the 
relatively non-distensible pericardium, impedes left ventricular filling, and thereby reduces 
stroke volume (Atherton et al., 1997b). When right ventricular filling is reduced, the septum 
moves across towards the right side, reducing the impediment to left ventricular filling and 
thereby increasing cardiac output. This can be measured directly by nuclear cardiology 
techniques, or estimated by a change in the trans-septal gradient, which gives the net left 
ventricular filling pressure (left ventricular end-diastolic pressure – right ventricular end-
diastolic pressure) (Atherton et al., 1997a). 
 
As discussed in detail in section 1.5., nitrite has recently been shown to be an active 
vasodilator in humans, with the unique property of hypoxia-targeted vasodilatation (Maher et 
al., 2008). The balance of evidence seems to suggest that nitrite, through O2-sensing nitrite 
reductases such as myoglobin (as discussed in chapter 3), releases more NO in areas of low 
oxygen tension, such as the relatively hypoxic venous circulation. Recently, a study in rats 
showed that intravenous sodium nitrite significantly decreased pulmonary vascular resistance 
- 93 - 
and increased cardiac output (Casey et al., 2009). Harnessing this unique property, we 
hypothesised that nitrite would provide beneficial venodilation in ADHF, without the drop in 
systemic vascular resistance and arterial blood pressure that characterises therapy with 
organic nitrates. 
 
ADHF is a medical emergency, which poses significant challenges to the successful, ethical 
conduct of research. As Birmingham is a transplant centre, we took advantage of the 
opportunity to study nitrite infusions in those with advanced but stable heart failure. We 
prospectively split these patients into two groups; those predicted to exhibit significant DVI 
(PCWP ≥ 15 mmHg), and those predicted not to exhibit DVI (PCWP < 15 mmHg). 
Measurements of intra-cardiac pressures were taken using a right heart catheter that was 
inserted for clinical reasons as part of the transplant assessment protocol, after clinical studies 
had been completed. Measurement of intra-cardiac pressures using a right heart (Swan-Ganz) 
catheter is discussed in more detail in Methods 2.3.  
 
4.1.1. Hypothesis 
Short systemic infusions of sodium nitrite will have beneficial haemodynamic effects in 
advanced heart failure with significant DVI (pulmonary capillary wedge pressure ≥ 15 
mmHg), but not in heart failure without DVI (PCWP < 15 mmHg). 
 
4.2. Methods 
18 consecutive patients who were undergoing right heart catheterisation as part of the heart 
transplant assessment protocol and who gave informed consent were recruited to the study 
(baseline characteristics are summarised below). The Local Research Ethics Committee 
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approved the study protocol (REC #08/H1207/67). Methaemoglobinaemia may trigger 
haemolysis in patients with G6PD deficiency. This is a very common condition worldwide 
but rare in the Caucasian population (Cappellini and Fiorelli, 2008), in which redox stress 
causes haemolysis, which may be severe. It is an X-linked condition, so is extremely rare in 
females. For safety, we excluded males with a known history of G6PD deficiency and those 
with a high risk of having this condition. 
 
4.2.1. Inclusion Criteria 
1. Aged 18 years or over 
2. Admission to hospital for pulmonary artery catheterisation, under the transplant 
assessment protocol 
 
4.2.2. Exclusion Criteria 
1. Pre-existing inotrope therapy 
2. Recent ST-elevation myocardial infarction or thrombolysis 
3. G6PD Deficiency, or high risk of G6PD deficiency 
4. Women of child-bearing potential or nursing mothers 
 
4.2.3. Right heart catheterisation and protocol 
A Swan-Ganz catheter was inserted via a sheath into the right internal jugular vein under local 
anaesthesia with positioning confirmed by fluoroscopy and pressure waveform (a detailed 
description is given in Methods 2.4.). Right atrial and ventricular pressures were measured at 
the beginning of the study and again at the end of the protocol only, to avoid multiple 
insertions of the catheter into the pulmonary artery. Consequently, RA pressure was only 
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available at baseline and peak nitrite dose, which also limited measurements derived from RA 
pressure.  After baseline measurements, subjects received three five-minute infusions of 
sodium nitrite at escalating doses (1, 10 and 50 µg/kg/min) into the sheath (right internal 
jugular vein). At the end of each infusion, pulmonary artery (PA) pressure, pulmonary 
capillary wedge pressure (PCWP) and CO were measured. Blood pressure, electrocardiogram 
and oxygen saturation were monitored continuously. The protocol is summarised in figure 
4.1. 
 
4.2.4. Measurement of cardiac output by the Fick principle 
Cardiac output as measured by the Fick principle was used in preference to thermodilution. 
Indicator dilution techniques become unreliable in the presence of significant tricuspid 
regurgitation. This is because ventricular blood freely mixes with blood in the right atrium, 
diluting the indicator substance (in the case of thermodilution, cold dextrose solution), and 
giving an inappropriately low reading of cardiac output. In indicator dilution techniques all 
blood is assumed to move forwards through the circulation. In dilated cardiomyopathy, the 
fibro-cartilage skeleton of the heart expands, forcing the atrio-ventricular valve leaflets apart. 
This is known as functional mitral/tricuspid regurgitation.  
 
The Fick principle states that the amount of a substance taken up by an organ (or the whole 
body) per unit of time is equal to the blood flow multiplied by the difference in concentration 
of that substance between arterial and mixed venous blood, so for O2: 
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 Whole body uptake of O2 is estimated from body surface area: 
 
 
Though there are several factors that are estimated in this equation, they remain constant 
within a single study, therefore this technique is an exceptionally reliable way to measure 
change in cardiac output. In one case thermodilution was used due to mechanical failure of 
the blood gas analyser. Additionally, pressure data was discarded from one patient due to 
failure of the catheter after baseline measures. Mixed venous blood gas was analysed using a 
clinical analyser (Radiometer ABL800, Denmark).  
 
4.2.5. Power calculation 
This was planned as a 16 patients per group pilot study, with participants acting as their own 
control (baseline measures compared to three different doses of nitrite infusion), which 
increases the statistical power. This number was chosen to give a representative sample, based 
on our experience of physiological studies with nitrite and the typical patient groups 
undergoing transplant assessment. We had no metric to estimate the effect size of nitrite in 
this specific group (i.e. PCWP ≥ 15mmHg) but were guided by the calculation that 10 patients 
would give 80% power to detect a 20% rise in cardiac output with a standard deviation of 0.9 
L/min, at a p-value of < 0.05. 
- 97 - 
 4.2.6. Statistical Analysis 
Changes in trans–septal pressure gradient (i.e. LVEDP – RVEDP) during nitrite infusion were 
estimated as change in (PCWP – RA pressure) (Morris-Thurgood & Frenneaux 2000). We 
prospectively chose to divide patients into those with PCWP ≥ 15mmHg (n = 13) vs those 
with PCWP < 15 mmHg (n = 5). This was based on our observation in a previous study that 
PCWP ≥ 15mmHg was reasonably predictive of a ‘paradoxical’ increase in LV end-diastolic 
volume during application of lower body negative pressure (implying marked DVI) (Atherton 
et al. 1997a). Blood pressure and heart rate changes were assessed by linear mixed models 
analysis (SPSS v14), which is a variant of ANOVA that can correct for single missing data 
points. All other comparisons were by paired two-tailed t-test unless otherwise specified. Data 
are presented as mean ± SEM; a p-value of less than 0.05 was taken to indicate statistical 
significance.  
 
4.3. Results 
 
4.3.1 Patient Characteristics 
Baseline patient characteristics are given in Table 4.1. Two patients complained of 
orthopnoea on presentation. 
 
4.3.2. The effect of systemic nitrite infusion on pulmonary vascular resistance and 
systemic vascular resistance 
Overall, PVR fell from 2.55 ± 0.50 to 1.83 ± 0.30 wood units (p = 0.03). In the subgroup with 
PCWP ≥ 15 mmHg (n = 13), PVR fell from 2.96 ± 0.61 to 2.04 ± 0.41 wood units (p = 0.03) 
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at the highest dose of nitrite (50 µg/kg/min).  In the subgroup with PCWP < 15mmHg (n = 5), 
PVR was unchanged (from 1.19 ± 0.27 to 1.15 ± 0.12 wood units, p = NS) (figure 4.2a). By 
comparison, SVR fell from 17.4 ± 1.3 to 16.0 ± 1.1 wood units (p = 0.04) at the highest dose 
of nitrite. In the high PCWP subgroup, SVR fell from 18.3 ± 1.6 to 16.4 ± 1.3 wood units (p = 
0.02). In the low PCWP subgroup, SVR was unchanged (from 14.3 ± 0.7 to 14.8 ± 0.8 wood 
units, p = NS) (figure 4.2b). 
 
4.3.3. The effect of systemic nitrite infusion right atrial pressure and pulmonary 
capillary wedge pressure 
Overall, RA pressure fell from 11.2 ± 2.0 to 6.6 ± 1.7 mmHg compared to baseline (p = 
0.003). In the high PCWP subgroup, RA pressure fell from 13.7 ± 2.1 to 7.9 ± 1.8 mmHg (p = 
0.002).  In the low PCWP subgroup, RA pressure was unchanged (from 3.0 ± 1.7 to 2.0 ± 2.7 
mmHg, p = NS) (figure 4.3a).  Overall, PCWP fell from 20.7 ± 2.3 to 18.4 ± 2.5 mmHg 
compared to baseline (p = 0.06). In the high PCWP group, PCWP fell from 25.2 ± 1.6 to 22.4 
± 2.1 mmHg (p = 0.07).  In the low PCWP subgroup PVR was unchanged (from 6.3 ± 0.3 to 
5.3 ± 1.3 mmHg, n = 5, p = NS) (figure 4.3b). 
 
4.3.4. The effect of systemic nitrite infusion on blood pressure and heart rate 
Heart rate was unchanged at any dose of nitrite (figure 4.3c). There was a 3 mmHg fall in 
MAP, p = 0.005 (figure 4.3d). This was predominantly in the high PCWP group (4.0 mmHg 
vs. 0.4 mmHg in the low PCWP group). 
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4.3.5. The effect of systemic nitrite infusion on cardiac output and stroke volume 
There was a significantly higher resting stroke volume (SV) in the low PCWP group (p = 0.03 
by two tail unpaired t-test). SV was unchanged in the entire group (from 51.2 ± 5.1 to 54.4 ± 
4.2 ml, p = NS). SV increased from 44.9 ± 5.0 ml to 51.9 ± 4.9 ml in the high PCWP group (p 
= 0.008) and was unchanged in the low PCWP group (from 67.8 ± 8.7 ml to 60.8 ± 6.6 ml, p 
= NS) (figure 4.4a)). In all patients, CO rose from 3.79 ± 0.25 L/min to 4.11 ± 0.23 L/min (p 
= 0.02). In the high PCWP subgroup, CO rose from 3.49 ± 0.25 L/min to 3.98 ± 0.25 L/min (p 
= 0.009), but was unchanged in the low PCWP group (4.58 ± 0.46 L/min to 4.60 ± 0.38 
L/min, p = NS) (figure 4.4b).  
 
4.3.6. The effect of systemic nitrite infusion on estimated trans-septal gradient 
Trans-septal gradient increased (11.5 ± 1.9 to 14.5 ± 1.4 mmHg, n = 18, p = 0.01) in the high 
PCWP group overall (figure 4.4c), and was unchanged in the low PCWP group. 
 
4.3.7. The effect of systemic nitrite infusion on methaemoglobinaemia 
Methaemoglobinaemia rose from 0.3 ± 0.1% to 1.0 ± 0.5% at the highest dose of nitrite (n = 
18, p = 0.0001) (figure 4.5). 
 
4.4. Discussion 
 
Nitrite infusion decreased pulmonary vascular resistance to a greater degree than systemic 
vascular resistance. This fits with the observation that hypoxia potentiates vasorelaxation to 
nitrite in the mouse aorta, as the pulmonary artery is relatively hypoxic compared to the 
systemic circulation. Clearly, this is not the only difference between the two circulations, as 
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evidenced by the phenomenon of hypoxic vasoconstriction in the pulmonary circulation as 
opposed to vasodilatation in the systemic. This result may appear to discount a significant role 
of nitrite in physiological flow-regulation in the pulmonary circulation, but it is important that 
the doses of nitrite used in this study are far higher than physiological levels. Overall, this 
observation confirms our hypothesis, and may support future uses of nitrite in pathology such 
as pulmonary hypertension.  
 
The change in cardiac output correlated well with change in estimated trans-septal gradient. 
This cannot, of course, prove causation, but it lends support to the hypothesis that relief of 
DVI is involved. Estimated TS gradient rose overall and fell in only two patients 
(highlighted). CO also only fell in these two (figure 4.4c), which suggests that initial PCWP ≥ 
15mmHg is predictive of significant DVI. One of these two patients had a previous opration 
for congenital aortic stenosis, and may have had a pericardiectomy. It proved impossible to 
access the original operation notes to confirm this. If so, they would therefore not be subject 
to diastolic-ventricular interaction, as the phenomenon requires the constriction of an intact 
and relatively non-distendable pericardium. The trans-septal gradient was unchanged in the 
low PCWP subgroup. Overall, change in trans-septal gradient positively correlated with 
change in both SV (n = 18, R = 0.67, p = 0.004, figure 4.3d), and CO (n = 18, R = 0.79, p < 
0.001 figure 4.3e), suggesting that relief of DVI plays a major role in the increase in SV and 
CO. 
 
Cardiac output rose by approximately 8%. The change was largest in two patients that 
spontaneously reported orthopnoea: 60% and 40%. Symptoms were not formally assessed in 
the group as a whole during this study. In the 13 patients with a baseline PCWP ≥ 15 mmHg 
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the rise in CO was greater, at 15%, which implies the mechanism may be relief of diastolic 
ventricular interaction, and this hypothesis is supported by the correlation of cardiac output 
with the trans-mural gradient. Intravenous nitrite had a limited effect on pulmonary capillary 
wedge pressure itself which, combined with the profound drop in right atrial pressure, means 
that the trans-mural pressure is reduced, and consequently true left ventricular filling pressure 
is increased. This dramatic change with nitrite therapy underlies the increase in stroke volume 
and hence cardiac output. 
 
Overall, intravenous nitrite infusion in humans with advanced heart failure is safe and 
efficacious. Methaemoglobinaemia rose within safe levels during these infusions. Nitrite 
infusion appears to increase venous capacitance and to be a potent pulmonary vasodilator, 
while the effect on the systemic vascular resistance is much less profound. This may be due to 
consumption of nitrite and nitrosylated species across the pulmonary vascular bed, or reduced 
liberation of NO in conditions of higher oxygen tension (Maher et al., 2008). 
 
Glyceryl trinitrate is an established therapy for acute decompensated heart failure. There is 
evidence that patients with heart failure are resistant to organic nitrates, with at least an order 
of magnitude lower potency (Katz et al., 1992). Tolerance develops quickly, probably within 
12 hours (Elkayam, 1996). A drop in systolic blood pressure commonly prompts reduction in 
dose or cessation of GTN therapy. The average drop was 19% in one study of GTN in ADHF 
(Young et al., 2002), compared to 6% in the present study; such a drop may be accompanied 
by reflex tachycardia. Side effects are common with GTN therapy: 60-68% of patients 
experience one or more adverse effect; this is most commonly headache (in 20-29%) or 
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nausea (in 6%) (Loh et al., 2001; Young et al., 2002). None of the patients in the present 
study complained of any adverse effects.  
 
The low PCWP group had a significantly higher baseline stroke volume (67.8 ml vs. 44.9 ml, 
p = 0.03) and were also significantly older (57 vs. 42 years old). It may well be that a high 
PCWP predicts a “sicker” group of patients, with greater systolic dysfunction. Diastolic 
dysfunction may be a greater problem in the older low PCWP group, and indeed in the 
general population with heart failure, who tend to be elderly. Clearly, it is also not yet 
possible to extrapolate these results to patients with acute decompensated heart failure, though 
the favourable haemodynamic result along with high tolerability of nitrite infusion in the short 
term provides good pilot data for the study of such a therapeutic intervention. 
 
Sodium nitrite is known to cause methaemoglobinaemia, an effect that has been long utilised 
in the treatment of cyanide poisoning. The maximum level measured in any participant was 
2.9% (average 1.02 ± 0.13%) in this study, which is similar to the previous findings of 
Gladwin and colleagues (Dejam et al., 2007). This would need to be monitored over a longer 
time period to confirm the safety of systemic nitrite at vasodilating doses. These infusions 
were very short, at only five minutes per dose. Tolerance may occur within the time-frame of 
hours to days needed for successful treatment of ADHF, though the persistent vasodilatation 
seen in Chapter 3 suggests that the haemodynamic effects may in fact increase over a longer 
infusion. 
 
4.4.1. Limitations 
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Ideally, we would have compared the haemodynamic effects of nitrite with both a placebo 
group and a group treated with GTN. It proved challenging to recruit sufficient numbers of 
patients with a low (< 15 mmHg) PCWP. It appears that such patients represent a very small 
group on the transplant waiting list, which in view of their self-selection for severe disease 
should not, in retrospect, be surprising. We considered attempting to recruit patients from the 
general heart failure clinic, but it was felt that inserting a right heart catheter for non-clinical 
reasons in these patients would substantially change the risk-benefit ratio. We felt that this 
step may be unethical as the pilot data in 5 patients removes equipoise on the question of 
haemodynamic effects of nitrite in this group. 
 
4.5. Conclusions 
By invasively measuring haemodynamic effects, we have shown that the selective venodilator 
and pulmonary vasodilator actions of nitrite extend to patients with severe heart failure. 
Nitrite infusion is safe, and cardiac output can be markedly increased in this group, seemingly 
through relief of diastolic ventricular interaction. There is a negligible effect on blood 
pressure and therefore an absence of reflex tachycardia, in contrast to GTN therapy. These 
characteristics make nitrite an attractive candidate therapy for acute decompensated heart 
failure, though longer studies are needed to measure the stability of the haemodynamic 
response, and the development of metHb represents a potential barrier to its use. These will be 
investigated in the next chapter. 
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 4.6. Tables 
 
Table 4.1. 
 
 Low PCWP 
Mean ± SEM 
High PCWP 
Mean ± SEM 
Sig. 
 
M/F 
 
4/1 
 
8/5 
 
 
Age (years) 57 ± 3 42 ± 4 * 
Heart Rate (bpm) 71 ± 8 82 ± 5  
MAP (mmHg) 78 ± 6 74 ± 2  
PCWP 6 ± 0 25 ± 2 ** 
Diagnosis:    
Dilated Cardiomyopathy 2 (40%) 9 (69%)  
Ischaemic Heart Disease 2 (40%) 1 (8%)  
Primary Valve Disease 0 (0%) 2 (16%)  
Cardiac Amyloid 1 (20%) 1 (8%)  
Medications:    
ACE Inhibitor/AgIIRB 4/1 (100%) 11/2 (100%)  
Β-Blocker 3 (60%) 9 (69%)  
Digoxin 0 (0%) 3 (23%)  
Loop Diuretic 4 (80%) 13 (100%)  
Spironolactone/Eplerenone 4/0 (80%) 7/1 (62%)  
Warfarin/Enoxaparin 1/0 (20%) 4/2 (46%)  
 
Table 4.1: Clinical characteristics of patients with advanced heart failure 
Baseline patient characteristics (n = 18). *p < 0.05, **p < 0.001 
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4.7. Figures  
Figure 4.1. 
 
 
 
 
 
 
Figure 4.1: Protocol for acute nitrite infusions 
A diagram summarising the protocol for the acute nitrite infusions performed in chapter 4. 
Measurements performed at each time point are listed below the horizontal axis. 
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Figure 4.2. 
 
 
 
a) b) 
0
1
2
3
4
0 50
Nitrite (mcg/kg/min)
PV
R
 (w
oo
d 
un
its
)
*
 
0
5
10
15
20
25
0 50
Nitrite (mcg/kg/min)
SV
R
 (w
oo
d 
un
its
) 
*
 
 
 
 
Figure 4.2: The effect of systemic nitrite on pulmonary and systemic vascular resistance  
a) Pulmonary vascular resistance (PVR) fell from 2.96 ± 0.61 to 2.04 ± 0.38 wood units in the 
high PCWP subgroup, (filled circles, n = 13, p = 0.03). PVR fell from 1.19 ± 0.27 to 1.15 ± 
0.12 wood units in the low PCWP group, (hollow circles n = 5, p = NS). b) Systemic vascular 
resistance dropped from 18.3 ± 1.5 to 16.4 ± 1.3 wood units in the high PCWP group, (filled 
circles, n = 13, p = 0.02). SVR increased from 14.3 ± 0.7 to 14.8 ± 0.8 wood units in the low 
PCWP group, (hollow circles, n = 5, p = NS; * p < 0.05 compared to baseline 
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Figure 4.3. 
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Figure 4.3: The effect of systemic nitrite on right atrial pressure, pulmonary capillary 
wedge pressure, heart rate and blood pressure 
a) In the high PCWP subgroup, RA pressure fell from 12.7 ± 2.1 to 6.8 ± 1.8 mmHg, (filled 
circles, n = 13, p = 0.003).  In the low PCWP subgroup, RA pressure fell from 3.0 ± 1.5 to 2.0 
± 2.0 mmHg, (hollow circles, n = 5, p = NS) b) In the high PCWP group, PCWP fell from 
24.8 ± 1.7 to 22.0 ± 2.2 mmHg, (filled circles, n = 13, p = 0.09).  In the low PCWP subgroup, 
PCWP fell from 6.3 ± 0.3 to 5.3 ± 1.3 mmHg, (hollow circles, n = 5, p = NS) c) Heart rate 
was unchanged at any dose of nitrite (n = 18, p = NS) d) Systolic and mean arterial pressures 
were reduced by an average of 3 mmHg, (n = 18, p < 0.05 for each); * p < 0.05 compared to 
baseline, **p < 0.01 compared to baseline 
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Figure 4.4. 
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Figure 4.4: The effect of systemic nitrite on cardiac output, stroke volume and estimated 
trans-septal pressure 
a) Stroke volume increased in the high PCWP group from 44.9 ± 5.0 ml to 51.9 ± 4.9 ml, 
(filled circles, n = 13, p = 0.008) and fell in the low PCWP group by from 67.9 ± 8.7 ml to 
60.8 ± 6.6 ml (hollow circles, n = 5, p = NS). SV at baseline was significantly higher in the 
low PCWP subgroup, (n = 18, p = 0.03) b) Cardiac output increased in the high PCWP group 
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from 3.5 ± 0.3 L/min to 4.0 ± 0.3 L/min, (filled circles, n = 13, p = 0.009) and unchanged in 
the low PCWP group (from 4.58 ± 0.5 L/min to 4.60 ± 0.4 L/min, hollow circles, n = 5, p = 
NS) c) Change in estimated trans-septal gradient and cardiac output in high PCWP group - 
trans-septal gradient and cardiac output only fell in 2/13 patients (highlighted in red) d) 
Change in estimated trans-septal gradient positively correlated with change in SV in all 
patients, (n = 18, R = 0.67, p = 0.004) e) and with change in cardiac output, (n = 18, R = 0.79, 
p < 0.001); *p < 0.05 compared to baseline 
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 Figure 4.5.  
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Figure 4.5: The effect of systemic nitrite on methaemoglobinaemia 
Methaemoglobinaemia rose from 0.3 ± 0.1% to 1.0 ± 0.5% at the highest dose of nitrite (n = 
18, p = 0.0001) 
- 111 - 
5. CHRONIC INFUSION OF SODIUM NITRITE 
IN HEALTH AND HEART FAILURE 
 
5.1. Introduction 
It has been proposed that haemodynamic profiling of patients presenting with acute 
decompensated heart failure may provide useful information on prognosis and response to 
therapy. This was investigated in a landmark study by Nohria and colleagues (Nohria et al., 
2003). 
 
In one study, 452 heart failure patients were divided into four profiles on the basis of the 
presence or absence of congestion (pulmonary or systemic) and hypoperfusion. These were: 
patients with no evidence of congestion or hypoperfusion (dry-warm, n = 123); congestion 
with adequate perfusion (wet-warm, n = 222); congestion and hypoperfusion (wet-cold, n = 
91); and hypoperfusion without congestion (dry-cold, n = 16). Wet-cold patients had more 
severe disease than wet-warm patients, on the basis of lower LV ejection fraction (p = 
0.0004), serum sodium (p = 0.01), and systolic blood pressure (p < 0.0001), and higher 
NYHA functional class (p < 0.0001), and resting heart rate (p = 0.0004). Dry-warm patients 
had least severe disease, and the authors were guarded about interpreting the dry-cold group 
with only 16 patients. Wet-cold status was the strongest univariate predictor of one-year 
mortality tested, with a hazard ratio of 3.66 (2.16-6.21, p < 0.001) compared to dry-warm 
patients. It remained strongest in the multivariate analysis. By comparison, the next strongest 
were a diagnosis of ischaemic cardiomyopathy at 1.90 (1.35-2.68, p < 0.001), and NYHA 
functional class at 1.51 (1.23-1.85, p < 0.001).  
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 Wet-cold ADHF patients are often, but not universally, given therapy with intravenous 
nitrates (Forrester et al. 1976). Reduction in preload by venodilatation causes a paradoxical 
rise in cardiac output, through relief of DVI. Even so, the usefulness of organic nitrate 
vasodilators is limited by hypotension and the development of tolerance. 
 
As discussed in Chapter 3, NO-release from nitrite will preferentially occur in the venous 
system, unless substantial arterial hypoxaemia is present (pO2 < 85mmHg, 11.31kPa). We 
have seen in Chapter 4 that systemic nitrite in advanced heart failure induces less systemic 
hypotension for a given effect on preload, increasing cardiac output through relief of DVI. 
Inorganic nitrite (Dejam et al., 2007) and nitrate (Petersson et al., 2009) do not seem to induce 
tolerance, which would be a further advantage over therapy with organic nitrates. However, 
nitrite also has a unique disadvantage: the development of methaemoglobinaemia. The 
maximum level of metHb achieved in the previous study was low, at 2.9%, but may continue 
to rise during longer infusions. 
 
Nitrite has been known to oxidise Hb to metHb for over 100 years. Oxygen cannot bind to 
metHb, and therefore high levels in the blood ultimately inhibit cellular respiration and can be 
fatal. Production of metHb depends upon the relative concentration of nitrite and Hb, as well 
as the ability of nitrite to enter the cell. The reduction of metHb to Hb depends upon the 
metHb reductase system, which includes NADH- and NADPH-dependent enzymes (reviewed 
in (Umbreit, 2007). The former, known as NADH-cytochrome b5 reductase or diaphorase I, is 
responsible for 95% of physiological metHb reduction and exists in two main forms. The first 
is soluble and restricted in its expression to the erythrocyte. The second is membrane bound, 
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either in the endoplasmic reticulum or the mitochondrial inner membrane, and is more 
involved in lipid metabolism. Both enzymes are expressed as different transcripts of the same 
gene. Absence or lack of function of these enzymes leads to congenital 
methaemoglobinaemia, which is generally inherited as an autosomal recessive condition but 
may be sporadic, with the type depending on the particular enzyme subtype that is lacking. 
Type 1 is due to lack of the erythrocytic enzyme only and leads to visible cyanosis and 
relatively mild symptoms such as headaches and nausea on exercise. These patients have 
around 25% metHb at rest. Type 2 is due to lack of both types, including membrane-bound 
diaphorase I and is characterised by microcephaly, unremitting cognitive decline, athetosis 
and generalised hypertonia, caused by the loss of essential lipid synthesis. Type 3 is a 
historical entity, now considered identical to type 1, and type 4 has only been described in a 
single patient (Umbreit, 2007).  
 
The second enzyme system, NADPH methaemoglobin reductase or diaphorase II, is 
responsible for only 5% of metHb reduction in physiology, but has a central role in the 
treatment of methaemoglobinaemia with methylene blue. Methylene blue is a blue-coloured 
dye, which is stable in its oxidised form. Diaphorase II reduces methylene blue to 
leukomethylene blue using NADPH. This reduced form can chemically reduce metHb to 
Hb(Fe2+). Acquired methaemoglobinaemia results when the reductase system is overwhelmed 
by production. Until the oxidising agent is removed, metHb inexorably accumulates in the 
blood stream.  
 
As evidenced by the work presented in the preceding Chapter 4, short infusions of sodium 
nitrite have beneficial haemodynamic effects in heart failure. Taken with observations from 
- 114 - 
Chapter 3 that the vasorelaxing effects of nitrite persist even after its removal, we 
hypothesised that the beneficial haemodynamics we have shown would also persist, and may 
in fact increase, during a longer time frame of hours. Prior to testing this theory in our 
invasive heart failure model, we first performed a dose-ranging safety study in healthy 
volunteers, as patients with advanced heart failure may be particularly sensitive to the effects 
of methaemoglobinaemia. 
 
5.1.1. Hypothesis 
A dose of systemic sodium nitrite can be found that balances production of metHb with its 
elimination. This dose will have haemodynamic effects in heart failure, which persist, and 
may increase, over time. 
 
5.2. Methods  
 
5.2.1. Power calculation 
As a preliminary safety study we planned to recruit groups of 3-4 healthy volunteers to each 
dose of nitrite. As the safety threshold for heart failure patients (5% methaemoglobinaemia) 
was reached rather quickly at both upper doses of nitrite, no further participants were 
recruited to these groups. 
 
The intended group size in the heart failure study was guided by the calculation that 8 
participants would give a statistical power of 80% to detect a 0.9 L/min difference in cardiac 
output at a standard deviation of 0.9 L/min (Bonferroni post-hoc comparison of baseline and 3 
hour level, (Lenth, 2010)). 
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 5.2.2. Healthy volunteer protocol 
7 non-smoking healthy volunteers who gave written informed consent were recruited to the 
study. A cannula was placed in an antecubital vein in each arm. Continuous infusions at three 
different doses of nitrite (1, 10 and 60 mcg/kg/min) were given over a period of up to six 
hours into the dominant arm, while the second cannula was used to withdraw blood for 
analysis of metHb level at 30 minute intervals. Blood pressure and heart rate were monitored 
continuously and recorded at 30 minute intervals. Studies were discontinued once the safety 
cut-off point (metHb of 10%) was reached, or continued for up to six hours. Symptoms are 
reported to occur at levels of methaemoglobinaemia of 20-30% in healthy volunteers. One 
study was discontinued prematurely due to failure of the intravenous cannula (the participant 
refused a replacement). Approval for the study was given by the local Research Ethics 
Committee (REC #08/H1207/69). 
 
5.2.3. Heart failure patient protocol 
3 volunteers who were attending hospital for right heart catheterisation as part of the 
transplant assessment programme were recruited after giving informed consent. Infusions of 
nitrite at a dose of 10 μg/kg/min, which was established as a safe dose in the earlier protocol, 
were given to patients with advanced heart failure over a period of three hours. Blood 
pressure and heart rate were monitored continuously. Haemodynamic measurements were 
taken at baseline, and at 5, 15 and 30 minutes, and then at every subsequent 30 minutes. As in 
chapter 4, cardiac output was determined using the Fick method, for the reasons given in the 
preceding chapter, but also because thermodilution requires several 10 ml boluses of cold 5% 
dextrose solution for each measurement. Over the multiple measurements in this study, we 
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felt that this could affect haemodynamics in our heart failure patients. For this reason, it was 
additionally ensured that blood samples taken were replaced by an equal volume of normal 
saline. Approval for the study was given by the local Research Ethics Committee (REC 
#08/H1207/67). Inclusion and exclusion criteria for the study in heart failure are given below. 
The protocol is detailed in figure 5.1. 
 
5.2.4. Inclusion Criteria 
1. Aged 18 years or over 
2. Admission to hospital for pulmonary artery catheterisation, under the transplant 
assessment protocol 
3. High wedge pressure or significant DVI identified in clinical procedure 
 
5.2.5. Exclusion Criteria 
1. Pre-existing inotrope therapy 
2. Recent ST-elevation myocardial infarction or thrombolysis 
3. G6PD Deficiency, or high risk of G6PD deficiency 
4. Women of child-bearing potential or nursing mothers 
 
5.3. Results 
 
5.3.1. Participant characteristics 
Baseline characteristics are given for healthy volunteers (Table 5.1) and heart failure patients 
(Table 5.2). All participants in the healthy volunteer studies at higher doses of nitrite were 
withdrawn early from the study due to participant request or unsafe levels of 
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methaemoglobinaemia. One participant was withdrawn early from the 10 μg/kg/min group as 
one venous cannula tissued and the participant refused a second. One participant in the heart 
failure group was withdrawn early due to discomfort from the Swan-Ganz sheath. Studies 
were performed in the afternoon to minimise the effect of diurnal variation in vascular 
response. 
 
5.3.2. The effect of systemic nitrite infusion on methaemoglobinaemia in healthy 
volunteers 
At the highest dose of 60 μg/kg/min, metHb levels continued to increase, up to our safety cut-
off level of 10%. Infusions were discontinued at this point. At 30 μg/kg/min metHb also 
continued to climb, albeit at a slower rate, necessitating cessation of both studies. At a dose of 
10 μg/kg/min, metHb stabilised at a safe level of 1.75 ± 0.35% (maximum 2.4%) (figure 5.2). 
The increase in variability in the 30 μg/kg/min group results from withdrawal of participants 
as they reach the safety cut-off of 10% metHb; one was withdrawn at 150 minutes, then a 
second at 270 minutes. 
 
5.3.3. The effect of systemic nitrite infusion on heart rate and blood pressure in healthy 
volunteers 
Heart rate and blood pressure were stable in the healthy volunteers at the 10 μg/kg/min dose 
of nitrite (figure 5.3). At a dose of 60 μg/kg/min, both participants felt unwell towards the end 
of the study, and the study was ceased due to participant request. During this time an average 
BP fall of 8 mmHg was recorded.  
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5.3.4. The effect of systemic nitrite infusion on cardiac output and trans-septal gradient 
in heart failure patients 
Cardiac output rose from 3.3 ± 0.5 L/min to 4.4 ± 0.7 L/min at 3 hours, an increase of 33% 
(figure 5.4a). This change did not reach statistical significance but appears comparable to the 
15% rise recorded in the acute studies at the highest dose of nitrite (from 3.5 ± 0.3 L/min to 
4.0 ± 0.3 L/min, p = 0.009). This change appeared to correlate with change in trans-septal 
gradient at both 30 minutes (figure 5.4b) and 3 hours (figure 5.4c).  
 
5.3.5. The effect of systemic nitrite infusion on pulmonary and systemic vascular 
resistance, heart rate and blood pressure in heart failure patients 
The pulmonary vascular resistance appeared to trend towards a decrease throughout the 3-
hour infusion (from 3.5 ± 1.4 to 1.1 ± 0.5 wood units, figure 5.5a), though this did not reach 
statistical significance. Systemic vascular resistance was measured at 19.4 ± 1.8 and 16.1 ± 
1.4 wood units, at the beginning and end of the study repectively (figure 5.5b). As in the 
healthy volunteers at dose of 10 μg/kg/min nitrite, heart rate (figure 5.5c) and mean arterial 
BP (figure 5.5d) were steady throughout the 3-hour infusion. 
 
5.3.6. The effect of systemic nitrite infusion on methaemoglobinaemia in heart failure 
patients 
Methaemoglobinaemia rose throughout the study and had not reached plateau at 3 hours (2.0 
± 0.2%, maximum 2.2%, figure 5.6).  
 
5.4. Discussion 
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Blood pressure dropped by 8 mmHg towards the end of the infusions at 60 μg/kg/min. This 
may have been due to the vasodilating effect of nitrite, but it might be expected that this drop 
would occur cumulatively. As this drop correlated with symptoms of dizziness and nausea, it 
may in fact have been due to central vasovagal activity rather than vasodilatation by nitrite 
per se. Methaemoglobinaemia is known to cause sysmptoms such as nausea and shortness of 
breath, though these tend to occur at higher levels of metHb (Umbreit, 2007). 
 
Our preliminary dose-ranging study in healthy volunteers established that 10 μg/kg/min nitrite 
produced a safe level of methaemoglobinaemia (< 2%) that was stable over the six-hour time 
frame of the study. Both higher doses led to an inexorable rise in metHb, and the two 
participants who received the highest dose felt symptomatically unwell as they reached the 
biochemical safety threshold of 10% metHb. Clearly, higher doses are unlikely to be useful in 
heart failure and were not tested for safety reasons. 
 
We went on to investigate the physiological effects of nitrite at 10 μg/kg/min in patients with 
advanced heart failure and a PCWP of ≥ 15 mmHg. The kinetics of metHb production and 
reduction appear to have a “threshold” dose of nitrite, between 10 and 30 μg/kg/min, above 
which metHb will continue to accumulate until the nitrite infusion is ceased. This is consistent 
with a physiological model of constant metHb production with a saturable metHb reductase 
system of enzymes. 
 
The resting cardiac output in the heart failure group was 3.3 ± 0.5 L/min, which is around half 
that expected in healthy individuals. They represent a group at the severe end of the heart 
failure continuum. Such patients are admitted regularly to hospital with decompensation of 
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their fluid status, requiring intravenous diuretics and perhaps inotropic therapy to restore 
compensation. These therapies increase myocardial ischaemia and can compromise renal 
function, and so managing these patients is a significant challenge. A rise in cardiac ouput 
from 3.3 ± 0.5 L/min to 4.4 ± 0.7 L/min, should this prove to be sustained in a larger group in 
trial conditions, would be clinically significant. This rise was achieved with a tolerable level 
of metHb, and no significant fall in blood pressure or rise in heart rate. Tentatively, and 
extrapolating from data in the acute studies presented in the preceding chapter, the mechanism 
appears to be relief of diastolic interaction, which would limit the benefit to carefully selected 
patients. 
 
It proved extremely challenging to recruit heart failure patients to the long infusions study. 
Each study required the availability of a bed in the Coronary Care Unit at the Queen Elizabeth 
Hospital, which necessarily must prioritise high-dependency patients ahead of research 
subjects. Participants were most generous with their time, but recruitment was significantly 
lower than in the acute study. Patients with advanced heart failure are very prone to fatigue, 
and while we took this into account with the reduced length of the study (3 hours vs. 6 hours 
in the healthy volunteers), one patient could not complete the protocol. The exacting nature of 
the study was off-putting to other potential participants. With the limited datasets available, it 
is not surprising that no change in any parameter met statistical significance and these must 
therefore be regarded as very preliminary data.  
 
We considered attempting to recruit patients with less severe heart failure, but rejected this for 
two reasons. Firstly, such patients do not in general receive right heart catheters on clinical 
grounds, which changes the risk-benefit ratio of the study and may be a significant barrier to 
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recruitment (as we have found in other invasive research studies). Right heart catheterisation 
carries a small risk of death or serious injury, which is greater in patients with heart failure. 
Secondly, as shown in the preceding chapter, patients with a lower PCWP (who are in general 
less unwell) do not show dramatic haemodynamic responses to nitrite so may not be an 
adequate group in which to investigate a possible therapy for ADHF. 
 
5.4.1. Limitations 
We were unable to follow the clearance of metHb after cessation of the study, when the 10% 
safety level was reached, due to limitations in our ethical approval. Studies in animals suggest 
that metHb would decline to normal levels over the following 4-6 hours (Emerick et al., 
1965). Both participants given 60 μg/kg/min nitrite felt dizzy and nauseated when they 
approached a metHb level of 10%, and consequently we limited studies to 2 participants in 
this and the 30 μg/kg/min group. We felt this was reasonable as even levels of metHb over 
5% would be unacceptable in the group with advanced heart failure, and even more so in the 
eventual clinical target group with ADHF. The study in heart failure patients is ongoing, and 
we aim to recruit at least 8 participants to this group. 
 
5.5. Conclusions 
Systemic administration of 10 μg/kg/min sodium nitrite is safe in both healthy volunteers and 
patients with advanced heart failure. Although the data are very preliminary, these data are 
consistent with an increase in haemodynamic effects over time, to approximately the levels 
seen in the acute studies at the highest dose (50 μg/kg/min). This should encourage further 
investigation into sodium nitrite as a treatment for decompensated heart failure. 
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5.6. Tables 
Table 5.1. 
 
 
 
 
 
 
 Mean ± SEM 
 
M/F 
 
5/2 
Age (years) 27 ± 2 
Weight (kg) 72 ± 5 
Height (m) 1.77 ± 0.04 
BMI (kg/m2) 22.7 ± 0.5 
Hb (g/dL) 14.4 ± 0.6 
Na+ (mmol/L) 141.1 ± 0.8 
K+ (mmol/L) 3.90 ± 0.05 
HCO32- (mmol/L) 23.9 ± 0.6 
 
Table 5.1: Baseline characteristics (healthy volunteers) 
Table summarising the baseline characteristics of healthy volunteers in the long infusion 
study 
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Table 5.2. 
 
 
 
 
 
 Mean ± SEM 
 
M/F 
 
2/2 
Age (years) 54 ± 5 
Height (m) 1.66 ± 0.0 
Weight (kg) 70.8 ± 0.8 
BMI (kg/m2) 25.7 ± 0.8 
Heart Rate (bpm) 63 ± 6 
Mean Arterial Pressure (mmHg) 71 ± 7 
PCWP (mmHg) 15 ± 4 
Diagnosis:  
Dilated Cardiomyopathy 4 
Ischaemic Heart Disease 0 
Primary Valve Disease 0 
Cardiac Amyloid 0 
Medications:  
ACE Inhibitor/AgIIRB 4 
Β-Blocker 4 
Digoxin 1 
Loop Diuretic 4 
Spironolactone/Eplerenone 3 
Warfarin/Enoxaparin 0 
 
Table 5.2: Baseline characteristics (heart failure patients) 
Table summarising the baseline characteristics of participants in the long infusion (chronic 
heart failure) study  
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5.7. Figures 
 
 
Figure 5.1. 
 
 
 
 
 
 
 
Figure 5.1: Protocol for long infusions of nitrite in heart failure patients 
Details of measurements taken at each time point are listed below the horizontal axis 
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Figure 5.2. 
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Figure 5.2: The effect of longer systemic infusions of nitrite on methaemoglobinaemia in 
healthy volunteers 
Intravenous sodium nitrite given systemically at 10, 30 and 60 μg/kg/min caused a dose-
dependent rise in metHb (% of total Hb) over time (n = 3, 2, 2 respectively) 
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Figure 5.3. 
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Figure 5.3: The effect of longer systemic infusions of nitrite on heart rate and blood 
pressure in healthy volunteers  
a) Heart rate was steady over the course of the study b) Mean arterial blood pressure fell by 
an average of 8 mmHg in both volunteers at the 60 μg/kg/min dose of sodium nitrite. The 
studies were terminated for safety reasons. Data from the experiments with the 30 μg/kg/min 
dose are omitted for clarity. 
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Figure 5.4. 
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Figure 5.4: The effect of longer systemic infusions of nitrite on cardiac output in heart 
failure patients 
a) Cardiac output appears to rise over the course of the three-hour infusion (from 3.3 ± 0.5 
L/min at baseline to 4.4 ± 0.7 L/min, n = 3, p = 0.08 by single comparison one-way ANOVA) 
b) This increase appeared to correlate with the change in trans-septal gradient at 30 minutes (n 
= 3, R2 = 0.9594, p = NS) c) and at 180 minutes (n = 2) 
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Figure 5.5. 
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Figure 5.5: The effect of longer systemic infusions of nitrite on pulmonary and systemic 
vascular resistance, heart rate and blood pressure in heart failure patients 
a) The pulmonary vascular resistance appeared to decrease throughout the 3 hour infusion 
(from 3.5 ± 1.4 to 1.1 ± 0.5 wood units, n = 3) b) There was little change in systemic vascular 
resistance (from 19.4 ± 1.8 to 16.1 ± 1.4 wood units) c) Heart rate was steady throughout the 
infusion d) Mean arterial BP was also steady throughout 
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Figure 5.6. 
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Figure 5.6: The effect of longer systemic infusions of nitrite on methaemoglobinaemia in 
heart failure patients 
Maximum metHb levels were similar to those in the healthy volunteers at 3 hours (2.0 ± 0.2% 
vs. 1.6 ± 0.2%, maximum 2.2% vs. 2.1%, p = 0.36 for a difference by two-tailed t-test) 
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6. NITRITE AS A CYTOPROTECTIVE AGENT: 
THE ROLE OF ALDH2 
 
6.1. Introduction 
Several properties of NO make it a candidate cytoprotective agent: i) it reversibly inhibits 
mitochondrial respiration, thereby reducing the oxygen demand of ischaemic tissue, and 
extending the zone of adequate oxygenation to a greater distance from blood vessels (Loke et 
al., 1999; Thomas et al., 2001) ii) it causes vasodilatation of collateral vessels, promoting 
maximal oxygen delivery (Johnson, III et al., 1991); iii) NO-dependent S-nitrosylation of L-
type calcium channels prevents reperfusion injury by calcium overload (Hu et al., 1997); iv) 
NO also has a variety of effects on inflammatory pathways – it prevents platelet aggregation 
(Walter and Gambaryan, 2004), neutrophil adherence (Ma et al., 1993) and apoptosis (Li et 
al., 1999). 
 
In ischaemic conditions, NO synthesis by NOS may be diminished owing to scant availability 
of substrate, co-factors and oxygen (Becker et al., 2000). As demonstrated by the work 
described in Chapter 3, nitrite generates NO by a NOS-independent mechanism that is 
enhanced by ischaemia, making it an intriguing potential therapy in preventing IR injury. 
Indeed, as detailed in section 1.8.4, nitrite has now been shown to protect renal tissue 
(Milsom et al., 2010; Dezfulian et al., 2007)) liver (Duranski et al., 2005), brain (Jung et al., 
2006) and myocardium (Duranski et al., 2005; Gonzalez et al., 2008) from ischaemia-
reperfusion (IR) injury in animal models. Nitrate (NO3) given orally in beetroot juice, protects 
endothelium from IR injury in healthy human volunteers (Webb et al., 2008b). The authors 
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attributed this protection to a two-fold increase in plasma nitrite. Studies are underway to 
investigate first window preconditioning with nitrite (clinicaltrials.gov) but are yet to report. 
Mitochondrial aldehyde dehydrogenase (ALDH2) has been implicated as a central player in 
preconditioning with a variety of stimuli (Chen 2008). 
 
Mitochondrial aldehyde dehydrogenase (ALDH2) is a member of the 19-strong human 
aldehyde dehydrogenase family of NAD(P)+-dependent enzymes (Vasiliou and Nebert, 
2005). A common polymorphism in exon 12 (Glu487Lys, or Glu504Lys in the unspliced 
protein), known as the ALDH2*2 allele, is present in up to 50% of individuals of East Asian 
descent (Goedde et al., 1983). Heterozygosity at this allele results in a near inactive enzyme 
and produces the “Asian Flushing” phenotype; mutation of a single subunit destabilises the 
co-factor binding site and dimer interface such that heterozygotes are functionally similar to 
homozygotes with the variant allele (Larson et al., 2005). Individuals possessing one or two 
copies of the ALDH2*2 allele may be at greater risk of coronary artery disease (Guo et al., 
2010) and myocardial infarction (Takagi et al., 2002). Recently, ALDH2 has been postulated 
to be central to cardioprotection by a range of agents (Chen et al., 2008). In this study, 
increased ALDH2 dehydrogenase activity faithfully correlated with reduction in myocardial 
infarct size in rats. Additionally, such individuals have a diminished response to GTN, 
consistent with diminished bioactivation, both systemically (Li et al., 2006) and in the 
forearm (Mackenzie et al., 2005). Nitrite-dependent phosphorylation of ALDH2 was found in 
a recent proteomic search: this phosphorylation occurred in a dose-dependent manner after 
ischaemia-reperfusion injury (Perlman et al., 2009). Finally, ALDH2 itself exhibits intrinsic 
nitrite reductase activity (Li et al., 2008). We hypothesised that an interaction between 
ALDH2 and nitrite might contribute to IR protection in humans.   
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Disulfiram is an irreversible inhibitor of ALDH2. Administration mimics the “Asian 
Flushing” phenotype, which is used to deter from relapse in abstinent former alcoholics 
(Chick et al., 1992). Supporting this, disulfiram treatment reduces GTN-induced 
vasodilatation in wild-type individuals, to a level similar to that seen in people with the East 
Asian variant enzyme (ALDH2*2) (Mackenzie et al., 2005). 
 
We used two tools, genetic and pharmacological, in an established model of IR injury in the 
human forearm (Kharbanda et al., 2001) to investigate protection by nitrite and the role of 
ALDH2.  Given the likelihood that nitrite given before ischaemia (in the first preconditioning 
window) prevents IR injury in the forearm model, we chose initially to investigate the more 
clinically relevant second window. Having established a protocol for systemic nitrite that 
mitigates IR injury when given 24 hours before ischaemia, we went on to investigate whether 
such a protocol would prevent IR injury when used after the onset of ischaemia. This, 
potentially most useful method of protection, is known as periconditioning. 
 
6.1.1. Hypothesis 
Intravenous systemic sodium nitrite will protect from IR injury in wild-type individuals, but 
not in those with the Asian variant ALDH2*2 enzyme. 
 
6.2. Methods 
This study was approved by the local Research Ethics Committee (REC #09/H1207/99). All 
participants gave written informed consent. All studies were performed in a dedicated 
vascular laboratory, maintained at 22-24°C in quiet conditions. All participants were non-
smokers and none were on medications of any kind. All participants avoided nitrite/nitrate-
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rich foods (e.g. green leafy vegetables) or alcohol for 24 hours before the study, and abstained 
from caffeine on the day of the study (a standard measure in studies of vascular reactivity). 
Baseline characteristics are given in Table 6.1. 
 
6.2.1. Power calculation 
Based on previous studies we predicted a pre- vs. post-ischaemia difference in mean area 
under the curve of 1.5 with a standard deviation of 0.9. A group of 10 gives 90% power to 
detect a difference at a p-value of < 0.05.  
 
6.2.2. Forearm plethysmography  
Participants were seated upright on the bed with both arms exposed, fully extended and 
supported at heart level. Mercury-in-silastic strain gauges of an appropriate size were placed 
around the widest portion of each forearm. The non-dominant brachial artery was cannulated 
using a 27-gauge needle (Cooper’s Needleworks) attached to an epidural catheter and sealed 
with dental wax under aseptic conditions, with lignocaine anaesthesia at the participant’s 
discretion. Saline (0.9% NaCl) (or drugs) were infused at 0.5ml/min at all times to maintain 
needle patency. Venous access was gained in the antecubital fossa of the control arm. Blood 
pressure and heart rate were continuously monitored. Forearm blood flow (FBF) was 
measured simultaneously in both arms using venous occlusion plethysmography (VOP) to 
determine the FBF-ratio (detailed description of the technique is given in Methods 2.3.). 
Wrist cuffs were inflated to 200mmHg in order to exclude the hand circulation during 
measurements. FBF-R was measured at rest and again after 3-minute intra-arterial infusion of 
ACh into the study arm at each of 3 ascending doses (25, 50 and 100 nmol/min). Endothelial 
function was assessed using the change in FBF-ratio from baseline. Endothelium-independent 
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forearm blood flow was only measured at the end of each study in the main group (3 
ascending doses: 4, 8 and 16 nmol/min), in order to prevent potential confounding effects of 
GTN infusion before ischaemia (Chen 2008). 
 
6.2.3. Ischaemia-reperfusion protocol 
Following 15 minutes of acclimatization, baseline endothelial function was measured. 5 
minutes washout was allowed to elapse from the end of the last infusion, then the upper arm 
cuff on the study arm was inflated to >200 mmHg for a period of 20 minutes. Endothelial 
function was then re-measured after 15 minutes of reperfusion, to assess the level of IR injury. 
The study design is summarised in figure 6.1a, with progression through the study for each 
group of volunteers detailed in figure 6.1b. 
 
6.2.4. Nitrite infusion 
Sodium nitrite or saline placebo was infused intravenously into the control arm at a dose of 
1µg/kg/min. This dose was chosen as it does not cause significant vaso- or venodilation 
(Maher et al., 2008). Randomisation to nitrite or placebo was performed by coin toss before 
the first study day for each participant. They then received the other preparation on a separate 
research day at least 72 hours later. 
 
6.2.5. Blood sampling 
Venous blood samples were taken prior to ischaemia and then after 1 minute of reperfusion 
for the measurement of plasma nitrite, nitrite and RXNOs. Samples were placed in tubes 
spiked with Ethylenediaminetetraacetic acid (EDTA) and N-ethylmaleimide (NEM), 
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transferred on ice to a chilled (4°C) centrifuge and spun at 4000 rpm for 15 minutes. Plasma 
and cell samples were then snap frozen in liquid nitrogen and stored at -80°C. 
 
6.2.6. Genetic analysis  
Genetic analysis for ALDH2 genotype was performed after the completion of all studies, in 
order to maintain blinding – participants were recruited and studied blind to their ALDH2 
status, with the assumption that around 40% of East Asian participants would have the variant 
allele. DNA was extracted from venous blood samples (QIAamp, Qiagen) and analysed using 
commercial probes and primers (Taqman System, Applied Biosciences). The Taqman probe 
consists of a short complementary sequence (one for each allele), a dye (different colours for 
each allele) and a quenching molecule. Tightly bound probes are cleaved by the DNA 
polymerase, allowing the dye to fluoresce. This signal is read by the rt-PCR analyser and 
flags up the existence of one, other or both alleles, as below.  
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One participant was found to be homozygous at the *2 allele. This dataset was excluded from 
the analysis. Anonymised genotyping for each individual in the East Asian group is given in 
Table 6.2. 
 
6.2.7. Protocols 
Protocol 1: 12 Caucasian/West Asian participants were recruited to the delayed 
preconditioning group. Nitrite (1μg/kg/min for 10 minutes) was given intravenously 24 hours 
before the onset of ischaemia.  
 
Protocol 2: Having established an effective dose of nitrite, 22 healthy volunteers of East 
Asian origin were recruited to the main randomised double-blind placebo-controlled 
crossover study. Nitrite (1μg/kg/min for 10 minutes) or placebo (Normal saline at the same 
rate) was given for the latter 10 of 20 minutes of ischaemia.  
 
Protocol 3: 6 Caucasian/West Asian individuals were pre-treated with disulfuram 600mg 
daily for 2 days prior to the study. In previous studies this dose has been found to inhibit 
ALDH2 fully. Nitrite (1μg/kg/min for 10 minutes) was given for the latter 10 minutes of 
ischaemia as in protocol 2. 
 
6.2.8. Statistical Analysis 
Data from each study was analysed by an investigator who was blinded to the identity of the 
participant, their genetic status, and the protocol used. Statistical testing was performed using 
Graphpad Prism v5.03. Pre-and post-ischaemia dose-response curves were compared using 
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two-way ANOVA throughout, unless otherwise stated. A p-value of less than 0.05 was 
considered statistically significant. 
 
6.2.9. ALDH2-dependent soluble guanylate cyclase (sGC) activation in the presence of 
nitrite 
This work was done on behalf of the candidate by Prof Mayer’s group in the University of 
Zurich, Switzerland. Expression and purification of ALDH2 was performed as before (Beretta 
et al., 2010). Purified bovine lung sGC (50 ng) was incubated at 37 °C for 10 min in a final 
volume of 100 µL with the indicated concentrations of NaNO2 in the presence of 100 µg 
purified ALDH2*1 or ALDH2*2. Assay mixtures contained 50 mmol/L triethanolamine HCl 
(pH 7.4), 5 mmol/L MgCl2, 0.5 mmol/L [α-32P]GTP (~250,000 cpm) and 1 mmol/L cGMP. 
Reactions were terminated by the addition of 0.45 ml of zinc acetate (120 mmol/L) and 0.45 
ml of sodium bicarbonate (120 mmol/L), followed by isolation and quantification of 
[32P]cGMP as described previously (Schultz and Böhme, 1984). Blank values were 
determined in the absence of sGC. A second set of experiments was performed with a 
constant NaNO2 concentration (10 mmol/L). Where indicated, superoxide dismutase (SOD, 
1,000 U/mL) was additionally present. Chloral-hydrate (CH) inhibitable sGC stimulation was 
derived subtracting the activity values obtained in the presence of 10 mmol/L CH measured 
under the corresponding experimental conditions. 
 
6.2.10. ALDH2-dependent inactivation by nitrite 
This work was done on behalf of the candidate by Prof Mayer’s group in the University of 
Zurich, Switzerland. Dehydrogenase activity was measured by monitoring the formation of 
NADH as increase in light absorbance at 340 nm in 50 mmol/L sodium pyrophosphate buffer 
- 138 - 
(pH 7.5) containing 0.4 mmol/L acetaldehyde, 10 mmol/L MgCl2 and 5 mmol/L NAD. After 
2 min of equilibration, the reactions were started by the addition of ALDH2*1 or ALDH2*2 
(19 and 111 µg/mL final concentrations, respectively) and monitored for ~3 min to obtain 
initial reaction rates. Activities were subsequently measured after the addition of 10 mmol/L 
NaNO2 and of 1 mmol/L DTT. 
 
6.2.11 Measurement of plasma nitrite, nitrate and RXNO 
This work was done on behalf of the candidate by Prof Feelisch’s group in the University of 
Warwick. Plasma NOx (nitrite and nitrate) was measured from samples supplemented with 10 
mM EDTA and 2 mM N-ethyl-maleimide, using gas-phase chemiluminescence. The addition 
of NEM and EDTA serves the purpose of blocking SH-groups and inhibiting metal-catalysed 
transnitrosation reactions. Quantification of NO, RSNOs and RXNOs was achieved by group-
specific denitrosation (Bryan et al., 2004). Briefly, samples were injected into either a 
triiodide-containing reaction mixture (for the release of RXNO species) or a solution 
containing potassium ferricyanide (NO-heme species), which was constantly purged with 
nitrogen. NO was measured with a gas phase chemiluminescence detector (CLD 77am sp, 
EcoPhysics) under reduced ambient light conditions (<15 lux), as NO and adducts are 
susceptible to photolytic decomposition. 
 
6.3. Results 
6.2.1. Participant characteristics 
All subjects tolerated the procedures with no complications. Baseline characteristics of 
volunteers are given in Table 6.1. 
 
- 139 - 
6.3.2. Delayed preconditioning with nitrite in individuals with wild-type ALDH2 
1µg/kg/min sodium nitrite given intravenously 24 hours before the study prevented post-
ischaemia endothelial dysfunction in a group of homozygous wild-type (ALDH2*1/*1) 
participants (p = 0.78, n = 7) (figure 6.2). 
 
6.3.3. Periconditioning in individuals with wild-type and variant ALDH2 
The IR protocol did not affect heart rate or blood pressure in any group; resting heart rate and 
blood pressure was similar on each study day and endothelium-independent forearm blood 
flow was similar between groups. Twenty minutes of forearm ischaemia induced significant 
endothelial dysfunction in individuals with (p < 0.0001, n = 9) or without (p = 0.0001, n = 9) 
the ALDH2*2 allele (figures 6.3a&b). 1 µg/kg/min sodium nitrite given intravenously during 
the latter ten minutes of ischaemia prevented endothelial dysfunction in participants that were 
heterozygous for the ALDH2*2 allele (p = 0.63, n = 8)(figure 6.3c). Wild-type individuals 
did not display protection (p = 0.006, n = 10)(figure 6.3d) (p < 0.001 for a difference between 
groups). 
 
6.3.4. Periconditioning in individuals with wild-type ALDH2, pre-treated with the 
ALDH2 inhibitor disulfiram 
Homozygous wild-type participants pre-treated with disulfiram (600mg daily for two days) 
and given 1µg/kg/min sodium nitrite given intravenously during the latter ten minutes of 
ischaemia, displayed significant post-ischaemia endothelial dysfunction (p < 0.0001, n = 
6)(figure 6.4). 
 
6.3.5. In vitro measurements of the activity of wild-type and variant ALDH2 enzyme 
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The *1/*2 variant enzyme exhibits a rightward shift in the NO-generation curve in response to 
nitrite when compared to the wild-type enzyme (p < 0.0001, n = 3) (figure 6.5a). The 
majority of the difference in chloral hydrate inhibitable sGC stimulation is abolished by the 
addition of superoxide dismutase (SOD) (figure 6.5b). Sodium nitrite inhibits ALDH2*1 
aldehyde dehydrogenase activity but not that of the variant *2 enzyme – though the resting 
level of activity is far lower (figure 6.5c). 
 
6.3.6. Plasma NOx and RXNO levels before and after nitrite infusion in individuals with 
wild-type and variant ALDH2 
Plasma nitrite was identical in both groups at baseline and rose significantly in wild-type 
individuals after nitrite infusion (n = 7, p < 0.05). This rise did not reach statistical 
significance in variant individuals (figure 6.6a). Plasma nitrate did not increase significantly 
in either group and was not significantly different at baseline (n = 9 for each) (figure 6.6b). 
Plasma RXNO was not significantly different at baseline and did not rise significantly in 
either group (n = 7 for variant, n = 9 for wild-type) (figure 6.6c). 
 
6.4. Discussion 
 
There is growing interest in the potential of inorganic nitrite to prevent reperfusion-
reperfusion (IR) injury (Lundberg et al., 2009). Hitherto, the mechanism of protection by 
nitrite in animals remains incompletely understood, and protective effects have not been 
confirmed in humans. The present study addresses a number of these uncertainties. We have 
demonstrated for the first time that nitrite, given 24 hours before reperfusion, prevents IR 
injury in the human forearm model. Furthermore, we have shown that the same protocol of 
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nitrite administration, started after the onset of reperfusion, is efficacious in certain 
individuals, with protection depending upon ALDH2 genotype. This protection, in contrast to 
previous preconditioning work in myocardium (Chen et al., 2008) and in refutation of our 
original hypothesis, did not depend upon activation of the ALDH2 enzyme. 
 
In order to establish whether simple ALDH2 activity was responsible for the observed 
difference, a group of wild-type homozygous participants was pre-treated with disulfiram. 
Pharmacological inhibition of ALDH2 in healthy volunteers did not recapitulate the 
ALDH2*1/*2 phenotype with respect to nitrite efficacy. While we cannot exclude potential 
inhibitory effects of disulfiram elsewhere in the signalling cascade, this discrepancy suggests 
that downstream differences in individuals with the ALDH2*1/*1 and *1/*2 genotypes may 
in fact be responsible. Finally, further investigation of the variant and wild-type enzymes at 
the biochemical level confirmed significantly reduced aldehyde breakdown, as expected, but 
additionally revealed mildly reduced nitrite reductase activity as well as marked differences in 
ROS generation. It has been proposed that nitrite triggers a protective signalling cascade by 
reversible inhibition of mitochondrial complex I, with modulation of mitochondrial ROS 
generation at reperfusion (Shiva et al., 2007b), however, the relevance of this mechanism in 
humans is unclear. 
 
Toxic aldehydes, such as 4-HNE, are known to contribute to mPTP opening and subsequent 
cell death, and are among the toxic species which accumulate during ischaemia. ALDH2 
metabolises these aldehydes and this has been postulated to underlie its protective effects 
(Budas and Mochly-Rosen, 2007). ALDH2 activation is sufficient to induce cardioprotection 
in PKCε2 knockout mice, suggesting a downstream position in the mitochondrial signalling 
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cascade (Budas et al., 2010). Since PKCε2 has been suggested to be common to all 
cardioprotective signalling pathways, and ALDH2 is activated by a variety of successful 
stimuli, this places ALDH2 in a central position in cardioprotection (Garlid et al., 2009). It is 
intriguing that activation of ALDH2 does not appear to be required in periconditioning by 
nitrite and it may be that nitrite activates other targets, or a downstream target of ALDH2. It 
appears that reactive oxygen species may be important in this process. 
 
The failure of disulfiram to recapitulate the phenotype of the *2 variant individuals was 
unexpected. However, disulfiram is known to have effects on systems other than merely 
ALDH2, including NF-κB, which is known to have a role in cytoprotection (Lovborg et al., 
2006). Disulfiram may also, in itself, increase oxidative stress and thereby aggravate IR injury 
(Ningaraj and Rao, 1998). It may also be that chronic inactivity of ALDH2 induces 
compensatory changes that acute inhibition of ALDH2 with disulfiram does not mimic. 
 
Plasma NOx and RXNO levels are very variable between individuals and also vary from day-
to-day in the same person. It is therefore impossible to exclude subtle differences in these 
species that may contribute to the observed differences. However, the level of plasma nitrite 
achieved in the wild-type group was similar to that reported to protect endothelium in humans 
when given prior to ischaemia (Webb et al., 2008b), and is several orders of magnitude lower 
than doses which have been seen to prevent protection in other studies (Jung et al., 2006) 
which, taken together, implies that the observed difference (and unexpected result) is not 
merely a result of incorrect dosing. Repeating the study at a higher dose would be instructive 
but may be impractical. 
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6.4.1. Limitations 
There are several limitations to the interpretation of this study. The endothelial model of IR 
injury is well established but is not necessarily a surrogate for other organs. The present study 
is relatively small, though was powered as such. As the study involves puncture of the 
brachial artery, it was felt that it was not reasonable to require more than two runs from each 
participant. Ideally, the effect of disulfiram and delayed protection would have been studied in 
the East Asian population, but insufficient participants were recruited. Finally, our disulfiram 
group were all male, but there were no significant effects of gender found in any group. Our 
biochemical studies were performed with the homozygous variant enzyme since it is a 
dominant-negative polymorphism (Beretta et al., 2010).  
 
6.5. Conclusions 
The possibility cannot be excluded that different protocols of nitrite periconditioning might be 
efficacious in wild-type individuals (Hausenloy and Yellon, 2010). The effective dose of 
nitrite in the present study is rather low when compared with those successfully used in 
animal models (cf. 13.8 µg/kg/min, 0.2 µmol /kg/min, aiming for a plasma concentration of 5-
10 µmol/L in Gonzalez et al., 2008), but the protective effect seen in those with the variant 
enzyme, which our biochemical data suggests releases less NO and more superoxide for a 
given level of nitrite, and the protection afforded in previous preconditioning studies by this 
level of plasma nitrite (Webb et al., 2008b), argues against the lack of efficacy simply being 
due to inadequate dose. It has been seen that high levels of NO may prevent protection (Bolli, 
2001), but again our low dose of nitrite is unlikely to produce such levels. 
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A major difference between the endothelial model used in the present study, and previously 
successful myocardial models, is that nitrite or related species could not access the ischaemic 
endothelium until the onset of reperfusion. In studies of myocardial infarction, small 
penetrating arteries or collaterals in the left ventricle may allow a small amount of nitrite to 
enter. The protective effect previously reported in the ischaemic canine myocardium 
(Gonzalez et al., 2008) therefore leaves the door open to further study of nitrite during 
percutaneous coronary intervention in humans. 
 
Epidemiologically speaking, this result is difficult to reconcile with the increased 
cardiovascular risk proposed to result from possession of the variant genotype. It seems 
unlikely that such a high prevalence of this allele should have persisted in the face of it 
causing serious harm to the reproductive ability of the individual, though it might be argued 
that coronary disease tends to affect people later in life. It does not exist simply though a 
founder effect (though that may explain the particularly high prevalence among Han Chinese 
people), and it is tempting to speculate that it might have a protective effect, similar to that 
proposed for sickle cell/thallasaemia against malaria, cystic fibrosis against cholera, or 
haemochromatosis against bacterial assault. It has been proposed that the variant enzyme 
protects against alcoholism (though it should be noted that data from Japan are contradictory 
to those from China in this respect) but it is hard to believe that this would have an effect over 
an evolutionary timescale. If people with variant ALDH2 are protected against certain types 
of ischaemia-reperfusion injury then this is an important result for millions of people 
worldwide. 
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6.6. Tables  
Table 6.1. 
 
 
 
 
 
 
 
 Delayed ALDH2*1/*2 ALDH2*1/*1 Disulfiram  
Number 12 11 10 6 
Height (m) 1.72 ± 0.05 1.72 ± 0.03 1.68 ± 0.03* 1.83 ± 0.03* 
Weight (kg) 65.9 ± 5.8 61.6 ± 4.4 63.7 ± 2.6 77.5 ± 4.5 
BMI (kgm-2) 21.9 ± 0.7 20.6 ± 0.8 22.6 ± 0.6 23.1 ± 1.0 
Forearm (cm) 23.6 ± 0.9 23.0 ± 0.8 24.2 ± 0.4 25.6 ± 0.9 
Age (years) 25 ±1 23 ± 0.7 23 ± 0.7 24 ± 1.3 
Gender (male) 4(57%) 6(60%) 7(64%) 6(100%) 
HR Placebo (bpm)  75 ± 3 61 ± 1  
HR Nitrite (bpm)  66 ± 3 73 ± 3 64 ± 3 62 ± 5 
mBP Placebo 
(mmHg) 
 84 ± 4 84 ± 5  
mBP Nitrite (mmHg) 87 ± 4 85 ± 3 81 ± 3 89 ± 3 
 
 
 
Table 6.1: Baseline characteristics 
Table summarising the baseline characteristics of participants in each group; *p < 0.05 for 
difference between marked columns by one-way ANOVA (Bonferroni post-hoc test) 
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Table 6.2. 
 
 
 
 
Sample *2 Allele Detected *1 Allele Detected Interpretation 
1  1 *1/*1 
2  1 *1/*1 
3 1 1 *1/*2 
4  1 *1/*1 
5  1 *1/*1 
6  1 *1/*1 
7  1 *1/*1 
8  1 *1/*1 
9  1 *1/*1 
10 1  *2/*2 
11  1 *1/*1 
12 1 1 *1/*2 
13 1 1 *1/*2 
14  1 *1/*1 
15 1 1 *1/*2 
16 1 1 *1/*2 
17 1 1 *1/*2 
18 1 1 *1/*2 
19  1 *1/*1 
20  1 *1/*1 
21 1 1 *1/*2 
22  1 *1/*1 
23  1 *1/*1 
24 1 1 *1/*2 
25 1 1 *1/*2 
26  1 *1/*1 
27  1 *1/*1 
28  1 *1/*1 
29  1 *1/*1 
30  1 *1/*1 
31  1 *1/*1 
32 1 1 *1/*2 
33  1 *1/*1 
34  1 *1/*1 
35  1 *1/*1 
36  1 *1/*1 
37  1 *1/*1 
38  1 *1/*1 
 
 
Table 6.2: Summary of genotyping results and interpretation  
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6.6. Figures 
Figure 6.1. 
 
a) 
 
 
 
 
 
b) 
 
 
  
 
 
 
Figure 6.1: Recruitment and study design 
a) Figure summarising the basic study design and plan of each study day, ACh FBF: 
measurement of endothelium-dependent forearm blood flow; GTN FBF: measurement of 
endothelium-independent forearm blood flow b) Figure showing progression through study 
for each group. 
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Figure 6.2. 
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Figure 6.2: The effect of nitrite infusion 24 hours prior to ischaemia in ALDH2*1/*1 
individuals 
Intravenous sodium nitrite (1 μg/kg/min) given 24 hours prior to ischaemia prevented 
endothelial dysfunction in wild-type individuals (pre- vs. post-ischaemia FBF-R, p = 0.78, n = 
7); filled circles: pre-ischaemia FBF-R, hollow circles: post-ischaemia FBF-R 
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Figure 6.3. 
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Figure 6.3: The effect of nitrite or placebo infusion during ischaemia in ALDH2*1/*1 
and  ALDH2*1/*2 individuals 
a) IR produced significant endothelial dysfunction in ALDH2*1/*2 individuals, (p < 0.0001, 
n = 9) b) IR produced significant endothelial dysfunction in ALDH2*1/*1 individuals (p = 
0.0001, n = 9) c) Intravenous sodium nitrite (1μg/kg/min) given during the final 10 minutes of 
ischaemia prevented endothelial dysfunction in ALDH2*1/*2 individuals (p = 0.63, n = 8) d) 
Intravenous sodium nitrite (1μg/kg/min) given during the final 10 minutes of ischaemia did 
not prevent endothelial dysfunction in ALDH2*1/*1 individuals (p = 0.006, n = 10); filled 
circles: pre-ischaemia FBF-R, hollow circles: post-ischaemia FBF-R 
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Figure 6.4. 
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Figure 6.4. The effect of disulfiram pre-treatment and nitrite infusion during ischaemia 
in ALDH2*1/*1 individuals 
Pre-treatment with disulfiram (600mg daily for 2 days) did not rescue the wild-type 
phenotype (p < 0.0001, n = 6); filled circles: pre-ischaemia FBF-R, hollow circles: post-
ischaemia FBF-R 
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Figure 6.5.  
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c)  
 
Figure 6.5: In vitro studies of wild-type and variant ALDH2 enzymes 
a) The ALDH2*2 variant enzyme exhibits a rightward shift in the NO-generation curve in 
response to nitrite when compared to the wild-type enzyme (p < 0.0001, n = 3); solid line: 
ALDH2*1, dotted line: ALDH2*2 b) The majority of the difference in chloral hydrate 
inhibitable sGC stimulation is abolished by the addition of superoxide dismutase (SOD) (solid 
columns, ALDH2*1; hatched columns, ALDH2*2) (n = 3 for each) c) Sodium nitrite inhibits 
ALDH2*1 (p < 0.01 compared to baseline) but not *2 (n = 3 for each), d) blood results; **p < 
0.01, ***p < 0.0001 
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Figure 6.6.  
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Figure 6.6: Plasma nitrite, nitrate and RXNO levels 
a) Plasma nitrite increased significantly in wild-type but not variant individuals (n = 7 for 
each) b) Baseline and post-nitrite differences in plasma nitrate did not reach statistical 
significance (n = 9 for each) c) Baseline and post-nitrite differences in plasma RXNO did not 
reach statistical significance (n = 7 for variant, n = 9 for wild-type); filled circles, wild-type; 
hollow circles, *1/*2 variant; *p < 0.05 by two-way ANOVA. 
- 153 - 
7. GENERAL DISCUSSION 
AND CONCLUSIONS 
 
• Myoglobin is a nitrite reductase in vascular tissue, it affects the pharmacokinetic 
profile of exogenous nitrite, and may be important in vasodilatation in vivo 
• Nitrite shows acutely beneficial haemodynamic effects in patients with severe 
heart failure 
• Above a threshold dose of nitrite, metHb accumulates to dangerous levels 
• Below the threshold dose, metHb levels plateau, making it possible to select safe 
doses for chronic nitrite infusion 
• Chronic nitrite infusion produces beneficial haemodynamic effects in patients 
with severe heart failure, that persist and increase beyond the acute time-frame 
investigated above 
• Nitrite protects healthy endothelium from ischaemia-reperfusion injury when 
given 24 hours before injury 
• Nitrite protects endothelium when given during ischaemia in people with variant 
ALDH2, but not in those with classical ALDH2 
 
7.1. Myoglobin participates in the reduction of nitrite, and affects its pharmacokinetic 
profile 
The identity of the nitrite bioconverter is elusive. It appears likely that a number of species 
participate in this reaction, with different proteins taking the lead role under different 
physiological conditions. The work in Chapter 3 implicates myoglobin in this role, even in 
conditions of mild hypoxia that are surprisingly close to normal oxygenation in the 
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vasculature. The mechanism of this vasodilatation certainly involves release of NO, and 
seems to proceed along the established path of sGC stimulation, though the mechanism may 
be more esoteric. The intracellular positioning of the relatively sparse smooth muscle 
myoglobin, with direct access to the mitochondria, may have particular relevance in this 
regard. Recent work has shown that reactive oxygen species (and particularly hydrogen 
peroxide) can themselves vasodilate (Prieto et al., 2010; Feng et al., 2010). Nitric oxide, 
released by the reaction of nitrite and myoglobin in the vicinity of mitochondria, could inhibit 
the respiratory chain (Complex I in Hendgen-Cotta et al., 2008) to produce a burst of ROS, 
leading to vasodilatation. This is consistent with the relatively slow development of nitrite-
induced vasodilatation, when compared to that produced by other NO-donors. 
 
The duration of vasodilatation is increased by the presence of myoglobin. This feature of 
nitrite appears to have clinical relevance, as shown by the long infusions in Chapter 5, 
wherein the haemodynamic effects of sodium nitrite increased over a time period of minutes 
to hours. In the future, it would be most useful to investigate the mechanism of this prolonged 
effect. Primate myoglobin has an extra cysteine residue compared to that of other animals, 
which can also be nitrosylated, therefore this ability of myoglobin may be even more 
pronounced in primates. Living vessels from humans are difficult to source, and are 
technically challenging to use. I performed some preliminary studies with internal mammary 
artery rings, harvested at the time of cardiac surgery (and which are normally discarded), but 
these were very unreliable and it has not as yet been possible to produce reproducible results. 
The artery samples we were given initially had been sprayed with papaverine. This is standard 
practice among some surgeons, to prevent vasospasm, but it unfortunately makes the artery 
unusable for myography. When the surgeons harvested the tissue before papaverine, the rings 
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were still unresponsive, and it was only when I doubled the glucose content of the buffer that 
a proportion of the rings contracted. The failure of other samples may relate to differences 
between patients (i.e. level of atheroma) or surgical collection technique. The results gained 
from a small number of rings were very heterogeneous, and this technique will need further 
optimisation. Once perfected, future work could compare human and rodent rings, or perhaps 
make use of the gene transduction techniques used earlier in Chapter 3, to investigate a 
difference between knocked-in human and rodent myoglobin, with and without the unique 
cysteine 110, both on the myo-/- background.  
 
The experiments in Chapter 3 and studies discussed in the introduction together suggest that 
nitrite may have clinical utility in two distinct areas: selective vasodilatation in heart failure 
and cardioprotection in myocardial infarction. Both areas rely on the ability of nitrite to 
release NO in a NOS-independent manner, particularly in conditions of hypoxia or ischaemia. 
 
7.2. Nitrite infusion in decompensated heart failure 
The work in Chapter 4 demonstrates that intravenous sodium nitrite has beneficial 
haemodynamic effects in advanced heart failure. However, as shown by the work in healthy 
volunteers and in patients with advanced heart failure (Chapter 5), the maximum dose is 
limited by the development of methaemoglobinaemia, which accumulates over time. At a safe 
dose of 10 µg/kg/min, effects were more modest but increased over the course of the three-
hour infusion. As before, nitrite had more effect in the relatively hypoxic pulmonary 
circulation, while the reduction in systemic vascular resistance was minimal. Pulmonary 
vasodilatation, along with venodilatation (signified by a reduction in right atrial pressure), 
caused an increase in cardiac output through relief of diastolic ventricular interaction. It 
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remains to be investigated whether this statistically significant rise in cardiac output is 
clinically relevant; this can only be evaluated in a future trial. 
 
A randomised controlled trial of 10 µg/kg/min nitrite vs. GTN in acute decompensated heart 
failure should be performed to assess the true clinical impact of nitrite in this condition. 
Sodium nitroprusside has the disadvantage of being metabolised to cyanide, which 
accumulates during longer infusions. Inclusion criteria must be especially rigorous, as only a 
subset of such patients (‘cold and wet’ in the previous authors’ scheme (Forrester et al., 
1976)) would be expected to benefit from vasodilator therapy, and poor patient selection 
would dilute any difference in effect. A larger trial could stratify patients in the manner of 
Nohria et al. (2003). Nitrite would be predicted to produce better outcomes in the “cold and 
wet” group than in the remainder. Such a trial would examine the additive benefit of nitrite on 
standard therapy, as it would be unethical to replace standard therapies in the other groups. 
Endpoints should include clinically significant hypotension and reflex tachycardia, and 
tolerance must be assessed, as this is a potential advantage over nitrates. It may be that the 
narrow therapeutic window of nitrite with regard to methaemoglobinaemia means that it has 
no advantage over traditional inorganic nitrates. Another condition in which nitrite therapy 
may be beneficial would be pulmonary hypertension. Unfortunately, very few pulmonary 
hypertension patients are admitted to the transplant assessment programme in the Queen 
Elizabeth Hospital, Birmingham, and such patients are also very heterogeneous in clinical 
profile. In our centre the majority are secondary in aetiology to heart failure or lung disease of 
various types. Such a study could really only be performed in a regional specialist centre. 
With access to such a group, one could assess a variety of nitrite therapies, including 
ambulatory infusions or dietary nitrite supplementation in primary pulmonary hypertension 
- 157 - 
patients. Haemodynamic assessment of pulmonary artery pressures can be done non-
invasively using echocardiography, which would be an advantage over the present work, and 
more global measures such as quality of life and exercise performance could be measured 
over a longer period. Dietary nitrite could also be assessed in heart failure, perhaps compared 
to a nitrate/hydralazine regimen. 
 
7.3. Nitrite before surgery or at intervention in myocardial infarction 
The work in Chapter 6 demonstrates for the first time that nitrite infusion 24 hours prior to 
ischaemia protects the human endothelium. This provides a rationale for investigation of 
nitrite protection for planned events such as surgery or percutaneous coronary intervention. In 
most individuals, nitrite given during the latter part of ischaemia does not protect 
endothelium. It must be noted, however, that the endothelial model is imperfect to investigate 
the ischaemic myocardium, as no nitrite may enter the tissue until the beginning of 
reperfusion. The model therefore reflects postconditioning more than periconditioning and 
should not prevent investigation of nitrite periconditioning for the myocardium. The 
observation that nitrite post-conditioning protects the endothelium in ALDH2*2 variant 
individuals provides some encouragement that such a strategy may be successful. 
Periconditioning may have more clinical utility – most ischaemic events are unpredictable and 
a safe intervention given before reperfusion would be a valuable addition to the medical 
armoury. 
 
A clinical trial of nitrite infusion before primary percutaneous coronary intervention (for acute 
coronary syndrome) would establish whether this might be a useful clinical therapy in the 
future. Certainly, it would be practically simple and cheap as an intervention. There is also 
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good evidence that nitrite, especially at the extremely low doses required, would be very safe. 
The endpoints however might be more complicated. Indices of myocardial damage such as 
troponin release are very variable after acute coronary syndromes and would necessitate a 
very large trial to prove an effect. A more powerful strategy might be to use cardiac magnetic 
resonance imaging (with T2 weighting to show oedema) to gain an assessment of the area at 
risk of infarction, and an extremely accurate measurement of infarct size. Longer-term follow-
up could include the presence of heart failure (which is related to initial infarct size), and 
could be done using clinical assessment, diuretic use and echocardiography. Transgenic 
mouse models may be used to probe the relationship between nitrite and variant ALDH2. 
 
Myoglobin may have a particularly important role in cardioprotection by nitrite. In vivo 
administration of nitrite reduced infarct size by 60% in a mouse model, whereas the same 
protocol of nitrite administration did not protect in myo-/- mice (Hendgen-Cotta et al., 2008). 
This was attributed to the unique position of myoglobin within the cell, with NO released 
directly beside mitochondria where it nitrosylates mitochondrial complex I (Raat et al., 2009), 
inhibiting it, and protecting the mitochondrion from excess oxidative stress (Shiva et al., 
2007b). 
 
Nitrite is present in our food. The amount we ingest varies greatly depending on one’s diet, 
with high-nitrite food sources such as cereals and leafy green vegetables containing 2.0-4.0 
mg of nitrite per kilogram (van Faassen et al., 2008). While a change in diet is unlikely to 
cause central haemodynamic changes comparable to those in chapter 4, the approximate 
doubling of plasma nitrite by the low doses given in chapter 6 is achievable. This may 
explain some of the cardiovascular protection afforded by a diet rich in vegetables, though 
- 159 - 
admittedly it would be brave to commend a (similarly nitrite-rich) daily bacon sandwich to 
those seeking the same effect. 
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